monocarboxylic acid anion - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	monocarboxylic acid anion	go back to main search page
Accession:	CHEBI:35757	browse the term
Definition:	A carboxylic acid anion formed when the carboxy group of a monocarboxylic acid is deprotonated.
Synonyms:	related_synonym:	Carboxylate; Formula=CO2R; Monocarboxylate; SMILES=[O-]C([*])=O; a monocarboxylate; monocarboxylates; monocarboxylic acid anions
	alt_id:	CHEBI:13657; CHEBI:25382; CHEBI:3407
	xref:	KEGG:C00060
	cyclic_relationship:	is_conjugate_base_of CHEBI:25384

show annotations for term's descendants Sort by:
Rat (1591) Mouse (1606) Human (1661) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (8) Green Monkey (0) Naked Mole-rat (0) All
Genes (1591)

(R)-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

increases expression

Carnitine results in increased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

decreases expression
multiple interactions

Carnitine results in decreased expression of BAX protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein]

PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

gamma-butyrobetaine hydroxylase 1

multiple interactions
increases chemical synthesis

Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

BCL2, apoptosis regulator

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]

PMID:23213347 PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 3

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]
Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein]

PMID:19491382 PMID:23213347 PMID:26562095 PMID:32478940 PMID:36282381 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA]
Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein]

PMID:23213347 PMID:32478940

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA]

PMID:16889571 PMID:19294768 PMID:23213347

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cadherin 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

collagen type I alpha 1 chain

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA]

PMID:26581635 PMID:28973641

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

carnitine palmitoyltransferase 1A

multiple interactions

valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine]
[Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein]

PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions

Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome b-245 beta chain

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

fatty acid binding protein 3

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA]

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

fatty acid binding protein 9

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein]

NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873

G

follicle stimulating hormone subunit beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

glial fibrillary acidic protein

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutamic--pyruvic transaminase

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

multiple interactions

Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein]

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

heme oxygenase 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

harakiri, BCL2 interacting protein

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein]

NCBI chr12:38,387,484...38,409,652

G

heat shock protein family A (Hsp70) member 2

multiple interactions

Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein]

NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 10

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA]

PMID:26581635 PMID:33965443

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA]

PMID:26562095 PMID:26581635

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA]

PMID:26581635 PMID:33965443 PMID:37312617

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

decreases uptake
multiple interactions

INS1 protein results in decreased uptake of Carnitine
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein]

PMID:28298333 PMID:30256492

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

lactate dehydrogenase A

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein]

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

leptin receptor

affects abundance

LEPR affects the abundance of Carnitine

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

luteinizing hormone subunit beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

matrix metallopeptidase 9

multiple interactions

Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions
increases activity

[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein]

PMID:18597074 PMID:18852009

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrially encoded cytochrome c oxidase I

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA]

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA]

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

microsomal triglyceride transfer protein

multiple interactions

Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA]

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NFE2 like bZIP transcription factor 2

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 2

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA]

PMID:23213347 PMID:33965443

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression

Carnitine results in increased expression of NOS3

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

occludin

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases activity

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins]
Carnitine results in increased activity of PPARA protein

PMID:19491382 PMID:19735737

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

increases expression
multiple interactions

Carnitine results in increased expression of PPARG protein
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of PPARGC1A protein]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prostaglandin I2 synthase

increases expression
increases response to substance
multiple interactions

Carnitine results in increased expression of PTGIS mRNA
PTGIS protein results in increased susceptibility to Carnitine
[Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha

NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

sirtuin 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 22 (organic cation transporter), member 21

multiple interactions
increases uptake

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]

NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,104,122...38,130,671

G

solute carrier family 22 member 4

increases uptake

SLC22A4 protein results in increased uptake of Carnitine

PMID:21256917 PMID:33007874

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720

G

solute carrier family 22 member 5

multiple interactions
decreases expression
increases transport
increases uptake
increases expression
affects uptake
affects binding

[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin]
Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine deficiency results in increased expression of SLC22A5 mRNA
SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog
SLC22A5 protein affects the uptake of Carnitine
Carnitine binds to SLC22A5 protein

PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 More...

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 22 member 8

increases transport

SLC22A8 protein results in increased transport of Carnitine

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 25 member 20

multiple interactions
increases transport

Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

PMID:18452908 PMID:23402788

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

solute carrier family 2 member 4

increases expression
multiple interactions

Carnitine results in increased expression of SLC2A4 protein
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

snail family transcriptional repressor 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

sterol regulatory element binding transcription factor 1

multiple interactions

Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

steroidogenic acute regulatory protein

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

transforming growth factor, beta 1

multiple interactions

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA]

PMID:26562095 PMID:26581635 PMID:28973641

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

multiple interactions

Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tight junction protein 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

increases expression
multiple interactions
decreases expression

Carnitine deficiency results in increased expression of TNF mRNA
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein]
Carnitine results in decreased expression of TNF protein

PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vimentin

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

3,4-dihydroxybenzoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

endothelial PAS domain protein 1

increases expression
multiple interactions

3,4-dihydroxybenzoate results in increased expression of EPAS1 mRNA
[3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

hypoxia inducible factor 1 subunit alpha

increases expression
affects localization
multiple interactions

3,4-dihydroxybenzoate results in increased expression of HIF1A mRNA
3,4-dihydroxybenzoate affects the localization of HIF1A protein
[3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite] affects the localization of HIF1A protein
[3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heme oxygenase 1

multiple interactions
increases expression

[3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 mRNA; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 protein
3,4-dihydroxybenzoate results in increased expression of HMOX1 mRNA; 3,4-dihydroxybenzoate results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

solute carrier family 40 member 1

multiple interactions

3,4-dihydroxybenzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC40A1 protein]

NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481

G

superoxide dismutase 2

multiple interactions
increases expression

[3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SOD2 protein
3,4-dihydroxybenzoate results in increased expression of SOD2 protein

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

4-(trimethylammonio)butanoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gamma-butyrobetaine hydroxylase 1

multiple interactions

[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

6-aminohexanoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Aminocaproic Acid results in decreased expression of A2M protein

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

folate hydrolase 1

multiple interactions

[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [isospaglumic acid binds to FOLH1 protein]

NCBI chr 1:140,428,101...140,501,563
Ensembl chr 1:140,428,101...140,501,379

G

gastrin releasing peptide receptor

multiple interactions

[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [bombesin, Tyr(4)- binds to GRPR protein]

NCBI chr X:30,998,425...31,038,442
Ensembl chr X:30,998,416...31,038,442

G

mitogen activated protein kinase 1

multiple interactions

Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

plasminogen

multiple interactions

Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein]; Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786

G

serpin family C member 1

increases expression

Aminocaproic Acid results in increased expression of SERPINC1 protein

NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293

acetate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases secretion

Acetate increases secretion of Tnf protein from Kupffer cells

RGD

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Augmentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

aldo-keto reductase family 1 member B10

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

caspase 3

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cytochrome c, somatic

increases secretion

Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

fibroblast growth factor 19

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glucose-6-phosphate dehydrogenase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gamma-glutamyltransferase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic-oxaloacetic transaminase 1

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione-disulfide reductase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

malic enzyme 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

solute carrier family 10 member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 51 member A

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

solute carrier family 7 member 11

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

transketolase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

thioredoxin reductase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

benzoates

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosylhomocysteinase

decreases expression

Benzoates analog results in decreased expression of AHCY mRNA

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

aryl hydrocarbon receptor

decreases expression

Benzoates analog results in decreased expression of AHR mRNA

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

activated leukocyte cell adhesion molecule

decreases expression

Benzoates analog results in decreased expression of ALCAM mRNA

NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954

G

annexin A4

decreases expression

Benzoates analog results in decreased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

basic leucine zipper ATF-like transcription factor 3

increases expression

Benzoates analog results in increased expression of BATF3 mRNA

NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139

G

BCL2, apoptosis regulator

decreases expression

Benzoates analog results in decreased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 2

decreases expression

Benzoates analog results in decreased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

capping actin protein, gelsolin like

decreases expression

Benzoates analog results in decreased expression of CAPG mRNA

NCBI chr 4:104,594,743...104,611,856
Ensembl chr 4:104,594,753...104,611,856

G

caspase 3

increases expression
decreases expression

Benzoates analog results in increased expression of CASP3 protein modified form
Benzoates analog results in decreased expression of CASP3 mRNA

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin D2

decreases expression

Benzoates analog results in decreased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D3

decreases expression

Benzoates analog results in decreased expression of CCND3 mRNA

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin E1

decreases expression

Benzoates analog results in decreased expression of CCNE1 mRNA

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

CD44 molecule

affects expression

Benzoates analog affects the expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd48 molecule

increases expression

Benzoates analog results in increased expression of CD48 mRNA

NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142

G

Cd81 molecule

decreases expression

Benzoates analog results in decreased expression of CD81 mRNA

NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660

G

CDC42 small effector 2

decreases expression

Benzoates analog results in decreased expression of CDC42SE2 mRNA

NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059
Ensembl chr 1:38,836,555...38,905,059

G

cell division cycle 6

decreases expression

Benzoates analog results in decreased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cytokine inducible SH2-containing protein

increases expression

Benzoates analog results in increased expression of CISH mRNA

NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250

G

cytoskeleton-associated protein 4

increases expression

Benzoates analog results in increased expression of CKAP4 mRNA

NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914

G

colony stimulating factor 1

increases expression

Benzoates analog results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

cystatin F

increases expression

Benzoates analog results in increased expression of CST7 mRNA

NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557

G

cathepsin Z

increases expression

Benzoates analog results in increased expression of CTSZ mRNA

NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645

G

C-X-C motif chemokine ligand 10

increases expression

Benzoates analog results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 2

increases expression
decreases expression

Benzoates results in increased expression of CXCL2 protein
Benzoates results in decreased expression of CXCL2 protein

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytoplasmic FMR1 interacting protein 1

decreases expression

Benzoates analog results in decreased expression of CYFIP1 mRNA

NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386

G

decapping enzyme, scavenger

decreases expression

Benzoates analog results in decreased expression of DCPS mRNA

NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389

G

DENN domain containing 5A

increases expression

Benzoates analog results in increased expression of DENND5A mRNA

NCBI chr 1:163,928,183...163,994,207
Ensembl chr 1:163,928,183...163,994,316

G

dehydrogenase/reductase 3

decreases expression

Benzoates analog results in decreased expression of DHRS3 mRNA

NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417

G

extracellular matrix protein 1

decreases expression

Benzoates analog results in decreased expression of ECM1 mRNA

NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671

G

EEF1A lysine methyltransferase 1

decreases expression

Benzoates analog results in decreased expression of EEF1AKMT1 mRNA

NCBI chr15:31,694,284...31,711,367
Ensembl chr15:31,694,292...31,711,336

G

epithelial membrane protein 1

increases expression

Benzoates analog results in increased expression of EMP1 mRNA

NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904

G

estrogen receptor 1

increases activity

Benzoates results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

ETS variant transcription factor 4

decreases expression

Benzoates analog results in decreased expression of ETV4 mRNA

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

fumarylacetoacetate hydrolase

increases expression

Benzoates analog results in increased expression of FAH mRNA

NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505

G

fibrinogen-like 2

decreases expression

Benzoates analog results in decreased expression of FGL2 mRNA

NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207

G

Fms related receptor tyrosine kinase 3

increases response to substance

FLT3 protein mutant form results in increased susceptibility to Benzoates analog

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

G

GABA type A receptor associated protein like 1

increases expression

Benzoates analog results in increased expression of GABARAPL1 mRNA

NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450

G

growth arrest and DNA-damage-inducible, beta

increases expression

Benzoates analog results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

galactose mutarotase

decreases expression

Benzoates analog results in decreased expression of GALM mRNA

NCBI chr 6:14,837,540...14,889,484
Ensembl chr 6:14,837,548...14,889,310

G

guanylate binding protein 4

decreases expression

Benzoates analog results in decreased expression of GBP4 mRNA

NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879

G

growth hormone 1

multiple interactions

Benzoates analog inhibits the reaction [GH protein promotes the reaction [STAT5A protein binds to STAT5A protein]]; Benzoates analog inhibits the reaction [GH protein results in increased phosphorylation of STAT5A protein]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

glycerol-3-phosphate dehydrogenase 1

multiple interactions

[INS1 protein co-treated with Benzoates] results in increased activity of GPD1 protein

NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529

G

glutathione peroxidase 4

decreases expression

Benzoates analog results in decreased expression of GPX4 mRNA

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions

Benzoates analog binds to and results in decreased activity of GRIA1 protein

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions

Benzoates analog binds to and results in decreased activity of GRIA2 protein

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor AMPA type subunit 3

multiple interactions

Benzoates analog binds to and results in decreased activity of GRIA3 protein

NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096

G

glutamate ionotropic receptor AMPA type subunit 4

multiple interactions

Benzoates analog binds to and results in decreased activity of GRIA4 protein

NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979

G

glutamate ionotropic receptor kainate type subunit 1

multiple interactions

Benzoates analog binds to and results in decreased activity of GRIK1 protein

NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645

G

glutamate ionotropic receptor kainate type subunit 2

multiple interactions

Benzoates analog binds to and results in decreased activity of GRIK2 protein

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

glutathione S-transferase omega 1

decreases expression

Benzoates analog results in decreased expression of GSTO1 mRNA

NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468

G

hexokinase 2

decreases expression

Benzoates analog results in decreased expression of HK2 mRNA

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

interferon induced transmembrane protein 3

decreases expression

Benzoates analog results in decreased expression of IFITM3 mRNA

NCBI chr 1:196,111,026...196,112,135
Ensembl chr 1:196,111,043...196,112,203

G

interferon gamma receptor 1

increases expression

Benzoates analog results in increased expression of IFNGR1 mRNA

NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785

G

interleukin 10 receptor subunit alpha

decreases expression

Benzoates analog results in decreased expression of IL10RA mRNA

NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 1 alpha

increases expression

Benzoates results in increased expression of IL1A protein

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 2 receptor subunit beta

increases expression

Benzoates analog results in increased expression of IL2RB mRNA

NCBI chr 7:110,033,341...110,048,054
Ensembl chr 7:110,033,341...110,048,054

G

interleukin 3

multiple interactions

Benzoates analog inhibits the reaction [IL3 protein results in increased activity of STAT5A protein]

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 4 receptor

decreases expression

Benzoates analog results in decreased expression of IL4R mRNA

NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980

G

interleukin 6

multiple interactions

Benzoates analog inhibits the reaction [IL6 protein results in increased activity of STAT3 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[INS1 protein co-treated with Benzoates] results in increased activity of GPD1 protein

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

interferon regulatory factor 4

decreases expression

Benzoates analog results in decreased expression of IRF4 mRNA

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

interferon regulatory factor 8

decreases expression

Benzoates analog results in decreased expression of IRF8 mRNA

NCBI chr19:48,790,581...48,812,363
Ensembl chr19:48,790,588...48,811,829

G

integrin subunit alpha 6

decreases expression

Benzoates analog results in decreased expression of ITGA6 mRNA

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

KLF transcription factor 6

increases expression

Benzoates analog results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

LIF, interleukin 6 family cytokine

decreases expression

Benzoates analog results in decreased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

mitogen-activated protein kinase kinase kinase 8

increases expression

Benzoates analog results in increased expression of MAP3K8 mRNA

NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216

G

MAPK activated protein kinase 2

decreases expression

Benzoates analog results in decreased expression of MAPKAPK2 mRNA

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

marker of proliferation Ki-67

decreases expression

Benzoates analog results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

max dimerization protein 1

increases expression

Benzoates analog results in increased expression of MXD1 mRNA

NCBI chr 4:119,097,353...119,118,080
Ensembl chr 4:119,097,353...119,117,751

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

Benzoates analog results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin 1C

affects expression

Benzoates analog affects the expression of MYO1C mRNA

NCBI chr10:60,498,372...60,520,752
Ensembl chr10:60,498,280...60,520,752

G

nuclear receptor coactivator 3

increases expression

Benzoates analog results in increased expression of NCOA3 mRNA

NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594

G

neuronal calcium sensor 1

decreases expression

Benzoates analog results in decreased expression of NCS1 mRNA

NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829

G

N-myc downstream regulated 1

increases expression

Benzoates analog results in increased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

nuclear factor, interleukin 3 regulated

increases expression

Benzoates analog results in increased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor zeta

increases expression

Benzoates analog results in increased expression of NFKBIZ mRNA

NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723

G

NOP2 nucleolar protein

decreases expression

Benzoates analog results in decreased expression of NOP2 mRNA

NCBI chr 4:157,932,731...157,944,462
Ensembl chr 4:157,932,716...157,944,459

G

ornithine decarboxylase 1

decreases expression

Benzoates analog results in decreased expression of ODC1 mRNA

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

purinergic receptor P2X 4

increases expression

Benzoates analog results in increased expression of P2RX4 mRNA

NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253

G

prolyl 4-hydroxylase subunit alpha 1

increases expression

Benzoates analog results in increased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

poly (ADP-ribose) polymerase 1

increases cleavage

Benzoates analog results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

platelet derived growth factor receptor beta

decreases expression

Benzoates analog results in decreased expression of PDGFRB protein

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

pleckstrin homology-like domain, family A, member 1

decreases expression

Benzoates analog results in decreased expression of PHLDA1 mRNA

NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861

G

putative homeodomain transcription factor 2

decreases expression

Benzoates analog results in decreased expression of PHTF2 mRNA

NCBI chr 4:14,215,190...14,330,549
Ensembl chr 4:14,215,263...14,330,513

G

Pim-1 proto-oncogene, serine/threonine kinase

decreases expression

Benzoates analog results in decreased expression of PIM1 mRNA

NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174

G

perilipin 2

increases expression

Benzoates analog results in increased expression of PLIN2 mRNA

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

phospholipid scramblase 1

increases expression

Benzoates analog results in increased expression of PLSCR1 mRNA

NCBI chr 8:92,784,279...92,804,698
Ensembl chr 8:92,784,356...92,804,692

G

purine nucleoside phosphorylase

decreases expression

Benzoates analog results in decreased expression of PNP mRNA

NCBI chr15:24,170,607...24,178,269
Ensembl chr15:24,170,602...24,203,986

G

prion protein

increases expression

Benzoates analog results in increased expression of PRNP mRNA

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

patched 1

increases expression

Benzoates analog results in increased expression of PTCH1 mRNA

NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333

G

peptidyl-tRNA hydrolase 2

decreases expression

Benzoates analog results in decreased expression of PTRH2 mRNA

NCBI chr10:71,505,113...71,515,297
Ensembl chr10:71,504,956...71,515,398

G

pseudouridine synthase 1

decreases expression

Benzoates analog results in decreased expression of PUS1 mRNA

NCBI chr12:45,880,364...45,889,196
Ensembl chr12:45,880,440...45,889,196

G

RAB GTPase activating protein 1-like

increases expression

Benzoates analog results in increased expression of RABGAP1L mRNA

NCBI chr13:72,464,114...73,059,845
Ensembl chr13:72,468,110...73,059,984

G

regulator of G-protein signaling 16

affects expression

Benzoates analog affects the expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

ras homolog family member H

increases expression

Benzoates analog results in increased expression of RHOH mRNA

NCBI chr14:42,341,135...42,371,971
Ensembl chr14:42,337,751...42,386,369

G

Ras-related GTP binding D

increases expression

Benzoates analog results in increased expression of RRAGD mRNA

NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356

G

SH3 domain binding glutamate-rich protein like 2

increases expression

Benzoates analog results in increased expression of SH3BGRL2 mRNA

NCBI chr 8:84,461,019...84,553,124
Ensembl chr 8:84,461,121...84,551,564

G

solute carrier family 1 member 5

increases expression

Benzoates analog results in increased expression of SLC1A5 mRNA

NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952

G

solute carrier family 2 member 3

increases expression

Benzoates analog results in increased expression of SLC2A3 mRNA

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

solute carrier family 39 member 8

decreases expression

Benzoates analog results in decreased expression of SLC39A8 mRNA

NCBI chr 2:224,171,787...224,319,326
Ensembl chr 2:224,256,654...224,319,129

G

sphingomyelin phosphodiesterase, acid-like 3A

increases expression

Benzoates analog results in increased expression of SMPDL3A mRNA

NCBI chr20:37,132,592...37,155,567
Ensembl chr20:37,132,592...37,155,567

G

sorting nexin 9

increases expression

Benzoates analog results in increased expression of SNX9 mRNA

NCBI chr 1:46,424,897...46,510,096
Ensembl chr 1:46,423,553...46,509,036

G

suppressor of cytokine signaling 2

increases expression

Benzoates analog results in increased expression of SOCS2 mRNA

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

sprouty-related, EVH1 domain containing 2

decreases expression

Benzoates analog results in decreased expression of SPRED2 mRNA

NCBI chr14:94,149,210...94,250,787
Ensembl chr14:94,148,837...94,249,162

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 4

affects expression

Benzoates analog affects the expression of ST3GAL4 mRNA

NCBI chr 8:33,415,666...33,465,319
Ensembl chr 8:33,415,671...33,524,389

G

signal transducer and activator of transcription 3

multiple interactions

Benzoates analog inhibits the reaction [IL6 protein results in increased activity of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 5A

decreases phosphorylation
multiple interactions

Benzoates analog results in decreased phosphorylation of STAT5A protein
Benzoates analog inhibits the reaction [GH protein promotes the reaction [STAT5A protein binds to STAT5A protein]]; Benzoates analog inhibits the reaction [GH protein results in increased phosphorylation of STAT5A protein]; Benzoates analog inhibits the reaction [IL3 protein results in increased activity of STAT5A protein]

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

signal transducer and activator of transcription 5B

multiple interactions

Benzoates analog binds to and results in decreased phosphorylation of STAT5B protein

NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668

G

switching B-cell complex subunit SWAP70

increases expression

Benzoates analog results in increased expression of SWAP70 mRNA

NCBI chr 1:164,267,588...164,328,796
Ensembl chr 1:164,267,609...164,328,794

G

synaptotagmin 11

increases expression

Benzoates analog results in increased expression of SYT11 mRNA

NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964

G

transglutaminase 2

decreases expression

Benzoates analog results in decreased expression of TGM2 mRNA

NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981

G

TIAM Rac1 associated GEF 1

decreases expression

Benzoates analog results in decreased expression of TIAM1 mRNA

NCBI chr11:29,031,347...29,380,153
Ensembl chr11:29,031,348...29,159,901

G

TNF receptor superfamily member 1B

decreases expression

Benzoates analog results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

TNF receptor superfamily member 21

decreases expression

Benzoates analog results in decreased expression of TNFRSF21 mRNA

NCBI chr 9:17,879,156...17,954,085
Ensembl chr 9:17,879,156...17,954,085

G

TNF receptor-associated factor 1

increases expression

Benzoates analog results in increased expression of TRAF1 mRNA

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

tetratricopeptide repeat domain 39B

increases expression

Benzoates analog results in increased expression of TTC39B mRNA

NCBI chr 5:97,603,329...97,708,103
Ensembl chr 5:97,609,392...97,736,270

G

uridine-cytidine kinase 2

decreases expression

Benzoates analog results in decreased expression of UCK2 mRNA

NCBI chr13:79,380,807...79,438,121
Ensembl chr13:79,383,846...79,438,352

G

uridine monophosphate synthetase

decreases expression

Benzoates analog results in decreased expression of UMPS mRNA

NCBI chr11:66,806,107...66,816,520
Ensembl chr11:66,806,045...66,821,903

G

X-box binding protein 1

increases expression

Benzoates analog results in increased expression of XBP1 mRNA

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

CAR(3:0(Me2))

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 5

affects binding
increases uptake
multiple interactions
increases transport

pivaloylcarnitine binds to SLC22A5 protein
SLC22A5 protein results in increased uptake of pivaloylcarnitine
Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]

PMID:18762717 PMID:19539806

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase beta

decreases expression

L-carnitine decreases expression of Acacb mRNA and protein in rat heart

RGD

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

carnitine palmitoyltransferase 1A

increases expression
multiple interactions

L-carnitine increases expression of Cpt1a mRNA and protein in rat heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

malonyl-CoA decarboxylase

increases expression
multiple interactions

L-carnitine increases expression of Mlycd protein in rat heart
L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression
multiple interactions

L-carnitine increases expression of Ampka2 protein in rat serum and heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

chlorhexidine gluconate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamic--pyruvic transaminase

increases secretion

chlorhexidine gluconate results in increased secretion of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

cholate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

multiple interactions

[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of A2M mRNA; [cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of A2M protein

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily B member 11

increases expression
decreases activity
multiple interactions

Cholates results in increased expression of ABCB11 mRNA
Cholates results in decreased activity of ABCB11 protein
Cholates inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

PMID:14684751 PMID:24014644

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 3

increases activity

Cholates results in increased activity of ABCC3 protein

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 5

multiple interactions
increases expression

Cholates promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]
Cholates results in increased expression of ABCG5 mRNA; Cholates results in increased expression of ABCG5 protein

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

multiple interactions
increases expression

Cholates promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol]
Cholates results in increased expression of ABCG8 mRNA; Cholates results in increased expression of ABCG8 protein

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

collagen type I alpha 1 chain

multiple interactions

[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of COL1A1 mRNA; resveratrol inhibits the reaction [[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Cholates results in decreased expression of CYP7A1 mRNA

PMID:10809780 PMID:14684751

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

mitogen-activated protein kinase 8

increases phosphorylation

Cholates results in increased phosphorylation of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

nuclear receptor subfamily 1, group H, member 4

increases activity
increases expression

Cholates results in increased activity of NR1H4 protein
Cholates results in increased expression of NR1H4 protein

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

PPARG coactivator 1 alpha

multiple interactions

[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

solute carrier family 19 member 1

decreases activity
multiple interactions

Cholates results in decreased activity of SLC19A1 protein
Cholates inhibits the reaction [SLC19A1 protein affects the transport of Methotrexate]

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

solute carrier family 22 member 8

multiple interactions

Cholates inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

sterol regulatory element binding transcription factor 1

multiple interactions

[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

transforming growth factor, beta 1

multiple interactions

[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of TNFAIP3 protein; resveratrol inhibits the reaction [[cocoa butter co-treated with Cholesterol, Dietary co-treated with Cholates] results in increased expression of TNFAIP3 protein]

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

eosin YS dye

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodotyrosine deiodinase

multiple interactions

Eosine Yellowish-(YS) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

erythrosin B

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

Erythrosine results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

caspase 9

multiple interactions

[Tartrazine co-treated with Erythrosine] affects the expression of CASP9 mRNA

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin D1

increases expression

Erythrosine results in increased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin dependent kinase 2

increases activity

Erythrosine results in increased activity of CDK2 protein

PMID:8927716 PMID:9168006

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

Erythrosine results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

Erythrosine results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Erythrosine results in increased expression of FOSL1 protein

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

glutathione S-transferase pi 1

multiple interactions

Erythrosine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

hepatitis A virus cellular receptor 1

multiple interactions

[Tartrazine co-treated with Erythrosine] affects the expression of HAVCR1 mRNA

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

hematopoietic prostaglandin D synthase

decreases activity

Erythrosine results in decreased activity of HPGDS protein

NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883

G

iodotyrosine deiodinase

decreases activity

Erythrosine results in decreased activity of IYD protein

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Erythrosine results in increased expression of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

orosomucoid 1

increases expression

Erythrosine results in increased expression of ORM1 protein

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

phosphate regulating endopeptidase X-linked

increases expression

Erythrosine results in increased expression of PHEX protein

NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469

G

tumor necrosis factor

multiple interactions

[Tartrazine co-treated with Erythrosine] results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases activity

Erythrosine results in increased activity of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thyrotropin releasing hormone

multiple interactions

Erythrosine promotes the reaction [TRH protein results in increased expression of TSHB protein]

NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637

G

thyroid stimulating hormone subunit beta

multiple interactions

Erythrosine promotes the reaction [TRH protein results in increased expression of TSHB protein]

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

UDP glucuronosyltransferase family 1 member A6

decreases activity

Erythrosine results in decreased activity of UGT1A6 protein

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

decreases activity

Erythrosine results in decreased activity of UGT2B7 protein

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

G

vascular endothelial growth factor A

increases expression

Erythrosine results in increased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

GGTI-2133

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

GGTI-2133 inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

mitogen activated protein kinase 1

multiple interactions

GGTI-2133 inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

GGTI-2133 inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions

GGTI-2133 inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]; GGTI-2133 inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

RAP1A, member of RAS oncogene family

decreases geranoylation

GGTI-2133 results in decreased geranoylation of RAP1A protein

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

glycyrrhetinate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein]

PMID:16904803 PMID:18204840 PMID:24380838

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB4 mRNA]

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 1

multiple interactions
increases activity

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA]
Glycyrrhetinic Acid results in increased activity of ABCC1 protein
[Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which results in increased abundance of fluorexon

PMID:18204840 PMID:28549656

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [ABCC2 protein results in increased transport of estradiol-17 beta-glucuronide]

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA]

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 2

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCG5 mRNA]

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

acetyl-CoA acetyltransferase 2

multiple interactions

18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA]

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

actin alpha 2, smooth muscle

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Monocrotaline results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aldo-keto reductase family 1, member C1

decreases activity

Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

decreases activity

Glycyrrhetinic Acid results in decreased activity of AKR1C2 protein

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

affects activity
decreases activity

18alpha-glycyrrhetinic acid affects the activity of AKR1C3 protein
Glycyrrhetinic Acid results in decreased activity of AKR1C3 protein

PMID:11165023 PMID:12604236

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

albumin

multiple interactions

ALB protein binds to and affects the transport of Glycyrrhetinic Acid

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, biomineralization associated

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

activating transcription factor 6

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ATF6 mRNA]

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATPase phospholipid transporting 8B1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ATP8B1 mRNA]

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

BCL2 associated X, apoptosis regulator

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein]
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein]

PMID:28414158 PMID:31325423 PMID:35699857

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein]

PMID:28414158 PMID:31325423 PMID:35699857

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone gamma-carboxyglutamate protein

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

bone morphogenetic protein 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

caspase 3

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of CASP3]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

collagen type I alpha 1 chain

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

colony stimulating factor 2

multiple interactions

Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of EIF2AK3 mRNA]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein]
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA]

PMID:29444456 PMID:35699857

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

gamma-glutamyltransferase 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GGT1 protein]

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic--pyruvic transaminase

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein]
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein]

PMID:28414158 PMID:28549656 PMID:36807597

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 2

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of GPX2 mRNA]

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

heme oxygenase 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HRas proto-oncogene, GTPase

decreases expression

Glycyrrhetinic Acid results in decreased expression of HRAS protein

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

hydroxysteroid 11-beta dehydrogenase 1

decreases activity

18alpha-glycyrrhetinic acid results in decreased activity of HSD11B1 protein

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

hydroxysteroid 11-beta dehydrogenase 2

decreases activity
multiple interactions

18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein
Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein]

PMID:24135201 PMID:31927052

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

[Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

heat shock protein family A (Hsp70) member 5

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of HSPA5 mRNA]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 1 beta

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein]
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA]

PMID:10460758 PMID:23373965 PMID:28414158

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]

PMID:21644799 PMID:23373965 PMID:24849676

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin-1 receptor-associated kinase 1

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

interleukin-1 receptor-associated kinase 3

increases expression
multiple interactions

Glycyrrhetinic Acid results in increased expression of IRAK3 protein
[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]]

NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121

G

lymphocyte antigen 96

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of MAP3K5 protein]

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

mitogen activated protein kinase 1

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

microsomal triglyceride transfer protein

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA]

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]
[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein]

PMID:23341968 PMID:28414158

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein]

PMID:23373965 PMID:24613819 PMID:28213090

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]

PMID:21644799 PMID:23373965

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA]

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

platelet derived growth factor subunit B

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

decreases activity

18alpha-glycyrrhetinic acid results in decreased activity of PIK3CD protein

NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma

decreases activity

18alpha-glycyrrhetinic acid results in decreased activity of PIK3CG protein

NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043

G

peroxisome proliferator-activated receptor gamma

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

prostaglandin-endoperoxide synthase 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]

PMID:23373965 PMID:24613819

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin

decreases activity

Glycyrrhetinic Acid results in decreased activity of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

ras homolog family member A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein]

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

Rho-associated coiled-coil containing protein kinase 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein]

NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein]

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

RUNX family transcription factor 2

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

SLC51 subunit beta

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA]

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier organic anion transporter family, member 1a4

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA]

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

superoxide dismutase 3

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD3 mRNA]

NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990

G

Sp7 transcription factor

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]

NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847

G

toll-like receptor 4

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]]
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein]
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]

PMID:21644799 PMID:24613819 PMID:28213090 PMID:28414158

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor associated factor 6

multiple interactions

Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]]

NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507

G

vascular endothelial growth factor A

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

X-box binding protein 1

multiple interactions

18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of XBP1 protein alternative form]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

ketorolac tromethamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aralkylamine N-acetyltransferase

multiple interactions

Ketorolac Tromethamine results in decreased localization of and results in decreased activity of AANAT protein

NCBI chr10:101,827,072...101,831,805
Ensembl chr10:101,827,301...101,831,801

G

catalase

multiple interactions
increases activity

Melatonin inhibits the reaction [Ketorolac Tromethamine results in increased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

epiregulin

increases expression

Ketorolac Tromethamine results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

glutathione peroxidase 1

decreases activity

Ketorolac Tromethamine results in decreased activity of GPX1 protein

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

increases activity

Ketorolac Tromethamine results in increased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

interleukin 24

increases expression

Ketorolac Tromethamine results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

monoamine oxidase A

multiple interactions
increases activity

Melatonin inhibits the reaction [Ketorolac Tromethamine results in increased activity of MAOA protein]

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

melatonin receptor 1A

increases localization

Ketorolac Tromethamine results in increased localization of MTNR1A protein

NCBI chr16:47,144,461...47,163,919
Ensembl chr16:47,144,461...47,163,919

G

prostaglandin-endoperoxide synthase 2

increases expression

Ketorolac Tromethamine results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

secretory leukocyte peptidase inhibitor

increases expression

Ketorolac Tromethamine results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

superoxide dismutase 1

decreases activity

Ketorolac Tromethamine results in decreased activity of SOD1 protein

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

decreases activity

Ketorolac Tromethamine results in decreased activity of SOD2 protein

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

lead tetraacetate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein

decreases expression

lead tetraacetate results in decreased expression of APP mRNA

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

microtubule-associated protein tau

decreases expression

lead tetraacetate results in decreased expression of MAPT mRNA

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

neurexin 1

decreases expression

lead tetraacetate results in decreased expression of NRXN1 mRNA

NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710

G

prion protein

decreases expression

lead tetraacetate results in decreased expression of PRNP mRNA

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

synaptophysin

decreases expression

lead tetraacetate results in decreased expression of SYP mRNA

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

tubulin, beta 3 class III

decreases expression

lead tetraacetate results in decreased expression of TUBB3 mRNA

NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243

lobaplatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

baculoviral IAP repeat-containing 2

increases degradation

Lobaplatin increases degradation of BIRC2 protein in human nasopharyngeal carcinoma cells

RGD

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

increases degradation

Lobaplatin increases degradation of BIRC3 protein in human nasopharyngeal carcinoma cells

RGD

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

meglumine amidotrizoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases expression

Diatrizoate Meglumine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression
decreases expression
multiple interactions

Diatrizoate Meglumine results in increased expression of BCL2 protein
Diatrizoate Meglumine results in decreased expression of BCL2 mRNA
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in decreased expression of BCL2 mRNA]

PMID:17173243 PMID:28412091

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 12

increases cleavage

Diatrizoate Meglumine results in increased cleavage of CASP12 protein

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

increases activity
increases expression
multiple interactions

Diatrizoate Meglumine results in increased activity of CASP3 protein
Diatrizoate Meglumine results in increased expression of CASP3 mRNA
[Diatrizoate Meglumine co-treated with Gentamicins] results in increased cleavage of CASP3 protein; [sulforaphane co-treated with Diatrizoate Meglumine] results in increased activity of CASP3 protein; CTF1 protein inhibits the reaction [[Diatrizoate Meglumine co-treated with Gentamicins] results in increased cleavage of CASP3 protein]; Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of CASP3 mRNA]; NFE2L2 protein affects the reaction [[sulforaphane co-treated with Diatrizoate Meglumine] results in increased activity of CASP3 protein]

PMID:17173243 PMID:23335628 PMID:28412091 PMID:31173751

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cardiotrophin 1

multiple interactions

CTF1 protein inhibits the reaction [[Diatrizoate Meglumine co-treated with Gentamicins] results in increased cleavage of CASP3 protein]; CTF1 protein inhibits the reaction [[Diatrizoate Meglumine co-treated with Gentamicins] results in increased expression of HAVCR1 protein]; CTF1 protein inhibits the reaction [[Diatrizoate Meglumine co-treated with Gentamicins] results in increased expression of SERPINE1 protein]

NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335

G

eukaryotic translation initiation factor 2A

increases phosphorylation

Diatrizoate Meglumine results in increased phosphorylation of EIF2A protein

NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation

Diatrizoate Meglumine results in increased phosphorylation of EIF2AK3 protein

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

glutathione S-transferase alpha 2

increases expression

Diatrizoate Meglumine results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

hepatitis A virus cellular receptor 1

multiple interactions

[Diatrizoate Meglumine co-treated with Gentamicins] results in increased expression of HAVCR1 protein; CTF1 protein inhibits the reaction [[Diatrizoate Meglumine co-treated with Gentamicins] results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

heme oxygenase 1

increases expression
decreases expression
multiple interactions

Diatrizoate Meglumine results in increased expression of HMOX1 mRNA
Diatrizoate Meglumine results in decreased expression of HMOX1 protein
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of HMOX1 mRNA]

PMID:28412091 PMID:31173751

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein 90 beta family member 1

increases expression

Diatrizoate Meglumine results in increased expression of HSP90B1 protein

NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788

G

heat shock protein family A (Hsp70) member 5

increases expression

Diatrizoate Meglumine results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 6

multiple interactions
increases expression

Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [sulforaphane inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 protein]]; sulforaphane inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 protein]
Diatrizoate Meglumine results in increased expression of IL6 mRNA; Diatrizoate Meglumine results in increased expression of IL6 protein

PMID:28412091 PMID:31173751

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression
increases expression

Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of NFE2L2 mRNA]; NFE2L2 protein affects the reaction [[sulforaphane co-treated with Diatrizoate Meglumine] results in increased activity of CASP3 protein]; NFE2L2 protein affects the reaction [sulforaphane inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 protein]]
Diatrizoate Meglumine results in decreased expression of NFE2L2 protein

PMID:28412091 PMID:31173751

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

serpin family E member 1

multiple interactions

[Diatrizoate Meglumine co-treated with Gentamicins] results in increased expression of SERPINE1 protein; CTF1 protein inhibits the reaction [[Diatrizoate Meglumine co-treated with Gentamicins] results in increased expression of SERPINE1 protein]

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

tumor protein p53

increases expression
multiple interactions

Diatrizoate Meglumine results in increased expression of TP53 mRNA
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of TP53 mRNA]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

merbromin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbonic anhydrase 2

decreases activity

Merbromin results in decreased activity of CA2 protein

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

glutathione S-transferase pi 1

multiple interactions

Merbromin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

N-methylnicotinate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

angiotensinogen

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

autophagy related 7

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

BCL2 associated X, apoptosis regulator

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]
[trigonelline co-treated with Cisplatin] results in increased expression of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein

PMID:31935362 PMID:33148531

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]
[trigonelline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein

PMID:31935362 PMID:33148531

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

beclin 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in decreased expression of BECN1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

caspase 3

increases activity
multiple interactions

trigonelline results in increased activity of CASP3 protein
[trigonelline co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]

PMID:26593444 PMID:31935362 PMID:33148531

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CD36 molecule

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of CD36 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of CD36 protein]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

DNA-damage inducible transcript 3

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

epidermal growth factor

multiple interactions

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
trigonelline results in decreased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

ferritin heavy chain 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTH1 mRNA

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTL mRNA

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

hexosaminidase subunit beta

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased secretion of HEXB protein]

NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223

G

heme oxygenase 1

decreases expression

trigonelline results in decreased expression of HMOX1 mRNA; trigonelline results in decreased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 1 beta

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]; trigonelline inhibits the reaction [INS2 protein affects the abundance of angiotensin I (1-7)]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

Kelch-like ECH-associated protein 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in decreased expression of KEAP1 mRNA

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

leptin receptor

affects abundance

LEPR affects the abundance of trigonelline

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
trigonelline results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
trigonelline results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

mechanistic target of rapamycin kinase

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

trigonelline results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]; trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Cisplatin]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]; trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]
trigonelline results in decreased phosphorylation of NFE2L2 protein

PMID:24015256 PMID:29211853 PMID:29959986 PMID:33148531

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
decreases expression

trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]
trigonelline results in decreased expression of NQO1 mRNA; trigonelline results in decreased expression of NQO1 protein

PMID:24015256 PMID:29959986 PMID:33148531

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

poly (ADP-ribose) polymerase 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased cleavage of PARP1 protein]
[trigonelline co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein

PMID:30208301 PMID:33148531

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phospholipase C, gamma 1

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased phosphorylation of PLCG1 protein]

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

perilipin 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PLIN1 protein]

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of PPARG protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

sequestosome 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SQSTM1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

tumor necrosis factor

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

O-acetyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

apurinic/apyrimidinic endodeoxyribonuclease 1

increases expression

Acetylcarnitine results in increased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

ATPase H+ transporting V1 subunit F

increases expression

Acetylcarnitine results in increased expression of ATP6V1F mRNA

NCBI chr 4:58,067,666...58,070,628

G

complement C1q A chain

decreases expression

Acetylcarnitine results in decreased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C4B

decreases expression

Acetylcarnitine results in decreased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

caspase 3

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA]

PMID:20067779 PMID:29278859

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA]

PMID:20067779 PMID:26349760 PMID:29278859

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Acetylcarnitine

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

citrate synthase

decreases activity

Acetylcarnitine results in decreased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

cathepsin S

decreases expression

Acetylcarnitine results in decreased expression of CTSS mRNA

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

C-X-C motif chemokine ligand 14

decreases expression

Acetylcarnitine results in decreased expression of CXCL14 mRNA

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

early growth response 1

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of EGR1 mRNA]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

glial fibrillary acidic protein

decreases expression

Acetylcarnitine results in decreased expression of GFAP mRNA

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutathione-disulfide reductase

multiple interactions

Acetylcarnitine inhibits the reaction [Acetaminophen results in decreased expression of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase pi 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

heme oxygenase 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA]

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

heat shock protein family B (small) member 1

decreases expression

Acetylcarnitine results in decreased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of Acetylcarnitine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 1 beta

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

microsomal glutathione S-transferase 1

increases expression

Acetylcarnitine results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

mitochondrially encoded cytochrome c oxidase I

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of COX1 mRNA]

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

nerve growth factor

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in decreased expression of NGF protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

phenylalanine hydroxylase

decreases expression

Acetylcarnitine results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

PTEN induced kinase 1

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PINK1]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Acetylcarnitine results in increased expression of PPARGC1A protein
[Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PRKN]

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

proteasome 20S subunit beta 6

increases expression

Acetylcarnitine results in increased expression of PSMB6 mRNA

NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586

G

prothymosin alpha

increases expression

Acetylcarnitine results in increased expression of PTMA mRNA

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S17

increases expression

Acetylcarnitine results in increased expression of RPS17 mRNA

NCBI chr 1:135,295,920...135,298,506
Ensembl chr 1:135,295,919...135,298,535
Ensembl chr 8:135,295,919...135,298,535

G

src kinase associated phosphoprotein 2

decreases expression

Acetylcarnitine results in decreased expression of SKAP2 mRNA

NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891

G

solute carrier family 25 member 20

multiple interactions

Acetylcarnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

synuclein alpha

multiple interactions

[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

troponin I3, cardiac type

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein]

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

O-butanoyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of butyrylcarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

O-octanoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carnitine O-octanoyltransferase

increases chemical synthesis

CROT protein results in increased chemical synthesis of octanoylcarnitine

NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109

O-palmitoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Palmitoylcarnitine

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

glutaminase

increases chemical synthesis

GLS protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

protein phosphatase 3, regulatory subunit B, alpha

decreases metabolic processing

PPP3R1 gene mutant form results in decreased metabolism of Palmitoylcarnitine

NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907

G

protein kinase AMP-activated catalytic subunit alpha 1

increases chemical synthesis

PRKAA1 protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

palmitoyl-CoA

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 1

increases metabolic processing
multiple interactions

ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A
[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

carboxylesterase 1D

increases hydrolysis

CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carnitine palmitoyltransferase 1A

multiple interactions

valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A]

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

diacylglycerol O-acyltransferase 1

multiple interactions

DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A]

NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299

G

glutathione S-transferase alpha 1

multiple interactions

Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

hepatocyte nuclear factor 4, alpha

decreases expression

Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

peroxisome proliferator activated receptor alpha

multiple interactions

Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein
Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]

PMID:11139385 PMID:18812576

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions

Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

sex hormone binding globulin

decreases expression

Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein

NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057

phosphoenolpyruvate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein

multiple interactions
increases secretion

Phosphoenolpyruvate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]
Phosphoenolpyruvate results in increased secretion of APP protein modified form

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

pyruvate kinase M1/2

multiple interactions
increases metabolic processing

3-hydroxyflavone inhibits the reaction [PKM protein results in increased metabolism of Phosphoenolpyruvate]; 5-hydroxyflavone inhibits the reaction [PKM protein results in increased metabolism of Phosphoenolpyruvate]; 6-hydroxyflavone inhibits the reaction [PKM protein results in increased metabolism of Phosphoenolpyruvate]; 7-hydroxyflavone inhibits the reaction [PKM protein results in increased metabolism of Phosphoenolpyruvate]; Apigenin inhibits the reaction [PKM protein results in increased metabolism of Phosphoenolpyruvate]; flavone inhibits the reaction [PKM protein results in increased metabolism of Phosphoenolpyruvate]; wogonin inhibits the reaction [PKM protein results in increased metabolism of Phosphoenolpyruvate]

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

physostigmine salicylate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

physostigmine salicylate results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

pitavastatin(1-)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

GW 6471 inhibits the reaction [pitavastatin results in increased expression of ABCA1 mRNA]
pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]
GW 6471 inhibits the reaction [pitavastatin results in increased expression of ABCA1 mRNA]; PPARA protein affects the reaction [pitavastatin results in increased expression of ABCA1 mRNA]

PMID:16415093 PMID:21554872

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
pitavastatin results in decreased activity of ABCB11 protein

PMID:15901796 PMID:24014644

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

affects transport

ABCB1 protein affects the transport of pitavastatin

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 2

multiple interactions
affects transport

ABCC2 protein binds to and results in increased uptake of pitavastatin analog; pitavastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]
ABCC2 protein affects the transport of pitavastatin

PMID:15955871 PMID:23562342

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily G member 2

affects transport

ABCG2 protein affects the transport of pitavastatin

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

activating transcription factor 4

multiple interactions
increases expression

EIF2AK3 protein affects the reaction [pitavastatin results in increased expression of ATF4 protein]

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

Bcl-2 binding component 3

multiple interactions
increases expression
affects response to substance

BBC3 protein affects the susceptibility to [S63845 co-treated with pitavastatin]; BBC3 protein affects the susceptibility to [venetoclax co-treated with pitavastatin]
pitavastatin results in increased expression of BBC3 mRNA; pitavastatin results in increased expression of BBC3 protein
BBC3 protein affects the susceptibility to pitavastatin

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

C-C motif chemokine ligand 2

multiple interactions

pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

EIF2AK3 protein affects the reaction [pitavastatin results in increased expression of ATF4 protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

forkhead box O1

decreases phosphorylation

pitavastatin results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

interferon beta 1

multiple interactions

pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]

NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523

G

interleukin 6

multiple interactions

pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; pitavastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interferon regulatory factor 3

multiple interactions

pitavastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein]; pitavastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein]

NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935

G

interferon regulatory factor 4

decreases expression

pitavastatin results in decreased expression of IRF4 protein

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

leptin

multiple interactions

pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

myostatin

increases expression

pitavastatin results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

nitric oxide synthase 2

multiple interactions

pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; pitavastatin inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions

NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H2 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol]

NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H3 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol]

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

poly (ADP-ribose) polymerase 1

increases cleavage

pitavastatin results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions
increases expression

2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [pitavastatin results in increased expression of PMAIP1 protein]

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

paraoxonase 1

multiple interactions
increases expression

farnesyl pyrophosphate inhibits the reaction [pitavastatin results in increased expression of PON1 mRNA]; Mevalonic Acid inhibits the reaction [pitavastatin results in increased expression of PON1 mRNA]; Plicamycin inhibits the reaction [pitavastatin results in increased expression of PON1 mRNA]

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases expression

pitavastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]; PPARA protein affects the reaction [pitavastatin results in increased expression of ABCA1 mRNA]
pitavastatin results in increased expression of PPARA mRNA

PMID:11779144 PMID:21554872

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

increases expression

pitavastatin results in increased expression of PPARD mRNA

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

RAP1A, member of RAS oncogene family

decreases prenylation
decreases expression

pitavastatin results in decreased prenylation of RAP1A protein
pitavastatin results in decreased expression of RAP1A protein alternative form

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

retinoid X receptor alpha

multiple interactions

pitavastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

solute carrier organic anion transporter family, member 1a4

affects transport

SLCO1A4 protein affects the transport of pitavastatin

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

signal transducer and activator of transcription 1

multiple interactions

pitavastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

tumor necrosis factor

multiple interactions

pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

rose bengal

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

Rose Bengal results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

Rose Bengal results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

Rose Bengal results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

glutathione S-transferase alpha 3

decreases response to substance

GSTA3 protein results in decreased susceptibility to Rose Bengal

NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240

G

iodotyrosine deiodinase

decreases activity

Rose Bengal results in decreased activity of IYD protein

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Rose Bengal results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

kallikrein B1

multiple interactions
decreases response to substance

7-Ala-angiotensin (1-7) inhibits the reaction [KLKB1 gene mutant form results in decreased susceptibility to Rose Bengal]; nimesulide inhibits the reaction [KLKB1 gene mutant form results in decreased susceptibility to Rose Bengal]; splitomicin inhibits the reaction [KLKB1 gene mutant form results in decreased susceptibility to Rose Bengal]

NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053

G

UDP glucuronosyltransferase family 1 member A6

decreases activity

Rose Bengal results in decreased activity of UGT1A6 protein

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

rosuvastatin calcium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

decreases expression
multiple interactions

Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions

Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]
[Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium

PMID:15901796 PMID:19853032

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

multiple interactions
increases expression
affects secretion

ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]
Rosuvastatin Calcium results in increased expression of ABCC2 protein
[Benzbromarone results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Probenecid results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Sulfasalazine results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Rosuvastatin Calcium promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein]
ABCC2 protein affects the secretion of Rosuvastatin Calcium

PMID:19853032 PMID:23562342 PMID:24909372

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Rosuvastatin Calcium results in increased expression of ABCC3 protein

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 1

decreases expression

Rosuvastatin Calcium results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

multiple interactions
increases activity

[Novobiocin results in decreased activity of ABCG2 protein] which results in decreased secretion of Rosuvastatin Calcium
Rosuvastatin Calcium results in increased activity of ABCG2 protein

PMID:19853032 PMID:30083819

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acetylcholinesterase

multiple interactions

[Piracetam co-treated with Rosuvastatin Calcium] inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein]; Rosuvastatin Calcium inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

AKT serine/threonine kinase 1

affects phosphorylation

Rosuvastatin Calcium affects the phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apolipoprotein A1

multiple interactions
increases expression

Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein]

PMID:12767421 PMID:15539964

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein B

decreases expression

Rosuvastatin Calcium results in decreased expression of APOB protein

PMID:15539964 PMID:18702965

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

BCL2 associated X, apoptosis regulator

multiple interactions

Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Rosuvastatin Calcium results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

complement C3

decreases expression

Rosuvastatin Calcium results in decreased expression of C3 mRNA

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

caspase 3

increases activity
increases expression

Rosuvastatin Calcium results in increased activity of CASP3 protein
Rosuvastatin Calcium results in increased expression of CASP3 protein

PMID:21478229 PMID:32771489

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

increases activity
multiple interactions

Rosuvastatin Calcium results in increased activity of CAT protein
[Rosuvastatin Calcium co-treated with Isoproterenol] inhibits the reaction [Interleukin-6 results in increased expression of CAT protein]; Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]

PMID:20146376 PMID:32007421 PMID:35130744

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

decreases expression

Rosuvastatin Calcium results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cAMP responsive element binding protein 5

decreases expression

Rosuvastatin Calcium results in decreased expression of CREB5 mRNA

NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325

G

C-reactive protein

multiple interactions

Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3]

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cytochrome b-245 alpha chain

multiple interactions
decreases expression

[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome b-245 beta chain

multiple interactions
decreases expression

Rosuvastatin Calcium inhibits the reaction [Nitroglycerin results in increased expression of CYBB mRNA]
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species

PMID:16633368 PMID:21562509

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

estrogen receptor 1

decreases expression

Rosuvastatin Calcium results in decreased expression of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Rosuvastatin Calcium results in increased expression of GCLC mRNA
[Tetradecanoylphorbol Acetate co-treated with Rosuvastatin Calcium] results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

G protein-coupled receptor 183

multiple interactions
increases expression

Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GPR183 mRNA]

NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559

G

granzyme K

multiple interactions
increases expression

Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GZMK mRNA]

NCBI chr 2:44,840,811...44,848,829
Ensembl chr 2:44,840,811...44,848,894

G

hepatocyte nuclear factor 4, alpha

increases secretion

HNF4A protein results in increased secretion of Rosuvastatin Calcium

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

interleukin 18 receptor accessory protein

decreases expression
multiple interactions

Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA]

NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959

G

interleukin 1 beta

decreases expression

Rosuvastatin Calcium results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Rosuvastatin Calcium results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 15

decreases expression

Rosuvastatin Calcium results in decreased expression of KCNJ15 mRNA

NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952

G

kinase insert domain receptor

multiple interactions

Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of KDR protein]

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

myoglobin

affects expression

Rosuvastatin Calcium affects the expression of MB protein

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

myostatin

increases expression

Rosuvastatin Calcium results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

NFE2 like bZIP transcription factor 2

multiple interactions

Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased expression of NFE2L2 mRNA]

PMID:32007421 PMID:35130744

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 2

increases expression
multiple interactions

Rosuvastatin Calcium results in increased expression of NOS2 mRNA
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of NOS2 mRNA]

PMID:21443142 PMID:32007421 PMID:35130744

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
increases expression
affects response to substance

Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3]; Rosuvastatin Calcium results in increased phosphorylation of and results in increased activity of NOS3 protein
Rosuvastatin Calcium results in increased expression of NOS3 mRNA
NOS3 protein affects the susceptibility to Rosuvastatin Calcium

PMID:12354446 PMID:15681303 PMID:18162361 PMID:21562509

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

orosomucoid 1

multiple interactions
decreases expression

Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ORM1 mRNA]

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

platelet and endothelial cell adhesion molecule 1

multiple interactions

Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PECAM1 protein]

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

selectin P

decreases expression

Rosuvastatin Calcium results in decreased expression of SELP mRNA

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

serpin family E member 2

multiple interactions

Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of SERPINE2 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein]

NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826

G

solute carrier organic anion transporter family, member 1a4

multiple interactions
increases uptake
decreases expression
affects transport

Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium]
diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium]
Rosuvastatin Calcium results in decreased expression of SLCO1A4 protein
SLCO1A4 protein affects the transport of Rosuvastatin Calcium

PMID:19833843 PMID:24909372 PMID:26888941 PMID:28867436

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

multiple interactions
increases uptake

Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium]
Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium]

PMID:26888941 PMID:31299240

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 2b1

increases uptake
multiple interactions

SLCO2B1 protein results in increased uptake of Rosuvastatin Calcium
Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Rosuvastatin Calcium]

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

superoxide dismutase 1

multiple interactions
increases expression

[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

trefoil factor 1

decreases expression

Rosuvastatin Calcium results in decreased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

transforming growth factor, beta 1

multiple interactions
decreases expression

Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TGFB1 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein]
Rosuvastatin Calcium results in decreased expression of TGFB1 mRNA

PMID:15681303 PMID:27097221

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

decreases expression
multiple interactions

Rosuvastatin Calcium results in decreased expression of TNF mRNA
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNF protein]

PMID:15681303 PMID:32007421 PMID:35130744

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

troponin I3, cardiac type

multiple interactions

Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNNI3 protein]

PMID:32007421 PMID:35130744

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

G

vanin 3

decreases expression

Rosuvastatin Calcium results in decreased expression of VNN3P mRNA

NCBI chr 1:21,571,364...21,583,626
Ensembl chr 1:21,571,364...21,583,626

G

WT1 transcription factor

increases expression

Rosuvastatin Calcium results in increased expression of WT1 mRNA

NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643

sodium acetate trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 1

increases expression

Sodium Acetate results in increased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase short-chain family member 1

increases expression

Sodium Acetate results in increased expression of ACSS1 mRNA

NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325

G

acyl-CoA synthetase short-chain family member 2

increases expression

Sodium Acetate results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

adenosine deaminase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of ADA protein]

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

apolipoprotein B

multiple interactions

[Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

caspase 3

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

catalase

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1A1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

gamma-glutamyltransferase 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of GGT1 protein]

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

interferon gamma

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 6

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

karyopherin subunit beta 1

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]

NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605

G

MYD88, innate immune signal transduction adaptor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

N-acetyltransferase 2

increases expression

Sodium Acetate results in increased expression of NAT2 mRNA

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

nuclear factor of activated T-cells 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]

NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325

G

NFKB inhibitor alpha

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

phosphoenolpyruvate carboxykinase 1

increases expression

Sodium Acetate results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

superoxide dismutase 2

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transforming growth factor, beta 1

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 2

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA]

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

xanthine dehydrogenase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of XDH protein]

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

sodium benzoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions
increases activity

Ascorbic Acid inhibits the reaction [Sodium Benzoate results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

aryl hydrocarbon receptor

multiple interactions

Sodium Benzoate inhibits the reaction [[DAO protein results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

calcium/calmodulin-dependent protein kinase II alpha

multiple interactions

Sodium Benzoate promotes the reaction [Cocaine results in increased phosphorylation of and results in increased activity of CAMK2A protein]

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

caspase 3

multiple interactions
increases expression
increases activity

Sodium Benzoate inhibits the reaction [Asbestos, Amosite results in increased activity of CASP3 protein]
Sodium Benzoate results in increased expression of CASP3 protein
Ascorbic Acid inhibits the reaction [Sodium Benzoate results in increased expression of CASP3 protein]
Sodium Benzoate results in increased activity of CASP3 protein

PMID:11329530 PMID:32911041 PMID:35187746

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Sodium Benzoate inhibits the reaction [Asbestos, Amosite results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases activity
multiple interactions

Sodium Benzoate results in decreased activity of CAT protein
Ascorbic Acid inhibits the reaction [Sodium Benzoate results in decreased activity of CAT protein]

PMID:32911041 PMID:35187746

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Sodium Benzoate inhibits the reaction [[DAO protein results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

D-amino-acid oxidase

multiple interactions
decreases activity

Sodium Benzoate inhibits the reaction [[DAO protein results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]
Sodium Benzoate results in decreased activity of DAO protein

PMID:19860415 PMID:20952482

NCBI chr12:42,592,342...42,613,046
Ensembl chr12:42,592,343...42,612,741

G

estrogen receptor 1

decreases activity

Sodium Benzoate results in decreased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

follicle stimulating hormone subunit beta

increases expression

Sodium Benzoate results in increased expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

interferon gamma

multiple interactions

Sodium Benzoate inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]
[Food Preservatives results in increased abundance of Sodium Benzoate] which results in increased expression of IFNG mRNA

PMID:26706697 PMID:32179172

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

[Food Preservatives results in increased abundance of Sodium Benzoate] which results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

[Food Preservatives results in increased abundance of Sodium Benzoate] which results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases expression

Sodium Benzoate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
[Food Preservatives results in increased abundance of Sodium Benzoate] which results in increased expression of IL6 mRNA
Sodium Benzoate results in increased expression of IL6 protein

PMID:26706697 PMID:32179172 PMID:32911041

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

luteinizing hormone subunit beta

increases expression

Sodium Benzoate results in increased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

macrophage scavenger receptor 1

multiple interactions

Sodium Benzoate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA alternative form]; Sodium Benzoate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA]

NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676

G

ornithine transcarbamylase

multiple interactions

Sodium Benzoate affects the reaction [OTC gene mutant form affects the abundance of Hydroxyindoleacetic Acid]; Sodium Benzoate affects the reaction [OTC gene mutant form affects the metabolism of Glycine]; Sodium Benzoate affects the reaction [OTC gene mutant form affects the metabolism of Serotonin]; Sodium Benzoate affects the reaction [OTC gene mutant form results in increased abundance of Ammonium Compounds]

PMID:3091026 PMID:3374991

NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918

G

transcription factor A, mitochondrial

increases expression

Sodium Benzoate results in increased expression of TFAM protein

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

tumor necrosis factor

multiple interactions
increases expression

Sodium Benzoate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
[Food Preservatives results in increased abundance of Sodium Benzoate] which results in increased expression of TNF mRNA; Ascorbic Acid inhibits the reaction [Sodium Benzoate results in increased expression of TNF protein]

PMID:26706697 PMID:32179172 PMID:32911041 PMID:35187746

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions
increases expression

Sodium Benzoate inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA]
Sodium Benzoate results in increased expression of TP53 protein

PMID:16357363 PMID:32911041

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

uncoupling protein 2

increases expression

Sodium Benzoate results in increased expression of UCP2 protein

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

xanthine dehydrogenase

increases activity

Sodium Benzoate results in increased activity of XDH protein

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

sodium cholate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, biomineralization associated

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein]

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions

[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of CCL2 mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA

PMID:23665937 PMID:26606054

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions

[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin D1

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

carboxylesterase 1D

increases expression

Sodium Cholate results in increased expression of CES1 mRNA

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

cystatin C

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CST3 protein

NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822

G

cytochrome b-245 beta chain

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CYBB mRNA

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[1,2-dilauroylphosphatidylcholine co-treated with 1,2-oleoylphosphatidylcholine co-treated with Phosphatidylserines co-treated with Sodium Cholate] results in increased activity of CYP3A2 protein
[1,2-dilauroylphosphatidylcholine co-treated with 1,2-oleoylphosphatidylcholine co-treated with Phosphatidylserines co-treated with Sodium Cholate] results in increased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Sodium Cholate co-treated with Dietary Fats] results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

fatty acid binding protein 1

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of FABP1 protein

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutathione peroxidase 2

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

hepatitis A virus cellular receptor 1

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HAVCR1 mRNA

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

[Sodium Cholate co-treated with Dietary Fats] results in decreased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

intercellular adhesion molecule 1

multiple interactions

[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

multiple interactions

[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of IL1B mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA

PMID:23665937 PMID:26606054

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

mitogen activated protein kinase 1

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

MET gene mutant form affects the susceptibility to [Cholesterol, Dietary co-treated with Sodium Cholate]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [[[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Lipids] which results in increased abundance of Thiobarbituric Acid Reactive Substances]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased abundance of Triglycerides]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Glutathione]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of Bile Acids and Salts]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased uptake of and results in increased oxidation of Lipids]

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

N-acetyl-alpha-glucosaminidase

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of NAGLU protein

NCBI chr10:86,001,545...86,009,049
Ensembl chr10:86,001,566...86,008,972

G

NFE2 like bZIP transcription factor 2

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NPHS1 adhesion molecule, nephrin

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in decreased expression of NPHS1 mRNA

NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein]

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein]

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

retinoic acid receptor, alpha

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein]

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

S100 calcium binding protein A8

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

stearoyl-CoA desaturase

multiple interactions

[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA]

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sterol O-acyltransferase 2

multiple interactions

[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA]

NCBI chr 7:133,281,818...133,294,915
Ensembl chr 7:133,281,818...133,294,915

G

superoxide dismutase 2

multiple interactions

[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

transforming growth factor, beta 1

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 4

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TLR4 mRNA

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vascular cell adhesion molecule 1

multiple interactions

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

sodium propionate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in increased expression of and results in increased cleavage of CASP3 mRNA]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in increased expression of CASP8 mRNA]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

claudin 1

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in decreased expression of CLDN1 protein]

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

sodium propionate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

sodium propionate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; sodium propionate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

histone deacetylase 2

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in increased expression of HDAC2 mRNA]; sodium propionate inhibits the reaction [Ethanol results in increased expression of HDAC2 protein]

NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609

G

histone deacetylase 6

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in increased expression of HDAC6 mRNA]

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

interferon gamma

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 6

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

metallothionein 1

multiple interactions
increases expression

[sodium propionate co-treated with Cadmium] results in increased expression of MT1A mRNA; [sodium propionate co-treated with Dexamethasone] results in increased expression of MT1A mRNA
sodium propionate results in increased expression of MT1A mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

MYD88, innate immune signal transduction adaptor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

NFKB inhibitor alpha

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NADPH oxidase 1

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in increased expression of NOX1 mRNA]; sodium propionate inhibits the reaction [TNF protein affects the acetylation of NOX1 promoter]

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

occludin

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in decreased expression of OCLN protein]

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

transforming growth factor, beta 1

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tight junction protein 1

multiple interactions

sodium propionate inhibits the reaction [Ethanol results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

toll-like receptor 2

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]; sodium propionate inhibits the reaction [TNF protein affects the acetylation of NOX1 promoter]

PMID:35639301 PMID:37269894

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

sodium propionate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA]

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

sodium stibogluconate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions

[Lovastatin results in decreased activity of ABCC1 protein] which results in increased susceptibility to Antimony Sodium Gluconate

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

BCL6, transcription repressor

decreases expression

Antimony Sodium Gluconate results in decreased expression of BCL6 protein

NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389

G

C-C motif chemokine ligand 2

decreases expression

Antimony Sodium Gluconate results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

erythropoietin

decreases expression

Antimony Sodium Gluconate results in decreased expression of EPO mRNA; Antimony Sodium Gluconate results in decreased expression of EPO protein

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

intercellular adhesion molecule 1

affects response to substance

ICAM1 protein affects the susceptibility to Antimony Sodium Gluconate

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

decreases expression
multiple interactions
affects response to substance

Antimony Sodium Gluconate results in decreased expression of IFNG mRNA
[IFNG protein co-treated with Antimony Sodium Gluconate] results in decreased expression of IL10 mRNA; [IFNG protein co-treated with Antimony Sodium Gluconate] results in decreased expression of IL4 mRNA; [IFNG protein co-treated with Antimony Sodium Gluconate] results in increased expression of IL12B mRNA; [IFNG protein co-treated with Antimony Sodium Gluconate] results in increased expression of NOS2 mRNA; IFNG protein affects the reaction [IL10RA protein affects the susceptibility to Antimony Sodium Gluconate]
IFNG protein affects the susceptibility to Antimony Sodium Gluconate
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in increased expression of IFNG protein

PMID:9234779 PMID:9498473 PMID:10603400 PMID:12870129 PMID:17911647 More...

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interferon gamma receptor 1

increases expression

Antimony Sodium Gluconate results in increased expression of IFNGR1 mRNA; Antimony Sodium Gluconate results in increased expression of IFNGR1 protein

NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785

G

interleukin 10

multiple interactions
decreases expression
affects response to substance

[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of IL10 protein
Antimony Sodium Gluconate results in decreased expression of IL10 mRNA
IL10 protein affects the susceptibility to Antimony Sodium Gluconate
[IFNG protein co-treated with Antimony Sodium Gluconate] results in decreased expression of IL10 mRNA

PMID:9234779 PMID:9498473 PMID:12379707 PMID:17911647 PMID:20102417

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 10 receptor subunit alpha

multiple interactions
affects response to substance

IFNG protein affects the reaction [IL10RA protein affects the susceptibility to Antimony Sodium Gluconate]

PMID:12379707 PMID:12870129

NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 12B

multiple interactions

[IFNG protein co-treated with Antimony Sodium Gluconate] results in increased expression of IL12B mRNA

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 beta

decreases expression

Antimony Sodium Gluconate results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

decreases expression
multiple interactions
affects response to substance

Antimony Sodium Gluconate results in decreased expression of IL4 mRNA
[IFNG protein co-treated with Antimony Sodium Gluconate] results in decreased expression of IL4 mRNA
IL4 protein affects the susceptibility to Antimony Sodium Gluconate

PMID:7960131 PMID:9234779 PMID:11069076 PMID:20102417

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

integrin subunit alpha M

increases expression

Antimony Sodium Gluconate results in increased expression of ITGAM protein

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

nitric oxide synthase 2

multiple interactions

[IFNG protein co-treated with Antimony Sodium Gluconate] results in increased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

protein tyrosine phosphatase, non-receptor type 6

decreases activity

Antimony Sodium Gluconate results in decreased activity of PTPN6 protein

NCBI chr 4:157,526,034...157,550,783
Ensembl chr 4:157,526,035...157,550,984

G

transforming growth factor, beta 1

multiple interactions

[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

decreases expression

Antimony Sodium Gluconate results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 18

increases response to substance

TNFRSF18 protein results in increased susceptibility to Antimony Sodium Gluconate

NCBI chr 5:166,618,461...166,622,353
Ensembl chr 5:166,618,969...166,622,353

G

TNF receptor superfamily member 1A

decreases expression

Antimony Sodium Gluconate results in decreased expression of TNFRSF1A protein

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

TNF receptor superfamily member 1B

decreases expression

Antimony Sodium Gluconate results in decreased expression of TNFRSF1B protein

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

sodium valproate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

histone deacetylase 8

decreases activity

Sodium valproate attenuates the reaction [deoxycorticosterone acetate increases activity of Hdac8 protein in the heart]

RGD

NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923

tartrazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

adhesion G protein-coupled receptor G1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 4 (class II), pi polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA

NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591

G

alcohol dehydrogenase 6 (class V)

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA

NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534

G

aldo-keto reductase family 1, member D1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

aldo-keto reductase family 7, member A2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA

NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909

G

aldo-keto reductase family 7 member A3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

albumin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

adenosine monophosphate deaminase 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

apolipoprotein A1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

ATPase phospholipid transporting 8B1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685

G

BTB domain and CNC homolog 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA

NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447

G

Bcl2-like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 9

multiple interactions

[Tartrazine co-treated with Erythrosine] affects the expression of CASP9 mRNA

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases activity
multiple interactions

Tartrazine results in decreased activity of CAT protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA

PMID:20678534 PMID:33819548

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

colony stimulating factor 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA

NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719

G

DnaJ heat shock protein family (Hsp40) member C18

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA

NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344

G

DnaJ heat shock protein family (Hsp40) member C9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA

NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

estrogen receptor 1

increases activity
multiple interactions

Tartrazine results in increased activity of ESR1 protein
fulvestrant inhibits the reaction [Tartrazine results in increased activity of ESR1 protein]

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

ferritin heavy chain 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

glutamate cysteine ligase, modifier subunit

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gap junction protein, beta 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA

NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177

G

G protein-coupled receptor, class C, group 5, member B

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA

NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932

G

glutamate ionotropic receptor NMDA type subunit 2A

multiple interactions

[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutathione S-transferase alpha 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase theta 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

hepatitis A virus cellular receptor 1

multiple interactions

[Tartrazine co-treated with Erythrosine] affects the expression of HAVCR1 mRNA

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

hemopexin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA

NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328

G

interferon, alpha-inducible protein 27

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA

NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294

G

interleukin 1 receptor type 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

lipase C, hepatic type

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lymphocyte antigen 96

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

MAF bZIP transcription factor

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA

NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365

G

MAF bZIP transcription factor F

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

mitogen activated protein kinase kinase 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen-activated protein kinase kinase 6

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

MAPK activated protein kinase 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA

NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568

G

microsomal glutathione S-transferase 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

mixed lineage kinase domain like pseudokinase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA

NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502

G

methylmalonyl-CoA mutase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA

NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046

G

microsomal triglyceride transfer protein

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

phenylalanine hydroxylase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA

NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA

NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544

G

phosphoinositide-3-kinase regulatory subunit 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA

NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583

G

protein phosphatase 1, regulatory subunit 3C

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA

NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961

G

protein kinase D3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA

NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443

G

retinoic acid receptor, alpha

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

ras related dexamethasone induced 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA

NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186

G

retinol dehydrogenase 16

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA

NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124

G

serpin family E member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

solute carrier family 10 member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 22 member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

superoxide dismutase 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sortilin related receptor 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sulfotransferase family 2A member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

trefoil factor 1

multiple interactions
increases expression

fulvestrant inhibits the reaction [Tartrazine results in increased expression of TFF1 mRNA]

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

toll-like receptor 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA

NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545

G

toll-like receptor 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

[Tartrazine co-treated with Erythrosine] results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

TNF superfamily member 10

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

thimerosal

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

abhydrolase domain containing 17B, depalmitoylase

increases expression

Thimerosal results in increased expression of ABHD17B mRNA

NCBI chr 1:219,198,294...219,232,733
Ensembl chr 1:219,198,471...219,231,933

G

ankyrin repeat and BTB domain containing 3

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABTB3 mRNA

NCBI chr 7:18,035,151...18,310,718
Ensembl chr 7:18,036,083...18,310,834

G

acetyl-CoA carboxylase beta

decreases expression

Thimerosal results in decreased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA synthetase long-chain family member 4

increases expression

Thimerosal results in increased expression of ACSL4 mRNA

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin maturation protease

decreases expression

Thimerosal results in decreased expression of ACTMAP mRNA

NCBI chr 1:82,490,313...82,499,841
Ensembl chr 1:82,490,363...82,499,841

G

actin related protein 2

decreases expression

Thimerosal results in decreased expression of ACTR2 mRNA

NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524

G

adenylate cyclase 7

decreases expression

Thimerosal results in decreased expression of ADCY7 mRNA

NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311

G

adhesion G protein-coupled receptor B2

decreases expression

Thimerosal results in decreased expression of ADGRB2 mRNA

NCBI chr 5:142,299,190...142,362,540
Ensembl chr 5:142,331,329...142,362,540

G

adhesion G protein-coupled receptor L3

increases expression

Thimerosal results in increased expression of ADGRL3 mRNA

NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860

G

adhesion G protein-coupled receptor V1

increases expression

Thimerosal results in increased expression of ADGRV1 mRNA

NCBI chr 2:11,331,434...11,911,713
Ensembl chr 2:11,331,442...11,911,688

G

adrenomedullin

decreases expression

Thimerosal results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenylosuccinate synthase 1

decreases expression

Thimerosal results in decreased expression of ADSS1 mRNA

NCBI chr 6:131,679,795...131,702,012
Ensembl chr 6:131,679,701...131,701,998

G

actin filament associated protein 1-like 1

decreases expression

Thimerosal results in decreased expression of AFAP1L1 mRNA

NCBI chr18:55,183,786...55,244,174
Ensembl chr18:55,183,786...55,244,146

G

ALF transcription elongation factor 4

decreases expression

Thimerosal results in decreased expression of AFF4 mRNA

NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751

G

AGBL carboxypeptidase 5

decreases expression

Thimerosal results in decreased expression of AGBL5 mRNA

NCBI chr 6:25,472,333...25,492,173
Ensembl chr 6:25,472,333...25,490,738

G

ArfGAP with FG repeats 1

decreases expression

Thimerosal results in decreased expression of AGFG1 mRNA

NCBI chr 9:84,124,845...84,182,615
Ensembl chr 9:84,125,120...84,178,128

G

argonaute RISC component 1

decreases expression

Thimerosal results in decreased expression of AGO1 mRNA

NCBI chr 5:138,722,111...138,757,118
Ensembl chr 5:138,722,111...138,773,546

G

1-acylglycerol-3-phosphate O-acyltransferase 1

decreases expression

Thimerosal results in decreased expression of AGPAT1 mRNA

NCBI chr20:4,135,955...4,144,880
Ensembl chr20:4,135,957...4,145,278

G

adenosylhomocysteinase

decreases expression

Thimerosal results in decreased expression of AHCY mRNA

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

AHNAK nucleoprotein 2

decreases expression

Thimerosal results in decreased expression of AHNAK2 mRNA

NCBI chr 6:131,830,668...131,876,311

G

apoptosis inducing factor, mitochondria associated 1

increases secretion

Thimerosal results in increased secretion of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

adenylate kinase 4

decreases expression

Thimerosal results in decreased expression of AK4 mRNA

NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618

G

A-kinase anchoring protein 11

increases expression

Thimerosal results in increased expression of AKAP11 mRNA

NCBI chr15:53,911,635...53,956,138
Ensembl chr15:53,911,657...53,941,605

G

A-kinase anchoring protein 8 like

increases expression

Thimerosal results in increased expression of AKAP8L mRNA

NCBI chr 7:11,332,671...11,362,287
Ensembl chr 7:11,332,672...11,362,275

G

A-kinase anchoring protein 9

increases expression

Thimerosal results in increased expression of AKAP9 mRNA

NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

Thimerosal promotes the reaction [wortmannin results in decreased phosphorylation of AKT1 protein]; wortmannin promotes the reaction [Thimerosal results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 3

decreases expression

Thimerosal results in decreased expression of AKT3 mRNA

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

5'-aminolevulinate synthase 1

decreases expression

Thimerosal results in decreased expression of ALAS1 mRNA

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

albumin

affects binding

Thimerosal binds to ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 3 family, member A2

decreases expression

Thimerosal results in decreased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

aldehyde dehydrogenase 5 family, member A1

decreases expression

Thimerosal results in decreased expression of ALDH5A1 mRNA

NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677

G

aldehyde dehydrogenase 6 family, member A1

decreases expression

Thimerosal results in decreased expression of ALDH6A1 mRNA

NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656

G

aldolase, fructose-bisphosphate A

decreases expression

Thimerosal results in decreased expression of ALDOA mRNA

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

aldolase, fructose-bisphosphate C

decreases expression

Thimerosal results in decreased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

ALG13, UDP-N-acetylglucosaminyltransferase subunit

increases expression

Thimerosal results in increased expression of ALG13 mRNA

NCBI chr X:107,906,320...107,968,232
Ensembl chr X:107,885,093...107,942,695

G

arachidonate 5-lipoxygenase

decreases expression

Thimerosal results in decreased expression of ALOX5 mRNA

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

angiopoietin 1

decreases expression

Thimerosal results in decreased expression of ANGPT1 mRNA

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

ankyrin 2

increases expression

Thimerosal results in increased expression of ANK2 mRNA

NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923

G

ankyrin repeat and death domain containing 1A

decreases expression

Thimerosal results in decreased expression of ANKDD1A mRNA

NCBI chr 8:66,017,571...66,043,738
Ensembl chr 8:66,017,773...66,042,651

G

ankyrin repeat and EF-hand domain containing 1

decreases expression

Thimerosal results in decreased expression of ANKEF1 mRNA

NCBI chr 3:123,847,832...123,883,060
Ensembl chr 3:123,847,817...123,883,059

G

ankyrin repeat domain 10

increases expression

Thimerosal results in increased expression of ANKRD10 mRNA

NCBI chr16:77,866,489...77,889,745
Ensembl chr16:77,864,261...77,889,745

G

ankyrin repeat domain 35

decreases expression

Thimerosal results in decreased expression of ANKRD35 mRNA

NCBI chr 2:184,207,076...184,227,063
Ensembl chr 2:184,207,071...184,227,063

G

ankyrin repeat domain 37

decreases expression

Thimerosal results in decreased expression of ANKRD37 mRNA

NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963

G

ankyrin repeat domain 44

increases expression

Thimerosal results in increased expression of ANKRD44 mRNA

PMID:24675092 PMID:27188386

NCBI chr 9:56,126,746...56,427,661
Ensembl chr 9:56,126,747...56,427,508

G

ankyrin repeat domain 9

decreases expression

Thimerosal results in decreased expression of ANKRD9 mRNA

NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923

G

anoctamin 4

decreases expression

Thimerosal results in decreased expression of ANO4 mRNA

NCBI chr 7:23,329,015...23,738,423
Ensembl chr 7:23,329,070...23,738,434

G

acidic nuclear phosphoprotein 32 family member B

decreases expression

Thimerosal results in decreased expression of ANP32B mRNA

NCBI chr 5:60,743,077...60,765,726
Ensembl chr 5:60,743,443...60,765,717

G

alanyl aminopeptidase, membrane

decreases expression

Thimerosal results in decreased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

APC regulator of WNT signaling pathway

increases expression

Thimerosal results in increased expression of APC mRNA

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

apolipoprotein H

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APOH mRNA

NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329

G

adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2

decreases expression

Thimerosal results in decreased expression of APPL2 mRNA

NCBI chr 7:20,135,248...20,184,757
Ensembl chr 7:20,135,375...20,184,754

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3

decreases expression

Thimerosal results in decreased expression of ARAP3 mRNA

NCBI chr18:29,806,214...29,834,217
Ensembl chr18:29,807,536...29,833,555

G

ARB2 cotranscriptional regulator A

decreases expression

Thimerosal results in decreased expression of ARB2A mRNA

NCBI chr 2:7,553,873...8,018,183
Ensembl chr 2:7,553,891...8,018,162

G

activity-regulated cytoskeleton-associated protein

increases expression

Thimerosal results in increased expression of ARC mRNA

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

ARFGEF family member 3

decreases expression

Thimerosal results in decreased expression of ARFGEF3 mRNA

NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084

G

arginine and glutamate rich 1

decreases expression

Thimerosal results in decreased expression of ARGLU1 mRNA

NCBI chr16:80,753,300...80,777,350
Ensembl chr16:80,753,315...80,777,349

G

Rho GTPase activating protein 18

decreases expression

Thimerosal results in decreased expression of ARHGAP18 mRNA

NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256

G

Rho GTPase activating protein 5

increases expression

Thimerosal results in increased expression of ARHGAP5 mRNA

NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660

G

Rho guanine nucleotide exchange factor 10

decreases expression

Thimerosal results in decreased expression of ARHGEF10 mRNA

NCBI chr16:74,647,147...74,738,784
Ensembl chr16:74,647,153...74,738,173

G

Rho guanine nucleotide exchange factor 12

increases expression

Thimerosal results in increased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366

G

Rho guanine nucleotide exchange factor 4

decreases expression

Thimerosal results in decreased expression of ARHGEF4 mRNA

NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:36,861,835...37,005,075

G

armadillo repeat containing 7

decreases expression

Thimerosal results in decreased expression of ARMC7 mRNA

NCBI chr10:100,723,080...100,739,636
Ensembl chr10:100,723,105...100,739,636

G

armadillo repeat containing, X-linked 5

increases expression

Thimerosal results in increased expression of ARMCX5 mRNA

NCBI chr X:98,709,921...98,714,347
Ensembl chr X:98,709,841...98,714,674

G

aryl hydrocarbon receptor nuclear translocator

decreases expression

Thimerosal results in decreased expression of ARNT mRNA

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

actin related protein 2/3 complex, subunit 1B

decreases expression

Thimerosal results in decreased expression of ARPC1B mRNA

NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747

G

arrestin domain containing 3

increases expression

Thimerosal results in increased expression of ARRDC3 mRNA

NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978

G

arylsulfatase family, member K

decreases expression

Thimerosal results in decreased expression of ARSK mRNA

NCBI chr 2:5,574,319...5,631,451
Ensembl chr 2:5,574,322...5,631,467

G

anti-silencing function 1A histone chaperone

increases expression

Thimerosal results in increased expression of ASF1A mRNA

NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808

G

acetylserotonin O-methyltransferase-like

decreases expression

Thimerosal results in decreased expression of ASMTL mRNA

NCBI chr12:16,315,335...16,318,083
Ensembl chr12:16,315,414...16,318,080

G

assembly factor for spindle microtubules

decreases expression

Thimerosal results in decreased expression of ASPM mRNA

NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755

G

ATPase family, AAA domain containing 2B

increases expression

Thimerosal results in increased expression of ATAD2B mRNA

NCBI chr 6:27,914,546...28,070,103
Ensembl chr 6:27,912,862...28,067,047

G

activating transcription factor 3

increases expression

Thimerosal results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 7 interacting protein

increases expression

Thimerosal results in increased expression of ATF7IP mRNA

NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650

G

autophagy related 10

increases expression

Thimerosal results in increased expression of ATG10 mRNA

NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233

G

autophagy related 13

decreases expression

Thimerosal results in decreased expression of ATG13 mRNA

NCBI chr 3:77,647,069...77,681,028
Ensembl chr 3:77,645,790...77,681,043

G

autophagy related 2B

decreases expression

Thimerosal results in decreased expression of ATG2B mRNA

NCBI chr 6:124,522,283...124,592,412
Ensembl chr 6:124,525,523...124,592,015

G

ATM serine/threonine kinase

increases expression

Thimerosal results in increased expression of ATM mRNA

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase phospholipid transporting 11B (putative)

decreases expression

Thimerosal results in decreased expression of ATP11B mRNA

NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:118,585,342...118,690,232

G

ATPase 13A3

decreases expression

Thimerosal results in decreased expression of ATP13A3 mRNA

NCBI chr11:70,364,998...70,442,005
Ensembl chr11:70,365,322...70,441,235

G

ATPase Na+/K+ transporting subunit beta 2

decreases expression

Thimerosal results in decreased expression of ATP1B2 mRNA

NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933

G

ATP synthase F1 subunit delta

decreases expression

Thimerosal results in decreased expression of ATP5F1D mRNA

NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929

G

ATP synthase F1 subunit epsilon

increases expression

Thimerosal results in increased expression of ATP5F1E mRNA

NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450

G

ATP synthase inhibitory factor subunit 1

decreases expression

Thimerosal results in decreased expression of ATP5IF1 mRNA

NCBI chr 5:144,738,950...144,742,668
Ensembl chr 5:144,738,950...144,742,668

G

ATPase H+ transporting V1 subunit D

increases expression

Thimerosal results in increased expression of ATP6V1D mRNA

NCBI chr 6:97,656,725...97,672,295
Ensembl chr 6:97,656,576...97,672,303

G

ATPase phospholipid transporting 8B3

decreases expression

Thimerosal results in decreased expression of ATP8B3 mRNA

NCBI chr 7:9,175,544...9,195,449
Ensembl chr 7:9,175,391...9,195,442

G

ATRX, chromatin remodeler

decreases expression

Thimerosal results in decreased expression of ATRX mRNA

NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330

G

ataxin 1

decreases expression

Thimerosal results in decreased expression of ATXN1 mRNA

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

ataxin 7-like 3B

decreases expression

Thimerosal results in decreased expression of ATXN7L3B mRNA

NCBI chr 7:48,322,451...48,325,975
Ensembl chr 7:48,321,755...48,328,878

G

5-azacytidine induced 2

increases expression

Thimerosal results in increased expression of AZI2 mRNA

NCBI chr 8:117,773,248...117,797,844
Ensembl chr 8:117,773,279...117,797,847

G

beta-1,3-N-acetylgalactosaminyltransferase 2

increases expression

Thimerosal results in increased expression of B3GALNT2 mRNA

NCBI chr17:51,334,921...51,377,469
Ensembl chr17:51,334,921...51,377,469

G

beta-secretase 1

decreases expression

Thimerosal results in decreased expression of BACE1 mRNA

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

beta-secretase 2

decreases expression

Thimerosal results in decreased expression of BACE2 mRNA

NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546

G

BAG cochaperone 3

increases expression

Thimerosal results in increased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BAG cochaperone 4

decreases expression

Thimerosal results in decreased expression of BAG4 mRNA

NCBI chr16:66,288,678...66,305,893
Ensembl chr16:66,288,678...66,308,663

G

BCL2 associated X, apoptosis regulator

increases expression

Thimerosal results in increased expression of BAX

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BBSome interacting protein 1

increases expression

Thimerosal results in increased expression of BBIP1 mRNA

NCBI chr 1:252,943,589...252,959,512
Ensembl chr 1:252,945,557...252,959,352

G

bublin coiled coil protein

decreases expression

Thimerosal results in decreased expression of BBLN mRNA

NCBI chr 3:15,674,577...15,677,322
Ensembl chr 3:15,674,580...15,677,374

G

BCAS3, microtubule associated cell migration factor

decreases expression

Thimerosal results in decreased expression of BCAS3 mRNA

NCBI chr10:70,213,710...70,673,080
Ensembl chr10:70,214,098...70,673,080

G

branched chain amino acid transaminase 2

decreases expression

Thimerosal results in decreased expression of BCAT2 mRNA

NCBI chr 1:96,040,407...96,060,008
Ensembl chr 1:96,042,625...96,060,007

G

BCL6B, transcription repressor

decreases expression

Thimerosal results in decreased expression of BCL6B mRNA

NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974

G

BCL2-associated transcription factor 1

increases expression

Thimerosal results in increased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832

G

BCL6 co-repressor

decreases expression

Thimerosal results in decreased expression of BCOR mRNA

NCBI chr X:10,609,756...10,729,613
Ensembl chr X:10,687,732...10,729,613

G

B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB

decreases expression

Thimerosal results in decreased expression of BDP1 mRNA

NCBI chr 2:31,378,407...31,470,140
Ensembl chr 2:31,378,924...31,470,119

G

basic helix-loop-helix family, member e40

decreases expression

Thimerosal results in decreased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

baculoviral IAP repeat-containing 3

multiple interactions
decreases expression

Glutathione inhibits the reaction [Thimerosal results in decreased expression of BIRC3 protein]

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

BIRC5 mutant form promotes the reaction [Thimerosal results in increased cleavage of CASP3 protein]; BIRC5 mutant form promotes the reaction [Thimerosal results in increased cleavage of CASP9 protein]; BIRC5 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP3 protein]; BIRC5 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP9 protein]; IGF1 protein inhibits the reaction [Thimerosal results in decreased expression of BIRC5 protein]; Thimerosal promotes the reaction [BIRC5 mutant form results in increased cleavage of CASP3 protein]; Thimerosal promotes the reaction [BIRC5 mutant form results in increased cleavage of CASP9 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

biogenesis of lysosomal organelles complex-1, subunit 3

decreases expression

Thimerosal results in decreased expression of BLOC1S3 mRNA

NCBI chr 1:79,155,873...79,158,247
Ensembl chr 1:79,155,693...79,158,505

G

bridge-like lipid transfer protein family member 3A

decreases expression

Thimerosal results in decreased expression of BLTP3A mRNA

NCBI chr20:5,910,261...5,954,641
Ensembl chr20:5,910,260...5,952,404

G

BMP-2 inducible kinase

increases expression

Thimerosal results in increased expression of BMP2K mRNA

NCBI chr14:12,481,194...12,579,411
Ensembl chr14:12,484,729...12,579,134

G

BCL2 interacting protein 3

decreases expression

Thimerosal results in decreased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

biorientation of chromosomes in cell division 1-like 1

decreases expression

Thimerosal results in decreased expression of BOD1L1 mRNA

NCBI chr14:69,108,483...69,163,255
Ensembl chr14:69,108,491...69,162,490

G

BCL2 family apoptosis regulator BOK

decreases expression

Thimerosal results in decreased expression of BOK mRNA

NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476

G

bolA family member 2

increases expression

Thimerosal results in increased expression of BOLA2 mRNA

NCBI chr 1:181,291,967...181,292,833
Ensembl chr 1:181,291,398...181,292,676

G

BRCA2, DNA repair associated

increases expression

Thimerosal results in increased expression of BRCA2 mRNA

NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567

G

bromodomain and WD repeat domain containing 1

increases expression

Thimerosal results in increased expression of BRWD1 mRNA

NCBI chr11:35,286,364...35,378,768
Ensembl chr11:35,288,313...35,378,768

G

bromodomain and WD repeat domain containing 3

decreases expression

Thimerosal results in decreased expression of BRWD3 mRNA

NCBI chr X:73,768,343...73,861,643
Ensembl chr X:73,774,340...73,861,622

G

BTG anti-proliferation factor 3

increases expression

Thimerosal results in increased expression of BTG3 mRNA

NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170

G

similar to human chromosome 3 open reading frame 38

increases expression

Thimerosal results in increased expression of C3ORF38 mRNA

NCBI chr11:2,483,983...2,488,631
Ensembl chr11:2,481,189...2,488,660

G

similar to human chromosome 1 open reading frame 115

decreases expression

Thimerosal results in decreased expression of C1ORF115 mRNA

NCBI chr13:96,422,308...96,432,044
Ensembl chr13:96,422,302...96,432,068

G

similar to human chromosome 1 open reading frame 53

increases expression

Thimerosal results in increased expression of C1ORF53 mRNA

NCBI chr13:50,413,785...50,418,974
Ensembl chr13:50,413,785...50,419,120

G

similar to chromosome 2 open reading frame 76

increases expression

Thimerosal results in increased expression of C2ORF76 mRNA

NCBI chr13:31,249,733...31,335,367
Ensembl chr13:31,249,959...31,314,943

G

similar to human chromosome 8 open reading frame 58

decreases expression

Thimerosal results in decreased expression of C8ORF58 mRNA

NCBI chr15:45,228,615...45,235,274
Ensembl chr15:45,228,615...45,233,254

G

similar to human chromosome 8 open reading frame 48

increases expression

Thimerosal results in increased expression of C8ORF48 mRNA

NCBI chr16:55,244,744...55,246,642
Ensembl chr16:55,236,322...55,246,650

G

similar to human chromosome 5 open reading frame 24

decreases expression

Thimerosal results in decreased expression of C5ORF24 mRNA

NCBI chr17:8,923,041...8,932,958
Ensembl chr17:8,922,675...8,933,356

G

C1q and TNF related 3

decreases expression

Thimerosal results in decreased expression of C1QTNF3 mRNA

NCBI chr 2:59,917,099...59,939,519
Ensembl chr 2:59,917,188...59,939,433

G

C1q and TNF related 4

decreases expression

Thimerosal results in decreased expression of C1QTNF4 mRNA

NCBI chr 3:76,854,368...76,872,991
Ensembl chr 3:76,857,735...76,874,139

G

complement C1r subcomponent like

decreases expression

Thimerosal results in decreased expression of C1RL mRNA

NCBI chr 4:157,394,183...157,410,771
Ensembl chr 4:157,394,200...157,410,134

G

similar to human chromosome 6 open reading frame 136

decreases expression

Thimerosal results in decreased expression of C6ORF136 mRNA

NCBI chr20:2,857,840...2,861,952

G

C2 calcium-dependent domain containing 2

decreases expression

Thimerosal results in decreased expression of C2CD2 mRNA

NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739

G

similar to human chromosome 1 open reading frame 174

increases expression

Thimerosal results in increased expression of C1ORF174 mRNA

NCBI chr 5:164,515,578...164,520,022
Ensembl chr 5:164,515,559...164,520,021

G

similar to human chromosome 8 open reading frame 82

decreases expression

Thimerosal results in decreased expression of C8ORF82 mRNA

NCBI chr 7:108,443,772...108,446,116
Ensembl chr 7:108,443,782...108,446,121

G

cell adhesion molecule 2

increases expression

Thimerosal results in increased expression of CADM2 mRNA

NCBI chr11:4,548,367...5,525,420
Ensembl chr11:4,555,159...5,525,400

G

cell adhesion molecule 3

decreases expression

Thimerosal results in decreased expression of CADM3 mRNA

NCBI chr13:85,784,785...85,817,412
Ensembl chr13:85,786,483...85,817,749

G

calmodulin 3

decreases expression

Thimerosal results in decreased expression of CALM3 mRNA

NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207

G

calmodulin-like 4

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALML4 mRNA

NCBI chr 8:63,323,426...63,335,234
Ensembl chr 8:63,323,351...63,335,234

G

calpain 5

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAPN5 mRNA

NCBI chr 1:152,416,252...152,472,923
Ensembl chr 1:152,416,252...152,472,923

G

calpain 9

increases expression

Thimerosal results in increased expression of CAPN9 mRNA

NCBI chr19:52,549,448...52,586,413
Ensembl chr19:52,549,448...52,586,413

G

carbonic anhydrase 10

increases expression

Thimerosal results in increased expression of CA10 mRNA

NCBI chr10:78,055,875...78,556,490
Ensembl chr10:78,054,114...78,555,834

G

carbonic anhydrase 14

decreases expression

Thimerosal results in decreased expression of CA14 mRNA

NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693

G

caspase recruitment domain family, member 10

decreases expression

Thimerosal results in decreased expression of CARD10 mRNA

NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224

G

coactivator-associated arginine methyltransferase 1

decreases expression

Thimerosal results in decreased expression of CARM1 mRNA

NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689

G

caspase 3

increases cleavage
multiple interactions
increases activity

Thimerosal results in increased cleavage of CASP3 protein
[[Thimerosal results in increased abundance of Reactive Oxygen Species] which results in increased activity of CASP3 protein] which results in increased cleavage of PTK2 protein; [SOD1 protein results in increased susceptibility to Thimerosal] which results in increased cleavage of CASP3 protein; [Thimerosal results in increased abundance of Reactive Oxygen Species] which results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [[[Thimerosal results in increased abundance of Reactive Oxygen Species] which results in increased activity of CASP3 protein] which results in increased cleavage of PTK2 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[[Thimerosal results in increased abundance of Reactive Oxygen Species] which results in increased activity of CASP3 protein] which results in increased cleavage of PTK2 protein]; Glutathione inhibits the reaction [Thimerosal results in increased activity of CASP3 protein]; Resveratrol inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Thimerosal results in increased activity of CASP3 protein]
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Thimerosal results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Thimerosal results in increased cleavage of CASP3 protein]; BIRC5 mutant form promotes the reaction [Thimerosal results in increased cleavage of CASP3 protein]; BIRC5 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP3 protein]; Thimerosal promotes the reaction [BIRC5 mutant form results in increased cleavage of CASP3 protein]; Thimerosal promotes the reaction [Wortmannin results in increased cleavage of CASP3 protein]; Wortmannin promotes the reaction [Thimerosal results in increased cleavage of CASP3 protein]
MC1568 inhibits the reaction [Thimerosal results in increased cleavage of and results in increased activity of CASP3 protein]; Thimerosal results in increased cleavage of and results in increased activity of CASP3 protein

PMID:12140745 PMID:15869795 PMID:16649253 PMID:17698513 PMID:17888894 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases cleavage
multiple interactions
increases activity

Thimerosal results in increased cleavage of CASP9 protein
Glutathione inhibits the reaction [Thimerosal results in increased activity of CASP9 protein]
benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Thimerosal results in increased cleavage of CASP9 protein]; BIRC5 mutant form promotes the reaction [Thimerosal results in increased cleavage of CASP9 protein]; BIRC5 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP9 protein]; IGF1 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP9 protein]; Thimerosal promotes the reaction [BIRC5 mutant form results in increased cleavage of CASP9 protein]; Thimerosal promotes the reaction [wortmannin results in increased cleavage of CASP9 protein]; wortmannin promotes the reaction [Thimerosal results in increased cleavage of CASP9 protein]

PMID:12140745 PMID:15869795 PMID:23145070

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

Cbl proto-oncogene

decreases expression

Thimerosal results in decreased expression of CBL mRNA

NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176

G

chromobox 3

increases expression

Thimerosal results in increased expression of CBX3 mRNA

NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283

G

chromobox 5

decreases expression

Thimerosal results in decreased expression of CBX5 mRNA

NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022

G

chromobox 7

decreases expression

Thimerosal results in decreased expression of CBX7 mRNA

NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973

G

coiled-coil and C2 domain containing 2B

decreases expression

Thimerosal results in decreased expression of CC2D2B mRNA

NCBI chr 1:239,561,506...239,655,771
Ensembl chr 1:239,561,987...239,682,416

G

coiled-coil domain containing 113

decreases expression

Thimerosal results in decreased expression of CFAP263 mRNA

NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923

G

coiled-coil domain containing 126

increases expression

Thimerosal results in increased expression of CCDC126 mRNA

NCBI chr 4:78,297,625...78,318,655
Ensembl chr 4:78,297,551...78,318,655

G

coiled-coil domain containing 183

decreases expression

Thimerosal results in decreased expression of CCDC183 mRNA

NCBI chr 3:8,428,784...8,438,948
Ensembl chr 3:8,428,787...8,437,194

G

coiled-coil domain containing 186

decreases expression

Thimerosal results in decreased expression of CCDC186 mRNA

NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935

G

coiled-coil domain containing 66

increases expression

Thimerosal results in increased expression of CCDC66 mRNA

NCBI chr16:2,662,125...2,694,031
Ensembl chr16:2,662,131...2,694,023

G

coiled-coil domain containing 71-like

decreases expression

Thimerosal results in decreased expression of CCDC71L mRNA

NCBI chr 6:48,960,020...48,964,112
Ensembl chr 6:48,960,191...48,960,841
Ensembl chr 6:48,960,191...48,960,841

G

coiled-coil domain containing 82

increases expression

Thimerosal results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

coiled-coil domain containing 85B

decreases expression

Thimerosal results in decreased expression of CCDC85B mRNA

NCBI chr 1:202,763,645...202,764,660
Ensembl chr 1:202,763,631...202,764,703

G

CCM2 like scaffold protein

decreases expression

Thimerosal results in decreased expression of CCM2L mRNA

NCBI chr 3:141,533,470...141,549,136
Ensembl chr 3:141,533,511...141,549,140

G

cellular communication network factor 1

increases expression

Thimerosal results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin B1

multiple interactions

Thimerosal results in increased expression of and results in increased activity of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression

Thimerosal results in decreased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

decreases expression

Thimerosal results in decreased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin T1

decreases expression

Thimerosal results in decreased expression of CCNT1 mRNA

NCBI chr 7:129,687,146...129,718,080
Ensembl chr 7:129,691,209...129,717,871

G

cyclin T2

increases expression

Thimerosal results in increased expression of CCNT2 mRNA

NCBI chr13:39,251,573...39,293,172
Ensembl chr13:39,251,573...39,292,019

G

coiled-coil serine-rich protein 1

increases expression

Thimerosal results in increased expression of CCSER1 mRNA

NCBI chr 4:90,153,873...91,391,441
Ensembl chr 4:90,292,780...91,388,786

G

chaperonin containing TCP1 subunit 6B

increases expression

Thimerosal results in increased expression of CCT6B mRNA

NCBI chr10:67,652,461...67,701,385
Ensembl chr10:67,652,546...67,701,284

G

Cd28 molecule

affects response to substance

CD28 affects the susceptibility to Thimerosal

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

CD40 molecule

decreases expression

Thimerosal results in decreased expression of CD40 mRNA

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

Cd6 molecule

decreases expression

Thimerosal results in decreased expression of CD6 mRNA

NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634

G

CD79b molecule

increases expression

Thimerosal results in increased expression of CD79B mRNA

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

Cd81 molecule

decreases expression

Thimerosal results in decreased expression of CD81 mRNA

NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660

G

CD86 molecule

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Thimerosal results in increased expression of CD86 protein]; Cysteine inhibits the reaction [Thimerosal results in increased expression of CD86 protein]; Glutathione inhibits the reaction [Thimerosal results in increased expression of CD86 protein]; Vitamin E inhibits the reaction [Thimerosal results in increased expression of CD86 protein]

PMID:15737199 PMID:20417223 PMID:20457211

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

CD99 molecule (Xg blood group)

decreases expression

Thimerosal results in decreased expression of CD99 mRNA

NCBI chr20:54,418,239...54,422,882

G

cell division cycle 20B

increases expression

Thimerosal results in increased expression of CDC20B mRNA

NCBI chr 2:44,688,349...44,738,056

G

cell division cycle 27

decreases expression

Thimerosal results in decreased expression of CDC27 mRNA

NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736

G

cell division cycle 37-like 1

increases expression

Thimerosal results in increased expression of CDC37L1 mRNA

NCBI chr 1:226,705,019...226,733,994
Ensembl chr 1:226,705,003...226,761,175

G

CDC42 small effector 2

increases expression

Thimerosal results in increased expression of CDC42SE2 mRNA

NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059
Ensembl chr 1:38,836,555...38,905,059

G

cell division cycle associated 2

decreases expression

Thimerosal results in decreased expression of CDCA2 mRNA

NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611

G

cadherin 8

increases expression

Thimerosal results in increased expression of CDH8 mRNA

NCBI chr19:5,494,038...5,901,810
Ensembl chr19:5,494,174...5,895,669

G

cadherin-related family member 1

increases expression

Thimerosal results in increased expression of CDHR1 mRNA

NCBI chr16:12,843,436...12,863,321
Ensembl chr16:12,843,437...12,863,396

G

cyclin-dependent kinase 1

increases expression

Thimerosal results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase 14

affects expression

Thimerosal affects the expression of CDK14 mRNA

NCBI chr 4:28,666,416...29,258,865
Ensembl chr 4:28,666,843...29,258,861

G

cyclin-dependent kinase 16

decreases expression

Thimerosal results in decreased expression of CDK16 mRNA

NCBI chr X:1,492,814...1,504,309
Ensembl chr X:1,492,814...1,504,148

G

cyclin-dependent kinase 4

decreases expression

Thimerosal results in decreased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 6

decreases expression

Thimerosal results in decreased expression of CDK6 mRNA

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase inhibitor 1C

decreases expression

Thimerosal results in decreased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

chromatin licensing and DNA replication factor 1

decreases expression

Thimerosal results in decreased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

centromere protein N

increases expression

Thimerosal results in increased expression of CENPN mRNA

NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012

G

centromere protein Q

increases expression

Thimerosal results in increased expression of CENPQ mRNA

NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789

G

centromere protein U

increases expression

Thimerosal results in increased expression of CENPU mRNA

NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823

G

centrosomal protein 126

decreases expression

Thimerosal results in decreased expression of CEP126 mRNA

NCBI chr 8:5,200,576...5,267,740
Ensembl chr 8:5,218,509...5,267,467

G

centrosomal protein 350

decreases expression

Thimerosal results in decreased expression of CEP350 mRNA

NCBI chr13:68,023,327...68,164,478
Ensembl chr13:68,026,891...68,165,214

G

centrosomal protein 89

decreases expression

Thimerosal results in decreased expression of CEP89 mRNA

NCBI chr 1:88,058,211...88,100,114
Ensembl chr 1:88,058,227...88,100,112

G

cilia and flagella associated protein 300

increases expression

Thimerosal results in increased expression of CFAP300 mRNA

NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807

G

cilia and flagella associated protein 44

increases expression

Thimerosal results in increased expression of CFAP44 mRNA

NCBI chr11:56,199,772...56,283,964
Ensembl chr11:56,201,049...56,283,986

G

cilia and flagella associated protein 96

decreases expression

Thimerosal results in decreased expression of CFAP96 mRNA

NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625

G

complement factor properdin

decreases expression

Thimerosal results in decreased expression of CFP mRNA

NCBI chr X:1,162,014...1,167,576
Ensembl chr X:1,161,979...1,167,573

G

glycoprotein hormones, alpha polypeptide

increases expression

Thimerosal results in increased expression of CGA mRNA

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

coiled-coil-helix-coiled-coil-helix domain containing 10

decreases expression

Thimerosal results in decreased expression of CHCHD10 mRNA

NCBI chr20:12,725,839...12,727,638
Ensembl chr20:12,725,842...12,732,763

G

chromodomain helicase DNA binding protein 4

decreases expression

Thimerosal results in decreased expression of CHD4 mRNA

NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541

G

chromodomain helicase DNA binding protein 9

increases expression

Thimerosal results in increased expression of CHD9 mRNA

NCBI chr19:15,941,535...16,146,220
Ensembl chr19:15,942,687...16,164,556

G

charged multivesicular body protein 5

increases expression

Thimerosal results in increased expression of CHMP5 mRNA

NCBI chr 5:56,081,385...56,098,529
Ensembl chr 5:56,081,343...56,098,529

G

chimerin 2

increases expression

Thimerosal results in increased expression of CHN2 mRNA

NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709

G

choline phosphotransferase 1

increases expression

Thimerosal results in increased expression of CHPT1 mRNA

NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103

G

calcium and integrin binding family member 2

decreases expression

Thimerosal results in decreased expression of CIB2 mRNA

NCBI chr 8:54,930,265...54,947,157

G

CBY1 interacting BAR domain containing 1

decreases expression

Thimerosal results in decreased expression of CIBAR1 mRNA

NCBI chr 5:25,613,993...25,632,440
Ensembl chr 5:25,614,033...25,632,489

G

cartilage intermediate layer protein 2

decreases expression

Thimerosal results in decreased expression of CILP2 mRNA

NCBI chr16:19,539,755...19,547,191
Ensembl chr16:19,539,706...19,547,191

G

CDGSH iron sulfur domain 2

increases expression

Thimerosal results in increased expression of CISD2 mRNA

NCBI chr 2:223,828,937...223,853,768
Ensembl chr 2:223,828,937...223,868,946

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

increases expression

Thimerosal results in increased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cytoplasmic linker associated protein 2

increases expression

Thimerosal results in increased expression of CLASP2 mRNA

NCBI chr 8:113,677,345...113,859,957
Ensembl chr 8:113,677,284...113,858,731

G

CDC-like kinase 4

increases expression

Thimerosal results in increased expression of CLK4 mRNA

NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352

G

cleavage factor polyribonucleotide kinase subunit 1

increases expression

Thimerosal results in increased expression of CLP1 mRNA

NCBI chr 3:69,806,774...69,818,633
Ensembl chr 3:69,806,778...69,810,421

G

clusterin

increases expression
decreases expression

Thimerosal results in increased expression of CLU mRNA
Thimerosal results in decreased expression of CLU mRNA

PMID:16870260 PMID:27188386

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

c-Maf-inducing protein

decreases expression

Thimerosal results in decreased expression of CMIP mRNA

NCBI chr19:45,304,597...45,510,653
Ensembl chr19:45,304,031...45,508,709

G

cornifelin

decreases expression

Thimerosal results in decreased expression of CNFN mRNA

NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747

G

CCR4-NOT transcription complex, subunit 7

increases expression

Thimerosal results in increased expression of CNOT7 mRNA

NCBI chr16:51,775,416...51,794,581
Ensembl chr16:51,775,412...51,794,576

G

CCR4-NOT transcription complex subunit 9

increases expression

Thimerosal results in increased expression of CNOT9 mRNA

NCBI chr 9:76,084,269...76,109,111
Ensembl chr 9:76,084,334...76,109,100

G

canopy FGF signaling regulator 2

decreases expression

Thimerosal results in decreased expression of CNPY2 mRNA

NCBI chr 7:748,877...754,352
Ensembl chr 7:749,008...755,519

G

contactin associated protein 2

decreases expression

Thimerosal results in decreased expression of CNTNAP2 mRNA

NCBI chr 4:74,109,455...76,366,434
Ensembl chr 4:74,109,472...76,362,027

G

cordon-bleu WH2 repeat protein-like 1

increases expression

Thimerosal results in increased expression of COBLL1 mRNA

NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194

G

component of oligomeric golgi complex 3

increases expression

Thimerosal results in increased expression of COG3 mRNA

NCBI chr15:51,020,808...51,071,288
Ensembl chr15:51,020,813...51,070,570

G

collagen type XXII alpha 1 chain

decreases expression

Thimerosal results in decreased expression of COL22A1 mRNA

NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462

G

collagen type IV alpha 6 chain

increases expression

Thimerosal results in increased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

collagen type IX alpha 2 chain

decreases expression

Thimerosal results in decreased expression of COL9A2 mRNA

NCBI chr 5:134,607,616...134,624,678
Ensembl chr 5:134,607,616...134,624,677

G

COP9 signalosome subunit 7B

increases expression

Thimerosal results in increased expression of COPS7B mRNA

NCBI chr 9:87,238,132...87,263,967
Ensembl chr 9:87,238,375...87,263,967

G

cytochrome c oxidase assembly homolog COX15

decreases expression

Thimerosal results in decreased expression of COX15 mRNA

NCBI chr 1:242,605,588...242,622,279
Ensembl chr 1:242,605,588...242,622,261

G

cytochrome c oxidase subunit 4i1

increases expression

Thimerosal results in increased expression of COX4I1 mRNA

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

cytoplasmic polyadenylation element binding protein 2

multiple interactions
increases expression

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPEB2 mRNA
Thimerosal results in increased expression of CPEB2 mRNA

NCBI chr14:67,787,503...67,839,973
Ensembl chr14:67,787,507...67,840,743

G

cytoplasmic polyadenylation element binding protein 3

increases expression

Thimerosal results in increased expression of CPEB3 mRNA

NCBI chr 1:234,749,138...234,931,219
Ensembl chr 1:234,751,733...234,931,560

G

copine 3

decreases expression

Thimerosal results in decreased expression of CPNE3 mRNA

NCBI chr 5:33,014,658...33,063,934
Ensembl chr 5:33,016,307...33,063,934

G

carbamoyl-phosphate synthase 1

decreases expression

Thimerosal results in decreased expression of CPS1 mRNA

NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033

G

CGRP receptor component

decreases expression

Thimerosal results in decreased expression of CRCP mRNA

NCBI chr12:26,623,968...26,659,756
Ensembl chr12:26,623,976...26,768,225

G

cAMP responsive element binding protein 1

decreases expression

Thimerosal results in decreased expression of CREB1 mRNA

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cysteine-rich protein 3

decreases expression

Thimerosal results in decreased expression of CRIP3 mRNA

NCBI chr 9:14,554,450...14,557,344
Ensembl chr 9:14,554,450...14,557,302

G

crystallin, alpha B

increases expression

Thimerosal results in increased expression of CRYAB mRNA

NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157

G

citrate synthase

decreases expression

Thimerosal results in decreased expression of CS mRNA

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

centrosome and spindle pole associated protein 1

increases expression

Thimerosal results in increased expression of CSPP1 mRNA

NCBI chr 5:9,077,161...9,192,402
Ensembl chr 5:9,077,161...9,193,377

G

CTD small phosphatase like 2

increases expression

Thimerosal results in increased expression of CTDSPL2 mRNA

NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227

G

catenin alpha 1

decreases expression

Thimerosal results in decreased expression of CTNNA1 mRNA

NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910

G

cortexin 3

increases expression

Thimerosal results in increased expression of CTXN3 mRNA

NCBI chr18:50,930,244...50,940,642
Ensembl chr18:50,930,235...50,940,641

G

similar to human chromosome X open reading frame 38

decreases expression

Thimerosal results in decreased expression of CXORF38 mRNA

NCBI chr X:10,128,070...10,150,904
Ensembl chr X:10,129,657...10,150,900

G

cytochrome b5 reductase 3

decreases expression

Thimerosal results in decreased expression of CYB5R3 mRNA

NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298

G

cytochrome b5 reductase 4

increases expression

Thimerosal results in increased expression of CYB5R4 mRNA

NCBI chr 8:87,975,596...88,048,356
Ensembl chr 8:87,981,116...88,045,832

G

cytochrome P450, family 39, subfamily a, polypeptide 1

increases expression

Thimerosal results in increased expression of CYP39A1 mRNA

NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775

G

dishevelled-binding antagonist of beta-catenin 3

decreases expression

Thimerosal results in decreased expression of DACT3 mRNA

NCBI chr 1:77,546,900...77,558,631
Ensembl chr 1:77,546,900...77,558,630

G

drebrin 1

decreases expression

Thimerosal results in decreased expression of DBN1 mRNA

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 13

increases expression

Thimerosal results in increased expression of DCAF13 mRNA

NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142

G

DDB1 and CUL4 associated factor 16

decreases expression

Thimerosal results in decreased expression of DCAF16 mRNA

NCBI chr14:65,449,631...65,450,015

G

DDB1 and CUL4 associated factor 4

decreases expression

Thimerosal results in decreased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DDB1 and CUL4 associated factor 7

decreases expression

Thimerosal results in decreased expression of DCAF7 mRNA

NCBI chr10:90,974,095...90,996,275
Ensembl chr10:90,974,095...90,996,275

G

DCC netrin 1 receptor

increases expression

Thimerosal results in increased expression of DCC mRNA

NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740

G

defective in cullin neddylation 1 domain containing 1

increases expression

Thimerosal results in increased expression of DCUN1D1 mRNA

NCBI chr 2:118,721,275...118,772,606
Ensembl chr 2:118,721,822...118,772,602

G

doublecortin

increases expression

Thimerosal results in increased expression of DCX mRNA

NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476

G

DExD-box helicase 39B

decreases expression

Thimerosal results in decreased expression of DDX39B mRNA

NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996

G

DEAD-box helicase 6

decreases expression

Thimerosal results in decreased expression of DDX6 mRNA

NCBI chr 8:44,931,127...44,967,773
Ensembl chr 8:44,931,974...44,964,405

G

DENN domain containing 1B

increases expression

Thimerosal results in increased expression of DENND1B mRNA

NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601

G

Dexi homolog

decreases expression

Thimerosal results in decreased expression of DEXI mRNA

NCBI chr10:5,126,021...5,138,746
Ensembl chr10:5,137,288...5,138,738

G

diacylglycerol O-acyltransferase 1

decreases expression

Thimerosal results in decreased expression of DGAT1 mRNA

NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299

G

24-dehydrocholesterol reductase

decreases expression

Thimerosal results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

decreases expression

Thimerosal results in decreased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

dehydrogenase/reductase 1

decreases expression

Thimerosal results in decreased expression of DHRS1 mRNA

NCBI chr15:29,236,522...29,243,807
Ensembl chr15:29,236,522...29,243,838

G

DEAH-box helicase 36

increases expression

Thimerosal results in increased expression of DHX36 mRNA

NCBI chr 2:146,856,469...146,894,577
Ensembl chr 2:146,856,469...146,894,572

G

DExH-box helicase 9

decreases expression

Thimerosal results in decreased expression of DHX9 mRNA

NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069

G

dickkopf like acrosomal protein 1

decreases expression

Thimerosal results in decreased expression of DKKL1 mRNA

NCBI chr 1:95,694,010...95,699,259
Ensembl chr 1:95,694,010...95,699,259

G

discs large MAGUK scaffold protein 1

decreases expression

Thimerosal results in decreased expression of DLG1 mRNA

NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689

G

DnaJ heat shock protein family (Hsp40) member B1

increases expression

Thimerosal results in increased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B4

increases expression

Thimerosal results in increased expression of DNAJB4 mRNA

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

DnaJ heat shock protein family (Hsp40) member C13

decreases expression

Thimerosal results in decreased expression of DNAJC13 mRNA

NCBI chr 8:104,767,785...104,877,317
Ensembl chr 8:104,767,788...104,877,317

G

DnaJ heat shock protein family (Hsp40) member C4

decreases expression

Thimerosal results in decreased expression of DNAJC4 mRNA

NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387

G

deoxyribonuclease 1

decreases expression

Thimerosal results in decreased expression of DNASE1 mRNA

NCBI chr10:11,498,930...11,505,151
Ensembl chr10:11,498,931...11,501,869

G

DNA methyltransferase 3 alpha

decreases expression

Thimerosal results in decreased expression of DNMT3A mRNA

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

dedicator of cytokinesis 11

decreases expression

Thimerosal results in decreased expression of DOCK11 mRNA

NCBI chr X:115,131,720...115,314,854
Ensembl chr X:115,131,909...115,314,854

G

dedicator of cytokinesis 4

increases expression

Thimerosal results in increased expression of DOCK4 mRNA

NCBI chr 6:57,512,929...57,902,597
Ensembl chr 6:57,512,908...57,901,855

G

dedicator of cytokinesis 6

decreases expression

Thimerosal results in decreased expression of DOCK6 mRNA

NCBI chr 8:20,342,430...20,394,660
Ensembl chr 8:20,342,089...20,394,552

G

dystonin

affects expression

Thimerosal affects the expression of DST mRNA

NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615

G

dual specificity phosphatase 1

increases expression

Thimerosal results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 7

decreases expression

Thimerosal results in decreased expression of DUSP7 mRNA

NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404

G

dynein light chain Tctex-type 2B

increases expression

Thimerosal results in increased expression of DYNLT2B mRNA

NCBI chr11:68,359,138...68,367,573
Ensembl chr11:68,358,263...68,367,499

G

enoyl CoA hydratase domain containing 2

decreases expression

Thimerosal results in decreased expression of ECHDC2 mRNA

NCBI chr 5:122,915,874...122,934,860
Ensembl chr 5:122,916,134...122,934,859

G

ECRG4 augurin precursor

decreases expression

Thimerosal results in decreased expression of ECRG4 mRNA

NCBI chr 9:45,992,954...46,012,605
Ensembl chr 9:45,992,954...46,012,595

G

endothelin receptor type B

decreases expression

Thimerosal results in decreased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

early endosome antigen 1

decreases expression

Thimerosal results in decreased expression of EEA1 mRNA

NCBI chr 7:30,554,686...30,722,186
Ensembl chr 7:30,554,552...30,718,487

G

eukaryotic translation elongation factor 1 alpha 2

decreases expression

Thimerosal results in decreased expression of EEF1A2 mRNA

NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071

G

EEF1A lysine methyltransferase 3

decreases expression

Thimerosal results in decreased expression of EEF1AKMT3 mRNA

NCBI chr 7:62,853,304...62,864,558
Ensembl chr 7:62,854,899...62,864,617

G

EF-hand calcium binding domain 14

decreases expression

Thimerosal results in decreased expression of EFCAB14 mRNA

NCBI chr 5:129,218,139...129,258,628
Ensembl chr 5:129,218,424...129,258,625

G

EGF-like-domain, multiple 7

decreases expression

Thimerosal results in decreased expression of EGFL7 mRNA

PMID:24675092 PMID:27188386

NCBI chr 3:9,404,622...9,416,879
Ensembl chr 3:9,407,520...9,416,879

G

egl-9 family hypoxia-inducible factor 1

decreases expression

Thimerosal results in decreased expression of EGLN1 mRNA

NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777

G

egl-9 family hypoxia-inducible factor 3

decreases expression

Thimerosal results in decreased expression of EGLN3 mRNA

NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766

G

EH domain binding protein 1

decreases expression

Thimerosal results in decreased expression of EHBP1 mRNA

NCBI chr14:96,093,327...96,380,502
Ensembl chr14:96,093,327...96,345,332

G

EH-domain containing 4

decreases expression

Thimerosal results in decreased expression of EHD4 mRNA

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

euchromatic histone lysine methyltransferase 1

decreases expression

Thimerosal results in decreased expression of EHMT1 mRNA

NCBI chr 3:7,580,680...7,729,046
Ensembl chr 3:7,580,683...7,729,007

G

eukaryotic translation initiation factor 3, subunit F

decreases expression

Thimerosal results in decreased expression of EIF3F mRNA

NCBI chr 1:162,934,220...162,943,204
Ensembl chr 1:162,934,212...162,943,204

G

eukaryotic translation initiation factor 4B

decreases expression

Thimerosal results in decreased expression of EIF4B mRNA

NCBI chr 7:133,206,637...133,228,436

G

eukaryotic translation initiation factor 4 gamma 1

decreases expression

Thimerosal results in decreased expression of EIF4G1 mRNA

NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941

G

eukaryotic translation initiation factor 5A2

decreases expression

Thimerosal results in decreased expression of EIF5A2 mRNA

NCBI chr 2:111,728,587...111,746,087
Ensembl chr 2:111,729,323...111,746,087

G

elaC ribonuclease Z 1

increases expression

Thimerosal results in increased expression of ELAC1 mRNA

NCBI chr18:67,321,231...67,341,358
Ensembl chr18:67,323,583...67,340,936

G

engulfment and cell motility 1

decreases expression

Thimerosal results in decreased expression of ELMO1 mRNA

NCBI chr17:44,286,495...44,822,668
Ensembl chr17:44,286,485...44,822,788

G

elongin A

decreases expression

Thimerosal results in decreased expression of ELOA mRNA

NCBI chr 5:148,231,600...148,246,760
Ensembl chr 5:148,231,596...148,246,765

G

EMAP like 5

increases expression

Thimerosal results in increased expression of EML5 mRNA

NCBI chr 6:118,046,655...118,175,831
Ensembl chr 6:118,046,655...118,175,831

G

enolase 1

decreases expression

Thimerosal results in decreased expression of ENO1 mRNA

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

enolase 2

decreases expression

Thimerosal results in decreased expression of ENO2 mRNA

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

enolase 3

decreases expression

Thimerosal results in decreased expression of ENO3 mRNA

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

ectonucleotide pyrophosphatase/phosphodiesterase family member 5

decreases expression

Thimerosal results in decreased expression of ENPP5 mRNA

NCBI chr 9:16,910,187...16,917,633
Ensembl chr 9:16,910,831...16,917,480

G

E1A binding protein p400

decreases expression

Thimerosal results in decreased expression of EP400 mRNA

NCBI chr12:45,891,886...46,002,523
Ensembl chr12:45,891,916...45,998,861

G

erythrocyte membrane protein band 4.1-like 1

decreases expression

Thimerosal results in decreased expression of EPB41L1 mRNA

NCBI chr 3:144,929,195...145,052,723
Ensembl chr 3:144,984,640...145,052,721

G

erythrocyte membrane protein band 4.1 like 4A

decreases expression

Thimerosal results in decreased expression of EPB41L4A mRNA

NCBI chr18:25,405,461...25,615,392
Ensembl chr18:25,406,057...25,615,149

G

erythrocyte membrane protein band 4.1 like 5

decreases expression

Thimerosal results in decreased expression of EPB41L5 mRNA

NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360

G

enhancer of polycomb homolog 1

increases expression

Thimerosal results in increased expression of EPC1 mRNA

NCBI chr17:54,503,358...54,594,444
Ensembl chr17:54,503,358...54,594,425

G

epithelial cell adhesion molecule

increases expression

Thimerosal results in increased expression of EPCAM mRNA

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

elongin BC and polycomb repressive complex 2 associated protein

decreases expression

Thimerosal results in decreased expression of EPOP mRNA

NCBI chr10:82,624,392...82,625,912
Ensembl chr10:82,624,392...82,625,912

G

glutamyl-prolyl-tRNA synthetase 1

decreases expression

Thimerosal results in decreased expression of EPRS1 mRNA

NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966

G

ELKS/RAB6-interacting/CAST family member 1

decreases expression

Thimerosal results in decreased expression of ERC1 mRNA

NCBI chr 4:152,763,664...153,055,724
Ensembl chr 4:152,767,419...153,055,639

G

ERCC excision repair 2, TFIIH core complex helicase subunit

decreases expression

Thimerosal results in decreased expression of ERCC2 mRNA

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

G

endoplasmic reticulum-golgi intermediate compartment 1

decreases expression

Thimerosal results in decreased expression of ERGIC1 mRNA

NCBI chr10:16,531,192...16,626,974
Ensembl chr10:16,531,194...16,626,957

G

ERGIC and golgi 2

increases expression

Thimerosal results in increased expression of ERGIC2 mRNA

NCBI chr 4:181,090,808...181,123,074
Ensembl chr 4:181,090,808...181,123,060

G

establishment of sister chromatid cohesion N-acetyltransferase 1

decreases expression

Thimerosal results in decreased expression of ESCO1 mRNA

NCBI chr18:1,630,560...1,686,803
Ensembl chr18:1,631,954...1,686,942

G

establishment of sister chromatid cohesion N-acetyltransferase 2

decreases expression

Thimerosal results in decreased expression of ESCO2 mRNA

NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306

G

ESF1 nucleolar pre-rRNA processing protein homolog

increases expression

Thimerosal results in increased expression of ESF1 mRNA

NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817

G

ethanolamine kinase 1

increases expression

Thimerosal results in increased expression of ETNK1 mRNA

NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770

G

EvC ciliary complex subunit 2

decreases expression

Thimerosal results in decreased expression of EVC2 mRNA

NCBI chr14:73,366,832...73,454,539
Ensembl chr14:73,367,963...73,454,516

G

ecotropic viral integration site 5

decreases expression

Thimerosal results in decreased expression of EVI5 mRNA

NCBI chr14:1,875,601...2,021,678
Ensembl chr14:1,875,647...2,021,678

G

exocyst complex component 6

increases expression

Thimerosal results in increased expression of EXOC6 mRNA

NCBI chr 1:235,314,612...235,457,824
Ensembl chr 1:235,300,369...235,457,015

G

coagulation factor XII

decreases expression

Thimerosal results in decreased expression of F12 mRNA

NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530

G

fatty acid binding protein 7

increases expression

Thimerosal results in increased expression of FABP7 mRNA

NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880

G

fatty acid desaturase 1

decreases expression

Thimerosal results in decreased expression of FADS1 mRNA

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

fatty acid desaturase 2

decreases expression

Thimerosal results in decreased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas associated factor family member 2

decreases expression

Thimerosal results in decreased expression of FAF2 mRNA

NCBI chr17:9,947,211...9,989,474
Ensembl chr17:9,947,220...9,989,485

G

fumarylacetoacetate hydrolase

decreases expression

Thimerosal results in decreased expression of FAH mRNA

NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505

G

family with sequence similarity 124 member B

decreases expression

Thimerosal results in decreased expression of FAM124B mRNA

NCBI chr 9:81,513,018...81,533,621
Ensembl chr 9:81,515,399...81,533,341

G

family with sequence similarity 135, member A

affects expression

Thimerosal affects the expression of FAM135A mRNA

NCBI chr 9:26,420,116...26,500,803
Ensembl chr 9:26,420,528...26,500,717

G

family with sequence similarity 149, member A

decreases expression

Thimerosal results in decreased expression of FAM149A mRNA

NCBI chr16:46,855,377...46,914,553
Ensembl chr16:46,854,635...46,912,066

G

family with sequence similarity 162, member A

decreases expression

Thimerosal results in decreased expression of FAM162A mRNA

NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239

G

family with sequence similarity 168, member B

decreases expression

Thimerosal results in decreased expression of FAM168B mRNA

NCBI chr 9:37,005,569...37,038,631
Ensembl chr 9:37,006,689...37,033,723

G

family with sequence similarity 234, member B

decreases expression

Thimerosal results in decreased expression of FAM234B mRNA

NCBI chr 4:168,048,313...168,124,017
Ensembl chr 4:168,048,396...168,097,338

G

FAM3 metabolism regulating signaling molecule C

increases expression

Thimerosal results in increased expression of FAM3C mRNA

NCBI chr 4:50,839,929...50,887,276
Ensembl chr 4:50,838,818...50,888,078

G

family with sequence similarity 76, member B

increases expression

Thimerosal results in increased expression of FAM76B mRNA

NCBI chr 8:10,689,396...10,711,847
Ensembl chr 8:10,688,963...10,711,861

G

family with sequence similarity 81, member B

increases expression

Thimerosal results in increased expression of FAM81B mRNA

NCBI chr 2:5,750,678...5,870,580
Ensembl chr 2:5,771,240...5,879,440

G

FA complementation group F

decreases expression

Thimerosal results in decreased expression of FANCF mRNA

NCBI chr 1:101,449,120...101,451,936
Ensembl chr 1:101,450,389...101,451,923

G

Fas cell surface death receptor

increases expression

Thimerosal results in increased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fatty acid synthase

decreases expression

Thimerosal results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

FAST kinase domains 2

increases expression

Thimerosal results in increased expression of FASTKD2 mRNA

NCBI chr 9:65,166,148...65,188,184
Ensembl chr 9:65,168,228...65,188,174

G

fibulin 2

decreases expression

Thimerosal results in decreased expression of FBLN2 mRNA

NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948

G

fibrillin 1

decreases expression

Thimerosal results in decreased expression of FBN1 mRNA

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

F-box protein 3

increases expression

Thimerosal results in increased expression of FBXO3 mRNA

NCBI chr 3:90,417,262...90,449,557
Ensembl chr 3:90,417,297...90,449,557

G

F-box protein 7

decreases expression

Thimerosal results in decreased expression of FBXO7 mRNA

NCBI chr 7:17,809,224...17,837,549
Ensembl chr 7:17,809,231...17,837,530

G

f-box protein 9

increases expression

Thimerosal results in increased expression of FBXO9 mRNA

NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949

G

FER tyrosine kinase

increases expression

Thimerosal results in increased expression of FER mRNA

NCBI chr 9:103,520,452...103,827,364
Ensembl chr 9:103,520,493...103,821,451

G

fer-1-like family member 4

decreases expression

Thimerosal results in decreased expression of FER1L4 mRNA

NCBI chr 3:144,536,099...144,571,634
Ensembl chr 3:144,536,099...144,571,634

G

FYVE, RhoGEF and PH domain containing 6

increases expression

Thimerosal results in increased expression of FGD6 mRNA

NCBI chr 7:28,597,609...28,712,908
Ensembl chr 7:28,597,609...28,712,456

G

fibroblast growth factor 11

decreases expression

Thimerosal results in decreased expression of FGF11 mRNA

NCBI chr10:54,516,508...54,522,067
Ensembl chr10:54,517,077...54,522,062

G

fibroblast growth factor binding protein 3

decreases expression

Thimerosal results in decreased expression of FGFBP3 mRNA

NCBI chr 1:234,644,023...234,646,028
Ensembl chr 1:234,644,019...234,646,547

G

FGFR1 oncogene partner 2

increases expression

Thimerosal results in increased expression of FGFR1OP2 mRNA

NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630

G

fibroblast growth factor receptor 2

decreases expression

Thimerosal results in decreased expression of FGFR2 mRNA

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

FKBP prolyl isomerase 10

decreases expression

Thimerosal results in decreased expression of FKBP10 mRNA

NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330

G

folliculin

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLCN mRNA

NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769

G

formin-like 2

decreases expression

Thimerosal results in decreased expression of FMNL2 mRNA

NCBI chr 3:37,348,791...37,624,746
Ensembl chr 3:37,348,574...37,624,754

G

fibronectin 1

increases secretion

Thimerosal results in increased secretion of FN1 protein

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

formin binding protein 4

decreases expression

Thimerosal results in decreased expression of FNBP4 mRNA

NCBI chr 3:76,733,012...76,763,077
Ensembl chr 3:76,733,027...76,763,079

G

fibronectin type III domain containing 10

decreases expression

Thimerosal results in decreased expression of FNDC10 mRNA

NCBI chr 5:166,299,587...166,311,477
Ensembl chr 5:166,300,122...166,310,326

G

fibronectin type III domain containing 11

decreases expression

Thimerosal results in decreased expression of FNDC11 mRNA

NCBI chr 3:168,330,607...168,333,111
Ensembl chr 3:168,330,602...168,334,617

G

fibronectin type III domain containing 4

decreases expression

Thimerosal results in decreased expression of FNDC4 mRNA

NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675

G

folate receptor alpha

decreases expression

Thimerosal results in decreased expression of FOLR1 mRNA

NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Thimerosal results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

Thimerosal results in increased expression of FOSB mRNA

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

forkhead box C1

decreases expression

Thimerosal results in decreased expression of FOXC1 mRNA

NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803

G

forkhead box P2

increases expression

Thimerosal results in increased expression of FOXP2 mRNA

NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683

G

FRA10A associated CGG repeat 1

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FRA10AC1 mRNA

NCBI chr 1:235,969,071...236,001,074
Ensembl chr 1:235,969,112...236,001,210

G

FERM domain containing 7

increases expression

Thimerosal results in increased expression of FRMD7 mRNA

NCBI chr X:130,375,925...130,423,836
Ensembl chr X:130,377,227...130,423,771

G

FERM and PDZ domain containing 3

increases expression

Thimerosal results in increased expression of FRMPD3 mRNA

NCBI chr X:103,964,168...104,113,864
Ensembl chr X:104,043,194...104,111,968

G

fibroblast growth factor receptor substrate 2

increases expression

Thimerosal results in increased expression of FRS2 mRNA

NCBI chr 7:52,711,255...52,792,738
Ensembl chr 7:52,711,257...52,792,743

G

follicle stimulating hormone subunit beta

increases expression

Thimerosal results in increased expression of FSHB mRNA; Thimerosal results in increased expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

fibrous sheath-interacting protein 2

increases expression

Thimerosal results in increased expression of FSIP2 mRNA

NCBI chr 3:67,962,345...68,032,866
Ensembl chr 3:67,962,360...68,032,868

G

fucosyltransferase 1

decreases expression

Thimerosal results in decreased expression of FUT1 mRNA

NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616

G

fucosyltransferase 11

decreases expression

Thimerosal results in decreased expression of FUT11 mRNA

NCBI chr15:3,598,768...3,602,328
Ensembl chr15:3,598,758...3,602,356

G

FXYD domain-containing ion transport regulator 6

decreases expression

Thimerosal results in decreased expression of FXYD6 mRNA

NCBI chr 8:45,679,054...45,705,958
Ensembl chr 8:45,678,885...45,705,958

G

frizzled class receptor 2

decreases expression

Thimerosal results in decreased expression of FZD2 mRNA

NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334

G

frizzled class receptor 7

decreases expression

Thimerosal results in decreased expression of FZD7 mRNA

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781

G

G3BP stress granule assembly factor 1

affects expression

Thimerosal affects the expression of G3BP1 mRNA

NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268

G

glucose-6-phosphate dehydrogenase

decreases expression

Thimerosal results in decreased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

gamma-aminobutyric acid type A receptor subunit alpha 1

increases expression

Thimerosal results in increased expression of GABRA1 mRNA

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864

G

gamma-aminobutyric acid type A receptor subunit rho 1

increases expression

Thimerosal results in increased expression of GABRR1 mRNA

NCBI chr 5:47,524,151...47,561,228
Ensembl chr 5:47,524,151...47,561,228

G

growth arrest and DNA-damage-inducible, gamma

increases expression

Thimerosal results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

GTPase activating protein and VPS9 domains 1

decreases expression

Thimerosal results in decreased expression of GAPVD1 mRNA

NCBI chr 3:17,968,345...18,041,888
Ensembl chr 3:17,969,599...18,055,218

G

GRB2 associated regulator of MAPK1 subtype 1

decreases expression

Thimerosal results in decreased expression of GAREM1 mRNA

NCBI chr18:12,420,169...12,585,323
Ensembl chr18:12,423,882...12,585,345

G

GRB2 associated regulator of MAPK1 subtype 2

decreases expression

Thimerosal results in decreased expression of GAREM2 mRNA

NCBI chr 6:26,228,965...26,255,576
Ensembl chr 6:26,230,048...26,241,762

G

growth arrest-specific 2 like 1

decreases expression

Thimerosal results in decreased expression of GAS2L1 mRNA

NCBI chr14:79,955,350...79,961,830
Ensembl chr14:79,950,555...79,961,438

G

1,4-alpha-glucan branching enzyme 1

decreases expression

Thimerosal results in decreased expression of GBE1 mRNA

NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210

G

gem (nuclear organelle) associated protein 4

decreases expression

Thimerosal results in decreased expression of GEMIN4 mRNA

NCBI chr10:61,062,420...61,073,529
Ensembl chr10:61,066,425...61,073,431
Ensembl chr10:61,066,425...61,073,431

G

G elongation factor, mitochondrial 1

increases expression

Thimerosal results in increased expression of GFM1 mRNA

NCBI chr 2:151,700,573...151,745,477
Ensembl chr 2:151,700,564...151,745,471

G

growth hormone 1

increases expression

Thimerosal results in increased expression of GH mRNA

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

growth hormone releasing hormone receptor

increases expression

Thimerosal results in increased expression of GHRHR mRNA

NCBI chr 4:84,498,159...84,532,851
Ensembl chr 4:84,500,212...84,532,776

G

GRB10 interacting GYF protein 1

increases expression

Thimerosal results in increased expression of GIGYF1 mRNA

NCBI chr12:19,166,070...19,181,570
Ensembl chr12:19,166,088...19,175,023

G

gypsy retrotransposon integrase 1

increases expression

Thimerosal results in increased expression of GIN1 mRNA

NCBI chr 9:98,293,596...98,315,155
Ensembl chr 9:98,293,597...98,315,848

G

GIT ArfGAP 2

decreases expression

Thimerosal results in decreased expression of GIT2 mRNA

NCBI chr12:41,829,717...41,872,621
Ensembl chr12:41,829,730...41,871,097

G

gap junction protein, alpha 4

decreases expression

Thimerosal results in decreased expression of GJA4 mRNA

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

glycosylated lysosomal membrane protein

decreases expression

Thimerosal results in decreased expression of GLMP mRNA

NCBI chr 2:173,794,273...173,797,863
Ensembl chr 2:173,794,255...173,799,960

G

glutaminase

increases expression

Thimerosal results in increased expression of GLS mRNA

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

ganglioside GM2 activator

decreases expression

Thimerosal results in decreased expression of GM2A mRNA

NCBI chr10:39,219,221...39,231,756
Ensembl chr10:39,219,243...39,231,757

G

GDP-mannose 4, 6-dehydratase

decreases expression

Thimerosal results in decreased expression of GMDS mRNA

NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961

G

G protein subunit alpha L

decreases expression

Thimerosal results in decreased expression of GNAL mRNA

NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599

G

G protein subunit beta 1

decreases expression

Thimerosal results in decreased expression of GNB1 mRNA

NCBI chr 5:166,075,508...166,142,223
Ensembl chr 5:166,075,629...166,142,124

G

G protein subunit gamma 4

increases expression

Thimerosal results in increased expression of GNG4 mRNA

NCBI chr17:86,448,708...86,497,560
Ensembl chr17:86,449,022...86,495,254

G

G protein subunit gamma 7

decreases expression

Thimerosal results in decreased expression of GNG7 mRNA

NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:8,697,521...8,761,240

G

gonadotropin releasing hormone receptor

increases expression

Thimerosal results in increased expression of GNRHR mRNA

NCBI chr14:21,856,871...21,874,861
Ensembl chr14:21,856,871...21,874,861

G

gon-4 like

decreases expression

Thimerosal results in decreased expression of GON4L mRNA

NCBI chr 2:174,233,461...174,306,636
Ensembl chr 2:174,233,461...174,306,634

G

glycerophosphocholine phosphodiesterase 1

increases expression

Thimerosal results in increased expression of GPCPD1 mRNA

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

glucose-6-phosphate isomerase

decreases expression

Thimerosal results in decreased expression of GPI mRNA

NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086

G

G protein-coupled receptor 135

decreases expression

Thimerosal results in decreased expression of GPR135 mRNA

NCBI chr 6:90,627,533...90,630,661
Ensembl chr 6:90,629,178...90,630,551

G

G protein-coupled receptor 22

increases expression

Thimerosal results in increased expression of GPR22 mRNA

NCBI chr 6:48,309,619...48,317,864
Ensembl chr 6:48,310,505...48,317,486

G

gremlin 2, DAN family BMP antagonist

decreases expression

Thimerosal results in decreased expression of GREM2 mRNA

NCBI chr13:86,778,543...86,871,509
Ensembl chr13:86,778,500...86,871,615

G

glutamate ionotropic receptor kainate type subunit 2

increases expression

Thimerosal results in increased expression of GRIK2 mRNA

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

glutamate ionotropic receptor kainate type subunit 5

affects expression

Thimerosal affects the expression of GRIK5 protein

NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125

G

glutamate ionotropic receptor NMDA type subunit 1

decreases expression

Thimerosal results in decreased expression of GRIN1 protein

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2B

decreases expression

Thimerosal results in decreased expression of GRIN2B protein

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

G protein-coupled receptor kinase 3

decreases expression

Thimerosal results in decreased expression of GRK3 mRNA

NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262

G

glutathione S-transferase mu 1

affects response to substance

GSTM1 affects the susceptibility to Thimerosal

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

decreases expression

Thimerosal results in decreased expression of GSTM2 mRNA

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase theta 1

affects response to substance
decreases expression

GSTT1 affects the susceptibility to Thimerosal
Thimerosal results in decreased expression of GSTT1 mRNA

PMID:11007341 PMID:27188386

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

general transcription factor 2A subunit 1

decreases expression

Thimerosal results in decreased expression of GTF2A1 mRNA

NCBI chr 6:110,488,891...110,521,502
Ensembl chr 6:110,488,931...110,521,511

G

general transcription factor IIB

increases expression

Thimerosal results in increased expression of GTF2B mRNA

NCBI chr 2:231,767,317...231,785,626
Ensembl chr 2:231,767,238...231,785,651

G

general transcription factor IIF subunit 1

decreases expression

Thimerosal results in decreased expression of GTF2F1 mRNA

NCBI chr 9:1,844,027...1,853,455
Ensembl chr 9:1,843,901...1,853,423

G

guanylate cyclase activator 1A

decreases expression

Thimerosal results in decreased expression of GUCA1A mRNA

NCBI chr 9:13,588,988...13,598,566
Ensembl chr 9:13,588,525...13,598,565

G

GULP PTB domain containing engulfment adaptor 1

increases expression

Thimerosal results in increased expression of GULP1 mRNA

NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005

G

glucoside xylosyltransferase 1

decreases expression

Thimerosal results in decreased expression of GXYLT1 mRNA

NCBI chr 7:124,400,896...124,434,682
Ensembl chr 7:124,400,896...124,434,699

G

H1.0 linker histone

decreases expression

Thimerosal results in decreased expression of H1-0 mRNA

NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694

G

H1.10 linker histone

decreases expression

Thimerosal results in decreased expression of H1-10 mRNA

NCBI chr 4:120,440,515...120,441,578
Ensembl chr 4:120,440,870...120,441,448

G

H1.4 linker histone, cluster member

decreases expression

Thimerosal results in decreased expression of H1-4 mRNA

NCBI chr17:41,486,574...41,487,355
Ensembl chr17:41,486,560...41,487,403

G

H1.3 linker histone, cluster member

decreases expression

Thimerosal results in decreased expression of H1-3 mRNA

NCBI chr17:41,551,524...41,552,303
Ensembl chr17:41,529,667...41,552,334

G

3-hydroxyacyl-CoA dehydratase 2

decreases expression

Thimerosal results in decreased expression of HACD2 mRNA

NCBI chr11:65,667,671...65,762,903
Ensembl chr11:65,670,281...65,762,889

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

decreases expression

Thimerosal results in decreased expression of HADHA mRNA

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

histone acetyltransferase 1

increases expression

Thimerosal results in increased expression of HAT1 mRNA

NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517

G

heparin-binding EGF-like growth factor

increases expression

Thimerosal results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

HBS1-like translational GTPase

increases expression

Thimerosal results in increased expression of HBS1L mRNA

NCBI chr 1:16,092,529...16,170,082
Ensembl chr 1:16,092,547...16,170,074

G

host cell factor C1 regulator 1

decreases expression

Thimerosal results in decreased expression of HCFC1R1 mRNA

NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850

G

histone deacetylase 4

multiple interactions
increases expression

MC1568 inhibits the reaction [Thimerosal results in increased expression of HDAC4 protein]

NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164

G

highly divergent homeobox

increases expression

Thimerosal results in increased expression of HDX mRNA

NCBI chr X:76,552,539...76,697,177
Ensembl chr X:76,560,665...76,869,972

G

HEAT repeat containing 1

decreases expression

Thimerosal results in decreased expression of HEATR1 mRNA

NCBI chr17:58,053,288...58,093,895
Ensembl chr17:58,051,700...58,093,948

G

heme binding protein 1

decreases expression

Thimerosal results in decreased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

HECT domain E3 ubiquitin protein ligase 1

decreases expression

Thimerosal results in decreased expression of HECTD1 mRNA

NCBI chr 6:69,181,429...69,268,045
Ensembl chr 6:69,181,436...69,268,053

G

HECT domain E3 ubiquitin protein ligase 2

increases expression

Thimerosal results in increased expression of HECTD2 mRNA

NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487

G

HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1

increases expression

Thimerosal results in increased expression of HECW1 mRNA

NCBI chr17:50,671,239...51,084,536
Ensembl chr17:50,670,954...51,080,720

G

helicase, lymphoid specific

increases expression

Thimerosal results in increased expression of HELLS mRNA

NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844

G

HEN methyltransferase 1

increases expression

Thimerosal results in increased expression of HENMT1 mRNA

NCBI chr 2:196,585,732...196,603,700
Ensembl chr 2:196,586,797...196,599,738

G

hephaestin

decreases expression

Thimerosal results in decreased expression of HEPH mRNA

NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980

G

hes family bHLH transcription factor 1

decreases expression

Thimerosal results in decreased expression of HES1 mRNA

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

hes family bHLH transcription factor 3

decreases expression

Thimerosal results in decreased expression of HES3 mRNA

NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261

G

hypoxia inducible factor 3 subunit alpha

decreases expression

Thimerosal results in decreased expression of HIF3A mRNA

NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758

G

huntingtin interacting protein 1

decreases expression

Thimerosal results in decreased expression of HIP1 mRNA

NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725

G

homeodomain interacting protein kinase 2

decreases expression

Thimerosal results in decreased expression of HIPK2 mRNA

NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223

G

hexokinase 1

decreases expression

Thimerosal results in decreased expression of HK1 mRNA

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

hexokinase 2

decreases expression

Thimerosal results in decreased expression of HK2 mRNA

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

high mobility group AT-hook 1

decreases expression

Thimerosal results in decreased expression of HMGA1 mRNA

NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752

G

high mobility group box 1

increases expression

Thimerosal results in increased expression of HMGB1 mRNA

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group nucleosome binding domain 5

increases expression

Thimerosal results in increased expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441

G

heme oxygenase 1

increases expression

Thimerosal results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A0

decreases expression

Thimerosal results in decreased expression of HNRNPA0 mRNA

NCBI chr17:6,507,728...6,510,385
Ensembl chr17:6,507,275...6,509,375

G

heterogeneous nuclear ribonucleoprotein U-like 2

decreases expression

Thimerosal results in decreased expression of HNRNPUL2 mRNA

NCBI chr 1:205,713,431...205,725,553
Ensembl chr 1:205,711,886...205,725,553

G

hydroxysteroid (17-beta) dehydrogenase 6

decreases expression

Thimerosal results in decreased expression of HSD17B6 mRNA

NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425

G

heat shock transcription factor 2

increases expression

Thimerosal results in increased expression of HSF2 mRNA

NCBI chr20:36,819,864...36,847,490
Ensembl chr20:36,819,864...36,850,174

G

heat shock protein 90 alpha family class B member 1

decreases expression

Thimerosal results in decreased expression of HSP90AB1 mRNA

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 13

increases expression

Thimerosal results in increased expression of HSPA13 mRNA

NCBI chr11:14,375,669...14,389,853
Ensembl chr11:14,373,275...14,389,895

G

heat shock protein family A (Hsp70) member 1A

increases expression
decreases expression

Thimerosal results in increased expression of HSPA1A mRNA
Thimerosal results in decreased expression of HSPA1A mRNA

PMID:16870260 PMID:24675092

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1B

increases expression

Thimerosal results in increased expression of HSPA1B mRNA

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 1 like

increases expression

Thimerosal results in increased expression of HSPA1L mRNA

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

heat shock protein family A (Hsp70) member 4 like

increases expression

Thimerosal results in increased expression of HSPA4L mRNA

NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084

G

heat shock protein family A (Hsp70) member 6 like, pseudogene 1

increases expression

Thimerosal results in increased expression of HSPA6 mRNA

NCBI chr13:83,273,176...83,274,317

G

heat shock protein family B (small) member 1

increases expression

Thimerosal results in increased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

HIV-1 Tat specific factor 1

decreases expression

Thimerosal results in decreased expression of HTATSF1 mRNA

NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607

G

5-hydroxytryptamine receptor 2C

increases expression

Thimerosal results in increased expression of HTR2C mRNA

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

HYLS1, centriolar and ciliogenesis associated

increases expression

Thimerosal results in increased expression of HYLS1 mRNA

NCBI chr 8:33,912,692...33,921,760
Ensembl chr 8:33,912,692...33,921,760

G

immediate early response 5-like

decreases expression

Thimerosal results in decreased expression of IER5L mRNA

PMID:24675092 PMID:27188386

NCBI chr 3:13,744,056...13,745,647
Ensembl chr 3:13,744,078...13,745,647

G

interferon gamma

affects response to substance
multiple interactions

IFNG affects the susceptibility to Thimerosal
Glutathione inhibits the reaction [Thimerosal inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]]; Thimerosal inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]

PMID:15808517 PMID:17079650

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

intraflagellar transport 80

increases expression

Thimerosal results in increased expression of IFT80 mRNA

NCBI chr 2:153,144,707...153,240,024
Ensembl chr 2:153,145,795...153,240,024

G

immunoglobulin superfamily, DCC subclass, member 3

decreases expression

Thimerosal results in decreased expression of IGDCC3 mRNA

NCBI chr 8:65,661,165...65,707,961
Ensembl chr 8:65,661,196...65,707,959

G

insulin-like growth factor 1

multiple interactions

Thimerosal affects the reaction [IGF1 protein results in increased activity of MTR protein]
IGF1 protein inhibits the reaction [Thimerosal results in decreased expression of BIRC5 protein]; IGF1 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Thimerosal results in increased cleavage of CASP9 protein]

PMID:14745455 PMID:23145070

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 2 mRNA binding protein 3

decreases expression

Thimerosal results in decreased expression of IGF2BP3 mRNA

NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865

G

insulin-like growth factor binding protein 2

decreases expression

Thimerosal results in decreased expression of IGFBP2 mRNA

NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937

G

insulin-like growth factor binding protein 5

decreases expression

Thimerosal results in decreased expression of IGFBP5 mRNA

NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156

G

IgLON family member 5

decreases expression

Thimerosal results in decreased expression of IGLON5 mRNA

NCBI chr 1:93,880,906...93,898,929
Ensembl chr 1:93,881,991...93,898,754

G

IKAROS family zinc finger 1

decreases expression

Thimerosal results in decreased expression of IKZF1 mRNA

NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416

G

interleukin 13

multiple interactions

[Thimerosal co-treated with Lipopolysaccharides] results in increased secretion of IL13 protein; Glutathione inhibits the reaction [[Thimerosal co-treated with Lipopolysaccharides] results in increased secretion of IL13 protein]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 13 receptor subunit alpha 1

decreases expression

Thimerosal results in decreased expression of IL13RA1 mRNA

NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681
Ensembl chr11:115,348,860...115,408,681

G

interleukin 17 receptor A

decreases expression

Thimerosal results in decreased expression of IL17RA mRNA

NCBI chr 4:153,667,534...153,690,174
Ensembl chr 4:153,667,534...153,690,174

G

interleukin 27 receptor subunit alpha

decreases expression

Thimerosal results in decreased expression of IL27RA mRNA

NCBI chr19:24,109,963...24,121,977
Ensembl chr19:24,109,972...24,121,938

G

interleukin 5

multiple interactions

[Thimerosal co-treated with Lipopolysaccharides] results in increased secretion of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

affects response to substance
multiple interactions

IL6 affects the susceptibility to Thimerosal
Glutathione inhibits the reaction [Thimerosal inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Thimerosal inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

PMID:15808517 PMID:17079650

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin enhancer binding factor 3

decreases expression

Thimerosal results in decreased expression of ILF3 mRNA

NCBI chr 8:19,922,409...19,960,495
Ensembl chr 8:19,922,460...19,960,350

G

inflammation and lipid regulator with UBA-like and NBR1-like domains

decreases expression

Thimerosal results in decreased expression of ILRUN mRNA

NCBI chr20:5,809,931...5,876,197
Ensembl chr20:5,809,936...5,876,012

G

inner mitochondrial membrane peptidase subunit 1

increases expression

Thimerosal results in increased expression of IMMP1L mRNA

NCBI chr 3:92,385,329...92,449,559
Ensembl chr 3:92,385,379...92,452,313

G

InaF-motif containing 1

decreases expression

Thimerosal results in decreased expression of INAFM1 mRNA

NCBI chr 1:76,976,808...76,978,292

G

inhibitor of growth family, member 3

increases expression

Thimerosal results in increased expression of ING3 mRNA

NCBI chr 4:50,477,954...50,505,168
Ensembl chr 4:50,477,962...50,503,715

G

INO80 complex subunit D

increases expression

Thimerosal results in increased expression of INO80D mRNA

NCBI chr 9:64,447,075...64,514,013
Ensembl chr 9:64,457,165...64,515,242

G

insulin induced gene 1

decreases expression

Thimerosal results in decreased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

integrator complex subunit 10

increases expression

Thimerosal results in increased expression of INTS10 mRNA

NCBI chr16:20,915,223...20,947,146
Ensembl chr16:20,916,082...20,967,610

G

integrator complex subunit 14

increases expression

Thimerosal results in increased expression of INTS14 mRNA

NCBI chr 8:65,475,788...65,500,807
Ensembl chr 8:65,475,910...65,500,804

G

integrator complex subunit 6

increases expression

Thimerosal results in increased expression of INTS6 mRNA

NCBI chr15:36,908,966...37,048,043
Ensembl chr15:36,933,724...37,021,527

G

IQ motif containing GTPase activating protein 1

decreases expression

Thimerosal results in decreased expression of IQGAP1 mRNA

NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755

G

inositol 1,4,5-triphosphate receptor associated 1

decreases expression

Thimerosal results in decreased expression of IRAG1 mRNA

NCBI chr 1:164,981,716...165,094,232
Ensembl chr 1:164,981,716...165,094,176

G

interferon regulatory factor 2 binding protein 2

decreases expression

Thimerosal results in decreased expression of IRF2BP2 mRNA

NCBI chr19:54,559,417...54,565,096
Ensembl chr19:54,560,128...54,566,642

G

inositol-3-phosphate synthase 1

decreases expression

Thimerosal results in decreased expression of ISYNA1 mRNA

NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979

G

inositol 1,4,5-trisphosphate receptor, type 3

decreases expression

Thimerosal results in decreased expression of ITPR3 mRNA

NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337

G

ITPR interacting domain containing 2

decreases expression

Thimerosal results in decreased expression of ITPRID2 mRNA

NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978

G

ITPRIP like 1

decreases expression

Thimerosal results in decreased expression of ITPRIPL1 mRNA

NCBI chr 3:114,403,123...114,407,917
Ensembl chr 3:114,402,270...114,414,497

G

ITPRIP like 2

decreases expression

Thimerosal results in decreased expression of ITPRIPL2 mRNA

NCBI chr 1:172,801,152...172,803,047
Ensembl chr 1:172,796,849...172,802,950

G

intersectin 2

decreases expression

Thimerosal results in decreased expression of ITSN2 mRNA

NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124

G

interacts with SUPT6H, CTD assembly factor 1

decreases expression

Thimerosal results in decreased expression of IWS1 mRNA

NCBI chr18:23,695,496...23,737,363
Ensembl chr18:23,695,425...23,736,172

G

jumonji domain containing 1C

decreases expression

Thimerosal results in decreased expression of JMJD1C mRNA

NCBI chr20:21,332,147...21,494,220
Ensembl chr20:21,332,147...21,463,122

G

junctophilin 3

decreases expression

Thimerosal results in decreased expression of JPH3 mRNA

NCBI chr19:49,793,967...49,855,338
Ensembl chr19:49,793,092...49,855,338

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Thimerosal results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunD proto-oncogene, AP-1 transcription factor subunit

decreases expression

Thimerosal results in decreased expression of JUND mRNA

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

KAT8 regulatory NSL complex subunit 1-like

increases expression

Thimerosal results in increased expression of KANSL1L mRNA

NCBI chr 9:68,211,151...68,316,992
Ensembl chr 9:68,211,189...68,300,222

G

lysine acetyltransferase 2B

increases expression

Thimerosal results in increased expression of KAT2B mRNA

NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064

G

lysine acetyltransferase 6A

decreases expression

Thimerosal results in decreased expression of KAT6A mRNA

NCBI chr16:69,084,914...69,165,923
Ensembl chr16:69,084,914...69,163,606

G

lysine acetyltransferase 8

decreases expression

Thimerosal results in decreased expression of KAT8 mRNA

NCBI chr 1:182,524,355...182,536,638
Ensembl chr 1:182,515,327...182,536,633

G

kelch repeat and BTB domain containing 2

decreases expression

Thimerosal results in decreased expression of KBTBD2 mRNA

NCBI chr 4:86,027,947...86,050,266
Ensembl chr 4:86,027,947...86,050,211

G

kelch repeat and BTB domain containing 8

increases expression

Thimerosal results in increased expression of KBTBD8 mRNA

NCBI chr 4:127,675,967...127,688,785
Ensembl chr 4:127,676,141...127,687,697

G

potassium voltage-gated channel subfamily B member 2

increases expression

Thimerosal results in increased expression of KCNB2 mRNA

NCBI chr 5:3,567,012...4,028,564
Ensembl chr 5:3,569,685...4,028,599

G

potassium voltage-gated channel interacting protein 3

multiple interactions

[SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased acetylation of and results in increased ubiquitination of KCNIP3 protein; [SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]; Resveratrol inhibits the reaction [[SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased acetylation of and results in increased ubiquitination of KCNIP3 protein]; Resveratrol inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]]

NCBI chr 3:114,677,027...114,742,923
Ensembl chr 3:114,677,030...114,743,556

G

potassium channel regulator

increases expression

Thimerosal results in increased expression of KCNRG mRNA

NCBI chr15:35,774,456...35,779,409
Ensembl chr15:35,774,326...35,779,415

G

KDEL endoplasmic reticulum protein retention receptor 1

decreases expression

Thimerosal results in decreased expression of KDELR1 mRNA

NCBI chr 1:96,347,258...96,358,145
Ensembl chr 1:96,347,150...96,358,157

G

lysine demethylase 4B

decreases expression

Thimerosal results in decreased expression of KDM4B mRNA

NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543

G

lysine demethylase 6A

decreases expression

Thimerosal results in decreased expression of KDM6A mRNA

NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062

G

ketohexokinase

decreases expression

Thimerosal results in decreased expression of KHK mRNA

NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717

G

kinesin family member 1A

decreases expression

Thimerosal results in decreased expression of KIF1A mRNA

NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480

G

kinesin family member 21B

decreases expression

Thimerosal results in decreased expression of KIF21B mRNA

NCBI chr13:47,576,129...47,626,112
Ensembl chr13:47,576,160...47,626,127

G

kinesin family member 22

decreases expression

Thimerosal results in decreased expression of KIF22 mRNA

NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401

G

KISS1 receptor

decreases expression

Thimerosal results in decreased expression of KISS1R mRNA

NCBI chr 7:9,785,135...9,790,283
Ensembl chr 7:9,785,135...9,788,793

G

KLF transcription factor 12

increases expression

Thimerosal results in increased expression of KLF12 mRNA

NCBI chr15:76,628,778...77,062,000
Ensembl chr15:76,637,654...77,062,056

G

KLF transcription factor 13

decreases expression

Thimerosal results in decreased expression of KLF13 mRNA

NCBI chr 1:117,505,857...117,536,626
Ensembl chr 1:117,503,602...117,551,227

G

KLF transcription factor 15

increases expression

Thimerosal results in increased expression of KLF15 mRNA

NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374

G

KLF transcription factor 4

increases expression

Thimerosal results in increased expression of KLF4 mRNA

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

kelch domain containing 10

decreases expression

Thimerosal results in decreased expression of KLHDC10 mRNA

NCBI chr 4:59,021,300...59,079,118
Ensembl chr 4:59,021,310...59,074,941

G

kelch-like family member 24

decreases expression

Thimerosal results in decreased expression of KLHL24 mRNA

NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636

G

kelch-like family member 3

decreases expression

Thimerosal results in decreased expression of KLHL3 mRNA

NCBI chr17:6,523,089...6,645,971
Ensembl chr17:6,521,912...6,642,154

G

kelch-like family member 41

increases expression

Thimerosal results in increased expression of KLHL41 mRNA

NCBI chr 3:54,434,291...54,447,415
Ensembl chr 3:54,434,234...54,449,222

G

lysine methyltransferase 2A

decreases expression

Thimerosal results in decreased expression of KMT2A mRNA

NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181

G

kinetochore scaffold 1

decreases expression

Thimerosal results in decreased expression of KNL1 mRNA

NCBI chr 3:106,029,627...106,091,915
Ensembl chr 3:106,029,661...106,091,915

G

KRAS proto-oncogene, GTPase

decreases expression

Thimerosal results in decreased expression of KRAS mRNA

NCBI chr 4:178,185,418...178,218,484

G

lysine-rich coiled-coil 1

increases expression

Thimerosal results in increased expression of KRCC1 mRNA

NCBI chr 4:103,261,642...103,274,672
Ensembl chr 4:103,261,536...103,277,156

G

KRR1, small subunit processome component homolog

increases expression

Thimerosal results in increased expression of KRR1 mRNA

NCBI chr 7:47,475,557...47,486,996
Ensembl chr 7:47,475,557...47,486,985

G

La ribonucleoprotein 1B

increases expression

Thimerosal results in increased expression of LARP1B mRNA

NCBI chr 2:123,936,057...123,969,254
Ensembl chr 2:123,935,983...123,968,896

G

La ribonucleoprotein 4

decreases expression

Thimerosal results in decreased expression of LARP4 mRNA

NCBI chr 7:131,104,470...131,152,692
Ensembl chr 7:131,101,564...131,150,811

G

La ribonucleoprotein 7, transcriptional regulator

increases expression

Thimerosal results in increased expression of LARP7 mRNA

NCBI chr 2:215,997,641...216,012,833
Ensembl chr 2:215,997,649...216,012,865

G

leucyl-tRNA synthetase 1

decreases expression

Thimerosal results in decreased expression of LARS1 mRNA

NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931

G

ligand dependent nuclear receptor corepressor-like

increases expression

Thimerosal results in increased expression of LCORL mRNA

NCBI chr14:65,271,339...65,407,732
Ensembl chr14:65,271,135...65,404,174

G

lactate dehydrogenase A

decreases expression

Thimerosal results in decreased expression of LDHA mRNA

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

galectin 3 binding protein

decreases expression

Thimerosal results in decreased expression of LGALS3BP mRNA

NCBI chr10:103,619,912...103,629,251
Ensembl chr10:103,619,908...103,629,256

G

galectin-like

decreases expression

Thimerosal results in decreased expression of LGALSL mRNA

NCBI chr14:94,996,991...95,004,499
Ensembl chr14:94,996,990...95,004,980

G

leucine rich repeat containing G protein coupled receptor 5

increases expression

Thimerosal results in increased expression of LGR5 mRNA

NCBI chr 7:51,087,059...51,221,882
Ensembl chr 7:51,088,239...51,222,446

G

leucine-rich repeat-containing G protein-coupled receptor 6

increases expression

Thimerosal results in increased expression of LGR6 mRNA

NCBI chr13:46,424,382...46,544,074
Ensembl chr13:46,424,383...46,543,945

G

luteinizing hormone subunit beta

increases expression

Thimerosal results in increased expression of LHB mRNA; Thimerosal results in increased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

LIM homeobox 9

decreases expression

Thimerosal results in decreased expression of LHX9 mRNA

NCBI chr13:50,389,052...50,409,947
Ensembl chr13:50,389,738...50,410,806

G

LIM domain and actin binding 1

decreases expression

Thimerosal results in decreased expression of LIMA1 mRNA

NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473

G

LIM zinc finger domain containing 1

increases expression

Thimerosal results in increased expression of LIMS1 mRNA

NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500

G

lin-7 homolog C, crumbs cell polarity complex component

increases expression

Thimerosal results in increased expression of LIN7C mRNA

NCBI chr 3:96,406,800...96,417,779
Ensembl chr 3:96,406,813...96,417,728

G

lin-9 DREAM MuvB core complex component

increases expression

Thimerosal results in increased expression of LIN9 mRNA

NCBI chr13:92,374,612...92,419,664
Ensembl chr13:92,374,593...92,419,654

G

lipopolysaccharide-induced TNF factor

decreases expression

Thimerosal results in decreased expression of LITAF mRNA

NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763

G

limb and CNS expressed 1 like

decreases expression

Thimerosal results in decreased expression of LIX1L mRNA

NCBI chr 2:184,136,018...184,161,918
Ensembl chr 2:184,136,038...184,161,916

G

LMBR1 domain containing 2

increases expression

Thimerosal results in increased expression of LMBRD2 mRNA

NCBI chr 2:58,189,558...58,251,565
Ensembl chr 2:58,189,558...58,247,076

G

lipase maturation factor 1

decreases expression

Thimerosal results in decreased expression of LMF1 mRNA

NCBI chr10:14,597,726...14,684,071
Ensembl chr10:14,597,594...14,684,119

G

leucyl and cystinyl aminopeptidase

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LNPEP mRNA

NCBI chr 1:58,258,642...58,355,532
Ensembl chr 1:58,258,642...58,354,544

G

lysophosphatidylcholine acyltransferase 1

increases expression

Thimerosal results in increased expression of LPCAT1 mRNA

NCBI chr 1:29,766,070...29,816,401
Ensembl chr 1:29,766,071...29,816,401

G

lysophosphatidylglycerol acyltransferase 1

decreases expression

Thimerosal results in decreased expression of LPGAT1 mRNA

NCBI chr13:103,294,622...103,365,372
Ensembl chr13:103,294,528...103,362,333

G

LDL receptor related protein 6

decreases expression

Thimerosal results in decreased expression of LRP6 mRNA

NCBI chr 4:167,269,856...167,400,364
Ensembl chr 4:167,270,353...167,400,497

G

leucine-rich pentatricopeptide repeat containing

increases expression

Thimerosal results in increased expression of LRPPRC mRNA

NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293

G

leucine rich repeat containing 26

decreases expression

Thimerosal results in decreased expression of LRRC26 mRNA

NCBI chr 3:8,102,361...8,103,687
Ensembl chr 3:8,102,361...8,103,687

G

leucine rich repeat containing 7

increases expression

Thimerosal results in increased expression of LRRC7 mRNA

NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547

G

leucine rich repeat containing 75B

decreases expression

Thimerosal results in decreased expression of LRRC75B mRNA

NCBI chr20:13,100,302...13,106,503
Ensembl chr20:13,100,302...13,106,503

G

LSM12 homolog

decreases expression

Thimerosal results in decreased expression of LSM12 mRNA

NCBI chr10:87,118,334...87,140,395
Ensembl chr10:87,118,416...87,140,396

G

LSM family member 14B

decreases expression

Thimerosal results in decreased expression of LSM14B mRNA

NCBI chr 3:167,125,633...167,136,417
Ensembl chr 3:167,125,628...167,136,432

G

LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

Thimerosal results in increased expression of LSM5 mRNA

NCBI chr 4:85,951,073...85,954,289
Ensembl chr 6:104,652,477...104,654,165
Ensembl chr 4:104,652,477...104,654,165

G

lanosterol synthase

decreases expression

Thimerosal results in decreased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

leukotriene A4 hydrolase

decreases expression

Thimerosal results in decreased expression of LTA4H mRNA

NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600

G

latent transforming growth factor beta binding protein 2

decreases expression

Thimerosal results in decreased expression of LTBP2 mRNA

NCBI chr 6:104,429,947...104,530,498
Ensembl chr 6:104,429,947...104,526,208

G

listerin E3 ubiquitin protein ligase 1

decreases expression

Thimerosal results in decreased expression of LTN1 mRNA

NCBI chr11:26,603,903...26,660,871
Ensembl chr11:26,603,903...26,660,886

G

leucine zipper protein 1

decreases expression

Thimerosal results in decreased expression of LUZP1 mRNA

NCBI chr 5:148,706,094...148,781,616
Ensembl chr 5:148,706,138...148,781,609

G

LysM domain containing 4

decreases expression

Thimerosal results in decreased expression of LYSMD4 mRNA

NCBI chr 1:120,839,180...120,845,148
Ensembl chr 1:120,839,282...120,845,135

G

MAF bZIP transcription factor B

increases expression

Thimerosal results in increased expression of MAFB mRNA

NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031

G

MAF bZIP transcription factor F

decreases expression

Thimerosal results in decreased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

MAGE family member L2

decreases expression

Thimerosal results in decreased expression of MAGEL2 mRNA

NCBI chr 1:115,880,142...115,884,684
Ensembl chr 1:115,880,474...115,884,250

G

membrane associated guanylate kinase, WW and PDZ domain containing 2

decreases expression

Thimerosal results in decreased expression of MAGI2 mRNA

NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240

G

MANSC domain containing 1

decreases expression

Thimerosal results in decreased expression of MANSC1 mRNA

NCBI chr 4:167,438,817...167,459,047
Ensembl chr 4:167,439,071...167,479,606

G

monoamine oxidase A

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen activated protein kinase kinase 2

decreases expression

Thimerosal results in decreased expression of MAP2K2 mRNA

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen-activated protein kinase kinase kinase 11

decreases expression

Thimerosal results in decreased expression of MAP3K11 mRNA

NCBI chr 1:202,975,353...202,988,655
Ensembl chr 1:202,975,353...202,988,652

G

mitogen activated protein kinase kinase kinase 3

decreases expression

Thimerosal results in decreased expression of MAP3K3 mRNA

NCBI chr10:91,020,174...91,088,852
Ensembl chr10:91,020,174...91,088,848

G

mitogen-activated protein kinase kinase kinase 6

decreases expression

Thimerosal results in decreased expression of MAP3K6 mRNA

NCBI chr 5:145,440,126...145,452,213
Ensembl chr 5:145,440,346...145,452,212

G

microtubule-associated protein 4

decreases expression

Thimerosal results in decreased expression of MAP4 mRNA

NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362

G

mitogen activated protein kinase kinase kinase kinase 1

decreases expression

Thimerosal results in decreased expression of MAP4K1 mRNA

NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493

G

mitogen-activated protein kinase kinase kinase kinase 5

decreases expression

Thimerosal results in decreased expression of MAP4K5 mRNA

NCBI chr 6:88,284,087...88,377,118
Ensembl chr 6:88,284,094...88,376,799

G

microtubule-associated protein 9

increases expression

Thimerosal results in increased expression of MAP9 mRNA

NCBI chr 2:167,708,661...167,743,927
Ensembl chr 2:167,708,765...167,740,736

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

Acetylcysteine inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

increases phosphorylation
decreases expression

Thimerosal results in increased phosphorylation of MAPK14 protein
Thimerosal results in decreased expression of MAPK14 mRNA

PMID:15737199 PMID:27188386

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions
increases phosphorylation

Thimerosal results in decreased phosphorylation of MAPK3 protein
Acetylcysteine inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK3 protein]
Thimerosal results in increased phosphorylation of MAPK3 protein

PMID:17698513 PMID:18495191

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

increases phosphorylation
increases expression

Thimerosal results in increased phosphorylation of MAPK8 protein
Thimerosal results in increased expression of MAPK8 mRNA

PMID:18495191 PMID:27188386

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases phosphorylation

Thimerosal results in increased phosphorylation of MAPK9 protein

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MAPK activated protein kinase 2

decreases expression

Thimerosal results in decreased expression of MAPKAPK2 mRNA

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

membrane associated ring-CH-type finger 1

increases expression

Thimerosal results in increased expression of MARCHF1 mRNA

NCBI chr16:23,255,551...24,114,290
Ensembl chr16:23,258,799...24,114,277

G

microtubule affinity regulating kinase 4

decreases expression

Thimerosal results in decreased expression of MARK4 mRNA

NCBI chr 1:79,075,353...79,108,882
Ensembl chr 1:79,068,904...79,108,556

G

methyl-CpG binding domain protein 2

decreases expression

Thimerosal results in decreased expression of MBD2 mRNA

NCBI chr18:64,174,002...64,240,795
Ensembl chr18:64,174,002...64,240,794

G

muscleblind-like splicing regulator 2

decreases expression

Thimerosal results in decreased expression of MBNL2 mRNA

NCBI chr15:97,385,278...97,542,924
Ensembl chr15:97,385,244...97,542,937

G

membrane bound O-acyltransferase domain containing 7

decreases expression

Thimerosal results in decreased expression of MBOAT7 mRNA

NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538

G

microcephalin 1

increases expression

Thimerosal results in increased expression of MCPH1 mRNA

NCBI chr16:71,021,855...71,224,067
Ensembl chr16:71,024,588...71,224,122

G

malate dehydrogenase 2

decreases expression

Thimerosal results in decreased expression of MDH2 mRNA

NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271

G

MTOR associated protein, eak-7 homolog

decreases expression

Thimerosal results in decreased expression of MEAK7 mRNA

NCBI chr19:47,813,899...47,836,830
Ensembl chr19:47,811,416...47,841,278

G

MDS1 and EVI1 complex locus

increases expression

Thimerosal results in increased expression of MECOM mRNA

NCBI chr 2:112,909,353...113,464,583
Ensembl chr 2:112,909,321...113,464,590

G

mediator complex subunit 13

decreases expression

Thimerosal results in decreased expression of MED13 mRNA

NCBI chr10:71,086,978...71,176,535
Ensembl chr10:71,090,516...71,177,242

G

mediator complex subunit 13L

increases expression

Thimerosal results in increased expression of MED13L mRNA

NCBI chr12:37,807,596...38,004,886
Ensembl chr12:37,808,285...38,004,473

G

mediator complex subunit 16

decreases expression

Thimerosal results in decreased expression of MED16 mRNA

NCBI chr 7:9,798,641...9,811,172
Ensembl chr 7:9,798,668...9,811,172

G

mediator complex subunit 17

increases expression

Thimerosal results in increased expression of MED17 mRNA

NCBI chr 8:12,101,594...12,120,592
Ensembl chr 8:12,101,594...12,120,592

G

mediator complex subunit 18

decreases expression

Thimerosal results in decreased expression of MED18 mRNA

NCBI chr 5:144,663,316...144,668,652
Ensembl chr 5:144,663,252...144,668,635

G

mediator complex subunit 21

increases expression

Thimerosal results in increased expression of MED21 mRNA

NCBI chr 4:179,560,509...179,583,811
Ensembl chr 4:179,560,579...179,567,548

G

mediator complex subunit 25

decreases expression

Thimerosal results in decreased expression of MED25 mRNA

NCBI chr 1:95,359,961...95,375,827
Ensembl chr 1:95,360,284...95,375,877

G

mesenteric estrogen-dependent adipogenesis

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEDAG mRNA

NCBI chr12:5,613,191...5,634,583
Ensembl chr12:5,613,208...5,634,767

G

multiple EGF-like-domains 6

decreases expression

Thimerosal results in decreased expression of MEGF6 mRNA

NCBI chr 5:164,738,272...164,839,142
Ensembl chr 5:164,738,352...164,839,139

G

methyltransferase 18, RPL3 N3(tau)-histidine

increases expression

Thimerosal results in increased expression of METTL18 mRNA

NCBI chr13:76,345,888...76,348,798
Ensembl chr13:76,345,957...76,348,836

G

O-6-methylguanine-DNA methyltransferase

decreases expression

Thimerosal results in decreased expression of MGMT mRNA

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

MIA SH3 domain ER export factor 3

increases expression

Thimerosal results in increased expression of MIA3 mRNA

NCBI chr13:94,970,421...95,012,071
Ensembl chr13:94,970,424...95,011,972

G

midline 1

decreases expression

Thimerosal results in decreased expression of MID1 mRNA

NCBI chr X:24,116,674...24,491,205
Ensembl chr X:24,120,293...24,248,353

G

MIER family member 3

increases expression

Thimerosal results in increased expression of MIER3 mRNA

NCBI chr 2:43,287,546...43,316,422
Ensembl chr 2:43,287,916...43,316,136

G

MHC I like leukocyte 1

decreases expression

Thimerosal results in decreased expression of MICA mRNA

NCBI chr 1:78,372,798...78,398,932
Ensembl chr 1:78,372,802...78,398,930

G

MIS18 binding protein 1

decreases expression

Thimerosal results in decreased expression of MIS18BP1 mRNA

NCBI chr 6:83,182,497...83,231,978
Ensembl chr 6:83,182,499...83,231,383

G

muskelin 1

increases expression

Thimerosal results in increased expression of MKLN1 mRNA

NCBI chr 4:59,815,912...60,124,047
Ensembl chr 4:60,002,464...60,123,993

G

makorin, ring finger protein, 3

decreases expression

Thimerosal results in decreased expression of MKRN3 mRNA

NCBI chr 1:115,926,774...115,929,288
Ensembl chr 1:115,926,776...115,929,283

G

myeloid leukemia factor 2

decreases expression

Thimerosal results in decreased expression of MLF2 mRNA

NCBI chr 4:157,739,651...157,744,325
Ensembl chr 4:157,728,756...157,744,317

G

matrix metallopeptidase 16

affects expression

Thimerosal affects the expression of MMP16 mRNA

NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388

G

MOB kinase activator 1A

decreases expression

Thimerosal results in decreased expression of MOB1A mRNA

NCBI chr 4:115,831,581...115,848,561
Ensembl chr 4:115,831,551...115,848,561

G

mannose phosphate isomerase

decreases expression

Thimerosal results in decreased expression of MPI mRNA

NCBI chr 8:57,947,883...57,956,205
Ensembl chr 8:57,947,893...57,956,150

G

melanocortin 2 receptor accessory protein 2

decreases expression

Thimerosal results in decreased expression of MRAP2 mRNA

NCBI chr 8:88,088,293...88,144,636
Ensembl chr 8:88,088,272...88,143,886

G

maestro heat-like repeat family member 1

decreases expression

Thimerosal results in decreased expression of MROH1 mRNA

NCBI chr 7:108,098,708...108,172,146
Ensembl chr 7:108,102,734...108,172,146

G

mitochondrial ribosomal protein L1

increases expression

Thimerosal results in increased expression of MRPL1 mRNA

NCBI chr14:13,300,522...13,359,654
Ensembl chr14:13,300,522...13,359,721

G

mitochondrial ribosomal protein L10

decreases expression

Thimerosal results in decreased expression of MRPL10 mRNA

NCBI chr10:82,026,031...82,034,451
Ensembl chr10:82,026,031...82,034,443

G

mitochondrial ribosomal protein L50

increases expression

Thimerosal results in increased expression of MRPL50 mRNA

NCBI chr 5:63,867,437...63,872,591

G

mitochondrial ribosomal protein S2

decreases expression

Thimerosal results in decreased expression of MRPS2 mRNA

NCBI chr 3:11,803,044...11,806,341
Ensembl chr 3:11,801,310...11,806,313

G

membrane spanning 4-domains A15

increases expression

Thimerosal results in increased expression of MS4A15 mRNA

NCBI chr 1:207,628,305...207,641,799
Ensembl chr 1:207,628,305...207,641,799

G

moesin

decreases expression

Thimerosal results in decreased expression of MSN mRNA

NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628

G

metallothionein 2A

increases expression

Thimerosal results in increased expression of MT2 mRNA; Thimerosal results in increased expression of MT2 protein

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

metallothionein 3

increases expression

Thimerosal results in increased expression of MT3 mRNA

NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158

G

metastasis associated 1

decreases expression

Thimerosal results in decreased expression of MTA1 mRNA

NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641

G

metastasis associated 1 family, member 2

decreases expression

Thimerosal results in decreased expression of MTA2 mRNA

NCBI chr 1:205,838,181...205,846,903
Ensembl chr 1:205,837,964...205,846,946

G

mitochondrial amidoxime reducing component 2

decreases expression

Thimerosal results in decreased expression of MTARC2 mRNA

NCBI chr13:96,362,810...96,397,284

G

microtubule crosslinking factor 2

increases expression

Thimerosal results in increased expression of MTCL2 mRNA

NCBI chr 3:145,669,102...145,741,578
Ensembl chr 3:145,675,443...145,740,871

G

MTCL family member 3

decreases expression

Thimerosal results in decreased expression of MTCL3 mRNA

NCBI chr 1:28,629,036...28,701,416
Ensembl chr 1:28,620,293...28,701,796

G

mitochondrial fission process 1

decreases expression

Thimerosal results in decreased expression of MTFP1 mRNA

NCBI chr14:78,968,434...78,972,274
Ensembl chr14:78,968,442...78,972,274

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like

increases expression

Thimerosal results in increased expression of MTHFD2L mRNA

NCBI chr14:17,089,947...17,170,036
Ensembl chr14:17,089,952...17,170,112

G

mitochondrial poly(A) polymerase

increases expression

Thimerosal results in increased expression of MTPAP mRNA

NCBI chr17:53,320,739...53,341,500
Ensembl chr17:53,320,741...53,341,538

G

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions
decreases expression

Glutathione inhibits the reaction [Thimerosal inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Thimerosal affects the reaction [IGF1 protein results in increased activity of MTR protein]; Thimerosal inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Thimerosal inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]
Thimerosal results in decreased expression of MTR mRNA

PMID:14745455 PMID:26989453 PMID:27188386

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

multivesicular body subunit 12A

decreases expression

Thimerosal results in decreased expression of MVB12A mRNA

NCBI chr16:18,252,227...18,257,111
Ensembl chr16:18,252,222...18,257,539

G

max dimerization protein 1

increases expression

Thimerosal results in increased expression of MXD1 mRNA

NCBI chr 4:119,097,353...119,118,080
Ensembl chr 4:119,097,353...119,117,751

G

matrix remodeling associated 8

decreases expression

Thimerosal results in decreased expression of MXRA8 mRNA

NCBI chr 5:166,448,919...166,453,645
Ensembl chr 5:166,449,154...166,453,636

G

myoneurin

increases expression

Thimerosal results in increased expression of MYNN mRNA

NCBI chr 2:112,779,654...112,797,188
Ensembl chr 2:112,779,657...112,796,397

G

myosin IE

decreases expression

Thimerosal results in decreased expression of MYO1E mRNA

NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169

G

myosin VA

decreases expression

Thimerosal results in decreased expression of MYO5A mRNA

NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918

G

myosin VI

decreases expression

Thimerosal results in decreased expression of MYO6 mRNA

NCBI chr 8:81,087,157...81,242,022
Ensembl chr 8:81,087,139...81,239,292

G

myosin IXA

increases expression

Thimerosal results in increased expression of MYO9A mRNA

NCBI chr 8:60,149,234...60,352,330
Ensembl chr 8:60,149,234...60,350,514

G

myeloid zinc finger 1

decreases expression

Thimerosal results in decreased expression of MZF1 mRNA

NCBI chr 1:73,670,522...73,682,885
Ensembl chr 1:73,670,541...73,681,635

G

NEDD4 binding protein 2-like 2

increases expression

Thimerosal results in increased expression of N4BP2L2 mRNA

NCBI chr12:137,342...200,292
Ensembl chr12:103,590...197,784

G

Nedd4 binding protein 3

decreases expression

Thimerosal results in decreased expression of N4BP3 mRNA

NCBI chr10:35,898,031...35,906,704
Ensembl chr10:35,899,096...35,907,001

G

N(alpha)-acetyltransferase 16, NatA auxiliary subunit

decreases expression

Thimerosal results in decreased expression of NAA16 mRNA

NCBI chr15:54,711,620...54,770,915
Ensembl chr15:54,711,621...54,770,896

G

N-acylethanolamine acid amidase

increases expression

Thimerosal results in increased expression of NAAA mRNA

NCBI chr14:15,777,306...15,796,411
Ensembl chr14:15,777,306...15,796,410

G

nicotinate phosphoribosyltransferase

decreases expression

Thimerosal results in decreased expression of NAPRT mRNA

NCBI chr 7:107,576,645...107,580,102
Ensembl chr 7:107,576,627...107,580,102

G

nuclear autoantigenic sperm protein

decreases expression

Thimerosal results in decreased expression of NASP mRNA

NCBI chr 5:130,057,363...130,083,003
Ensembl chr 5:130,057,363...130,082,928

G

N-acetyltransferase domain containing 1

decreases expression

Thimerosal results in decreased expression of NATD1 mRNA

NCBI chr10:45,580,154...45,590,333

G

neuron navigator 3

increases expression

Thimerosal results in increased expression of NAV3 mRNA

NCBI chr 7:45,052,206...45,840,471
Ensembl chr 7:45,054,296...45,840,698

G

NBAS subunit of NRZ tethering complex

decreases expression

Thimerosal results in decreased expression of NBAS mRNA

NCBI chr 6:36,048,357...36,353,206
Ensembl chr 6:36,048,191...36,352,984

G

neural cell adhesion molecule 1

decreases expression

Thimerosal results in decreased expression of NCAM1 mRNA

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

N-myc downstream regulated 1

decreases expression

Thimerosal results in decreased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

NADH:ubiquinone oxidoreductase subunit A5

increases expression

Thimerosal results in increased expression of NDUFA5 mRNA

NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598

G

NADH:ubiquinone oxidoreductase subunit A9

increases expression

Thimerosal results in increased expression of NDUFA9 mRNA

NCBI chr 4:159,659,242...159,688,034
Ensembl chr 4:159,659,242...159,688,018

G

NADH:ubiquinone oxidoreductase complex assembly factor 4

increases expression

Thimerosal results in increased expression of NDUFAF4 mRNA

NCBI chr 5:38,605,169...38,610,341
Ensembl chr 5:38,605,153...38,610,336

G

NADH:ubiquinone oxidoreductase subunit B7

decreases expression

Thimerosal results in decreased expression of NDUFB7 mRNA

NCBI chr19:24,568,241...24,572,579
Ensembl chr19:24,568,241...24,572,579

G

neurofilament heavy chain

decreases expression

Thimerosal results in decreased expression of NEFH mRNA

NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351

G

neuronal growth regulator 1

decreases expression

Thimerosal results in decreased expression of NEGR1 mRNA

NCBI chr 2:245,624,460...246,359,605
Ensembl chr 2:245,624,435...246,356,730

G

nestin

decreases expression

Thimerosal results in decreased expression of NES mRNA

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

neurofibromin 1

affects expression

Thimerosal affects the expression of NF1 mRNA

NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658

G

nuclear factor of activated T-cells 5

decreases expression

Thimerosal results in decreased expression of NFAT5 mRNA

NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675

G

nuclear factor of activated T-cells 2 interacting protein

decreases expression

Thimerosal results in decreased expression of NFATC2IP mRNA

NCBI chr 1:180,954,834...180,971,847
Ensembl chr 1:180,955,043...180,971,747

G

nuclear transcription factor Y subunit beta

increases expression

Thimerosal results in increased expression of NFYB mRNA

NCBI chr 7:20,964,988...20,980,569
Ensembl chr 7:20,964,993...20,980,565

G

nerve growth factor

multiple interactions
decreases response to substance

[Thimerosal co-treated with NGF protein] results in decreased phosphorylation of NTRK1 protein
NGF protein results in decreased susceptibility to Thimerosal

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

NIPA-like domain containing 3

decreases expression

Thimerosal results in decreased expression of NIPAL3 mRNA

NCBI chr 5:147,687,310...147,725,838
Ensembl chr 5:147,685,288...147,726,351

G

NIPBL, cohesin loading factor

decreases expression

Thimerosal results in decreased expression of NIPBL mRNA

NCBI chr 2:57,399,443...57,586,770
Ensembl chr 2:57,399,445...57,565,899

G

nipsnap homolog 1

decreases expression

Thimerosal results in decreased expression of NIPSNAP1 mRNA

NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098

G

sodium/potassium transporting ATPase interacting 2

decreases expression

Thimerosal results in decreased expression of NKAIN2 mRNA

NCBI chr 1:24,668,627...25,877,051
Ensembl chr 1:24,669,462...25,877,064

G

NLR family member X1

decreases expression

Thimerosal results in decreased expression of NLRX1 mRNA

NCBI chr 8:44,588,476...44,606,678
Ensembl chr 8:44,590,048...44,606,484

G

NME/NM23 nucleoside diphosphate kinase 4

decreases expression

Thimerosal results in decreased expression of NME4 mRNA

NCBI chr10:15,114,624...15,118,479
Ensembl chr10:15,002,926...15,118,479

G

noggin

multiple interactions
decreases expression

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APOH mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPEB2 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LNPEP mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP1LC3C mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEDAG mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PITPNM2 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEPSECS mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLCO4A1-AS1 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMC5 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABTB3 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALML4 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAPN5 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLCN mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FRA10AC1 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAOA mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OTULINL mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIAS2 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHF2 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POP1 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAPCD2 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A21 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A5 mRNA; [NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC39C mRNA
Thimerosal results in decreased expression of NOG mRNA

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

nucleolar protein 3

decreases expression

Thimerosal results in decreased expression of NOL3 mRNA

NCBI chr19:33,154,061...33,158,250
Ensembl chr19:33,154,062...33,158,250

G

NOP53 ribosome biogenesis factor

decreases expression

Thimerosal results in decreased expression of NOP53 mRNA

NCBI chr 1:76,629,084...76,636,902
Ensembl chr 1:76,629,069...76,636,902

G

neuronal PAS domain protein 3

increases expression

Thimerosal results in increased expression of NPAS3 mRNA

NCBI chr 6:70,702,773...71,527,928
Ensembl chr 6:70,703,170...71,524,884

G

nuclear protein, co-activator of histone transcription

increases expression

Thimerosal results in increased expression of NPAT mRNA

NCBI chr 8:53,932,993...53,970,875
Ensembl chr 8:53,932,993...53,970,875

G

nephrocystin 1

increases expression

Thimerosal results in increased expression of NPHP1 mRNA

NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234

G

NPR3-like, GATOR1 complex subunit

decreases expression

Thimerosal results in decreased expression of NPRL3 mRNA

NCBI chr10:15,355,361...15,395,812
Ensembl chr10:15,355,355...15,395,810

G

NAD(P)H quinone dehydrogenase 1

increases expression

Thimerosal results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 2, group C, member 2

decreases expression

Thimerosal results in decreased expression of NR2C2 mRNA

NCBI chr 4:124,610,216...124,666,813
Ensembl chr 4:124,608,960...124,661,902

G

nuclear receptor subfamily 4, group A, member 1

increases expression

Thimerosal results in increased expression of NR4A1 mRNA

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

nuclear receptor subfamily 4, group A, member 2

increases expression

Thimerosal results in increased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

nardilysin convertase

increases expression

Thimerosal results in increased expression of NRDC mRNA

NCBI chr 5:123,755,807...123,818,910
Ensembl chr 5:123,755,806...123,818,595

G

nurim

decreases expression

Thimerosal results in decreased expression of NRM mRNA

NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802

G

5'-nucleotidase domain containing 2

decreases expression

Thimerosal results in decreased expression of NT5DC2 mRNA

NCBI chr16:6,322,485...6,330,538
Ensembl chr16:6,322,236...6,330,537

G

neurotrophic receptor tyrosine kinase 1

multiple interactions

[Thimerosal co-treated with NGF protein] results in decreased phosphorylation of NTRK1 protein

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

neurotrophic receptor tyrosine kinase 3

decreases expression

Thimerosal results in decreased expression of NTRK3 mRNA

NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286

G

negative regulator of ubiquitin-like proteins 1

decreases expression

Thimerosal results in decreased expression of NUB1 mRNA

NCBI chr 4:10,442,917...10,473,689
Ensembl chr 4:10,442,917...10,473,694

G

NYN domain and retroviral integrase containing

decreases expression

Thimerosal results in decreased expression of NYNRIN mRNA

NCBI chr15:29,332,873...29,355,215
Ensembl chr15:29,332,869...29,355,215

G

ORC ubiquitin ligase 1

increases expression

Thimerosal results in increased expression of OBI1 mRNA

NCBI chr15:81,269,413...81,308,734
Ensembl chr15:81,269,416...81,308,734

G

obscurin like cytoskeletal adaptor 1

decreases expression

Thimerosal results in decreased expression of OBSL1 mRNA

NCBI chr 9:76,967,802...76,993,771
Ensembl chr 9:76,974,253...76,993,560

G

OCIA domain containing 1

decreases expression

Thimerosal results in decreased expression of OCIAD1 mRNA

NCBI chr14:34,897,851...34,915,291
Ensembl chr14:34,897,847...34,915,286

G

olfactory marker protein

increases expression

Thimerosal results in increased expression of OMP mRNA

NCBI chr 1:152,440,278...152,440,828
Ensembl chr 1:152,433,652...152,441,922

G

oxysterol binding protein-like 8

decreases expression

Thimerosal results in decreased expression of OSBPL8 mRNA

NCBI chr 7:46,596,944...46,749,888
Ensembl chr 7:46,596,983...46,749,888

G

OTU deubiquitinase, ubiquitin aldehyde binding 2

decreases expression

Thimerosal results in decreased expression of OTUB2 mRNA

NCBI chr 6:122,545,067...122,563,657
Ensembl chr 6:122,545,061...122,563,644

G

OTU deubiquitinase 4

decreases expression

Thimerosal results in decreased expression of OTUD4 mRNA

NCBI chr19:28,236,713...28,279,815
Ensembl chr19:28,236,713...28,279,815

G

OTU deubiquitinase 6B

increases expression

Thimerosal results in increased expression of OTUD6B mRNA

NCBI chr 5:28,181,992...28,214,486
Ensembl chr 5:28,023,594...28,214,334

G

OTU deubiquitinase with linear linkage specificity like

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OTULINL mRNA

NCBI chr 2:78,405,994...78,433,860
Ensembl chr 2:78,408,593...78,433,838

G

prolyl 4-hydroxylase subunit alpha 1

decreases expression

Thimerosal results in decreased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

protein kinase C and casein kinase substrate in neurons 1

decreases expression

Thimerosal results in decreased expression of PACSIN1 mRNA

NCBI chr20:5,718,134...5,768,064
Ensembl chr20:5,719,857...5,765,313

G

poly(A) binding protein interacting protein 2B

decreases expression

Thimerosal results in decreased expression of PAIP2B mRNA

NCBI chr 4:116,292,001...116,323,387
Ensembl chr 4:116,292,020...116,323,379

G

phosphatase domain containing, paladin 1

decreases expression

Thimerosal results in decreased expression of PALD1 mRNA

NCBI chr20:29,269,814...29,334,850
Ensembl chr20:29,270,193...29,334,858

G

pantothenate kinase 2

increases expression

Thimerosal results in increased expression of PANK2 mRNA

NCBI chr 3:118,483,382...118,519,551
Ensembl chr 3:118,483,444...118,518,320

G

par-3 family cell polarity regulator beta

increases expression

Thimerosal results in increased expression of PARD3B mRNA

NCBI chr 9:63,038,435...64,067,178
Ensembl chr 9:63,038,436...64,068,053

G

PARP1 binding protein

increases expression

Thimerosal results in increased expression of PARPBP mRNA

NCBI chr 7:22,511,427...22,580,834
Ensembl chr 7:22,511,427...22,573,695

G

pyruvate carboxylase

decreases expression

Thimerosal results in decreased expression of PC mRNA

NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380

G

poly(rC) binding protein 2

decreases expression

Thimerosal results in decreased expression of PCBP2 mRNA

NCBI chr 7:133,605,375...133,631,312
Ensembl chr 7:133,605,573...133,629,863

G

protocadherin alpha 9

increases expression

Thimerosal results in increased expression of PCDHA9 mRNA

Ensembl chr18:28,581,225...28,846,211

G

piccolo (presynaptic cytomatrix protein)

increases expression

Thimerosal results in increased expression of PCLO mRNA

NCBI chr 4:19,691,439...20,050,015
Ensembl chr 4:19,695,315...20,049,885

G

pericentriolar material 1

decreases expression

Thimerosal results in decreased expression of PCM1 mRNA

NCBI chr16:51,008,315...51,105,261
Ensembl chr16:51,008,315...51,105,091

G

PEST proteolytic signal containing nuclear protein

decreases expression

Thimerosal results in decreased expression of PCNP mRNA

NCBI chr11:44,592,766...44,607,372
Ensembl chr11:44,592,742...44,607,348

G

pecanex 1

increases expression

Thimerosal results in increased expression of PCNX1 mRNA

NCBI chr 6:101,565,461...101,702,339
Ensembl chr 6:101,565,580...101,702,271

G

Purkinje cell protein 4

increases expression

Thimerosal results in increased expression of PCP4 mRNA

NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725

G

proprotein convertase subtilisin/kexin type 2

increases expression

Thimerosal results in increased expression of PCSK2 mRNA

NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127

G

protein disulfide isomerase family A, member 3

decreases expression

Thimerosal results in decreased expression of PDIA3 mRNA

NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236

G

pyruvate dehydrogenase kinase 1

decreases expression

Thimerosal results in decreased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

PDZ and LIM domain 4

decreases expression

Thimerosal results in decreased expression of PDLIM4 mRNA

NCBI chr10:38,198,686...38,212,935
Ensembl chr10:38,198,689...38,212,938

G

decaprenyl diphosphate synthase subunit 2

decreases expression

Thimerosal results in decreased expression of PDSS2 mRNA

NCBI chr20:46,709,631...46,938,704
Ensembl chr20:46,709,649...46,938,708

G

prodynorphin

multiple interactions

[SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased expression of PDYN mRNA; Resveratrol inhibits the reaction [[SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased expression of PDYN mRNA]

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

plasmanylethanolamine desaturase 1

decreases expression

Thimerosal results in decreased expression of PEDS1 mRNA

NCBI chr 3:156,350,135...156,369,309
Ensembl chr 3:156,349,526...156,369,314

G

proline, glutamate and leucine rich protein 1

decreases expression

Thimerosal results in decreased expression of PELP1 mRNA

NCBI chr10:55,094,798...55,111,833
Ensembl chr10:55,094,796...55,111,994

G

peroxisomal biogenesis factor 6

decreases expression

Thimerosal results in decreased expression of PEX6 mRNA

NCBI chr 9:14,258,145...14,270,335
Ensembl chr 9:14,258,145...14,270,303

G

prefoldin subunit 4

increases expression

Thimerosal results in increased expression of PFDN4 mRNA

NCBI chr 3:159,303,173...159,311,221
Ensembl chr 3:159,303,071...159,311,219

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2

decreases expression

Thimerosal results in decreased expression of PFKFB2 mRNA

NCBI chr13:42,147,473...42,174,699
Ensembl chr13:42,147,478...42,174,699

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

decreases expression

Thimerosal results in decreased expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

phosphofructokinase, platelet

decreases expression

Thimerosal results in decreased expression of PFKP mRNA

NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018

G

profilin 1

decreases expression

Thimerosal results in decreased expression of PFN1 mRNA

NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631

G

phosphoglycerate mutase 1

decreases expression

Thimerosal results in decreased expression of PGAM1 mRNA

NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452

G

post-GPI attachment to proteins inositol deacylase 1

increases expression

Thimerosal results in increased expression of PGAP1 mRNA

NCBI chr 9:55,975,574...56,044,325
Ensembl chr 9:55,975,667...56,044,464

G

post-GPI attachment to proteins 2

decreases expression

Thimerosal results in decreased expression of PGAP2 mRNA

NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114

G

post-GPI attachment to proteins GalNAc transferase 4

decreases expression

Thimerosal results in decreased expression of PGAP4 mRNA

NCBI chr 5:63,931,916...63,947,004
Ensembl chr 5:63,930,682...63,951,716

G

post-GPI attachment to proteins 6

decreases expression

Thimerosal results in decreased expression of PGAP6 mRNA

NCBI chr10:15,138,918...15,148,431
Ensembl chr10:15,138,959...15,148,431

G

placental growth factor

increases expression

Thimerosal results in increased expression of PGF mRNA

NCBI chr 6:104,816,102...104,826,685
Ensembl chr 6:104,816,104...104,826,685

G

phosphoglycerate kinase 1

decreases expression

Thimerosal results in decreased expression of PGK1 mRNA

NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418

G

6-phosphogluconolactonase

decreases expression

Thimerosal results in decreased expression of PGLS mRNA

NCBI chr16:18,300,317...18,305,803
Ensembl chr16:18,300,317...18,305,803

G

phosphoglucomutase 1

decreases expression

Thimerosal results in decreased expression of PGM1 mRNA

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

pyroglutamyl-peptidase I

decreases expression

Thimerosal results in decreased expression of PGPEP1 mRNA

NCBI chr16:18,770,563...18,782,968
Ensembl chr16:18,771,021...18,783,478

G

phosphorylated adaptor for RNA export

increases expression

Thimerosal results in increased expression of PHAX mRNA

NCBI chr18:50,053,133...50,069,823
Ensembl chr18:50,053,023...50,069,823

G

PHD finger protein 20

increases expression

Thimerosal results in increased expression of PHF20 mRNA

NCBI chr 3:144,710,253...144,816,696
Ensembl chr 3:144,710,353...144,814,439

G

PHD finger protein 20-like 1

decreases expression

Thimerosal results in decreased expression of PHF20L1 mRNA

NCBI chr 7:98,330,580...98,396,526
Ensembl chr 7:98,330,580...98,396,526

G

PHD finger protein 21A

decreases expression

Thimerosal results in decreased expression of PHF21A mRNA

NCBI chr 3:78,158,760...78,331,903
Ensembl chr 3:78,194,549...78,331,865

G

phosphorylase kinase regulatory subunit beta

decreases expression

Thimerosal results in decreased expression of PHKB mRNA

NCBI chr19:21,013,719...21,210,671
Ensembl chr19:21,025,733...21,210,633

G

pleckstrin homology-like domain, family B, member 2

decreases expression

Thimerosal results in decreased expression of PHLDB2 mRNA

NCBI chr11:54,859,173...55,078,212
Ensembl chr11:54,859,135...55,078,467

G

pleckstrin homology-like domain, family B, member 3

decreases expression

Thimerosal results in decreased expression of PHLDB3 mRNA

NCBI chr 1:80,201,083...80,219,541
Ensembl chr 1:80,201,578...80,219,534

G

putative homeodomain transcription factor 2

increases expression

Thimerosal results in increased expression of PHTF2 mRNA

NCBI chr 4:14,215,190...14,330,549
Ensembl chr 4:14,215,263...14,330,513

G

phosphatidylinositol 4-kinase type 2 alpha

decreases expression

Thimerosal results in decreased expression of PI4K2A mRNA

NCBI chr 1:240,902,804...240,929,234
Ensembl chr 1:240,902,855...240,929,337

G

protein inhibitor of activated STAT, 2

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIAS2 mRNA

NCBI chr18:70,608,034...70,714,295
Ensembl chr18:70,607,665...70,710,033

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha

increases expression

Thimerosal results in increased expression of PIK3C2A mRNA

NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

increases expression

Thimerosal results in increased expression of PIK3CA mRNA

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

peptidylprolyl cis/trans isomerase, NIMA-interacting 4

decreases expression

Thimerosal results in decreased expression of PIN4 mRNA

NCBI chr X:67,232,066...67,238,709
Ensembl chr X:67,232,081...67,238,702

G

pirin

increases expression

Thimerosal results in increased expression of PIR mRNA

NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218

G

phosphatidylinositol transfer protein, membrane-associated 2

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PITPNM2 mRNA

NCBI chr12:32,347,455...32,479,103
Ensembl chr12:32,380,805...32,479,102

G

protein kinase N3

decreases expression

Thimerosal results in decreased expression of PKN3 mRNA

NCBI chr 3:13,350,082...13,363,572
Ensembl chr 3:13,335,041...13,363,567

G

phospholipase A and acyltransferase 1

decreases expression

Thimerosal results in decreased expression of PLAAT1 mRNA

NCBI chr11:71,517,492...71,537,142
Ensembl chr11:71,517,493...71,527,020

G

phospholipase C, beta 4

decreases expression

Thimerosal results in decreased expression of PLCB4 mRNA

NCBI chr 3:122,952,965...123,322,522
Ensembl chr 3:122,953,196...123,322,392

G

phospholipase C, gamma 1

increases cleavage

Thimerosal results in increased cleavage of PLCG1 protein

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

pleckstrin homology domain containing A2

decreases expression

Thimerosal results in decreased expression of PLEKHA2 mRNA

NCBI chr16:66,938,684...67,000,661
Ensembl chr16:66,939,109...66,999,395

G

pleckstrin homology domain containing A5

decreases expression

Thimerosal results in decreased expression of PLEKHA5 mRNA

NCBI chr 4:173,333,891...173,503,546
Ensembl chr 4:173,334,055...173,503,546

G

pleckstrin homology domain containing A6

decreases expression

Thimerosal results in decreased expression of PLEKHA6 mRNA

NCBI chr13:44,614,740...44,754,951
Ensembl chr13:44,615,011...44,754,673

G

pleckstrin homology domain containing B1

decreases expression

Thimerosal results in decreased expression of PLEKHB1 mRNA

NCBI chr 1:154,998,798...155,013,094
Ensembl chr 1:154,998,800...155,016,142

G

pleckstrin homology and FYVE domain containing 2

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHF2 mRNA

NCBI chr 5:24,091,077...24,106,758
Ensembl chr 5:24,090,688...24,106,601

G

pleckstrin homology and RhoGEF domain containing G4

decreases expression

Thimerosal results in decreased expression of PLEKHG4 mRNA

NCBI chr19:33,251,788...33,266,490
Ensembl chr19:33,249,706...33,266,357

G

polo-like kinase 2

increases expression

Thimerosal results in increased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1

decreases expression

Thimerosal results in decreased expression of PLOD1 mRNA

NCBI chr 5:158,340,674...158,367,581
Ensembl chr 5:158,340,490...158,367,620

G

phospholipid phosphatase related 3

decreases expression

Thimerosal results in decreased expression of PLPPR3 mRNA

NCBI chr 7:9,831,162...9,842,434
Ensembl chr 7:9,831,162...9,845,296

G

plexin C1

decreases expression

Thimerosal results in decreased expression of PLXNC1 mRNA

NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779

G

pro-melanin-concentrating hormone

increases expression

Thimerosal results in increased expression of PMCH mRNA

NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250

G

PML nuclear body scaffold

decreases expression

Thimerosal results in decreased expression of PML mRNA

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

patatin-like phospholipase domain containing 3

decreases expression

Thimerosal results in decreased expression of PNPLA3 mRNA

NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077

G

DNA polymerase epsilon 4, accessory subunit

increases expression

Thimerosal results in increased expression of POLE4 mRNA

NCBI chr 4:115,165,285...115,171,097
Ensembl chr 4:115,165,285...115,171,097

G

RNA polymerase mitochondrial

decreases expression

Thimerosal results in decreased expression of POLRMT mRNA

NCBI chr 7:9,959,532...9,969,791
Ensembl chr 7:9,959,576...9,969,791

G

proopiomelanocortin

increases expression

Thimerosal results in increased expression of POMC mRNA; Thimerosal results in increased expression of POMC protein

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)

decreases expression

Thimerosal results in decreased expression of POMGNT2 mRNA

NCBI chr 8:121,645,106...121,660,761
Ensembl chr 8:121,644,970...121,660,757

G

POP1 homolog, ribonuclease P/MRP subunit

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POP1 mRNA

NCBI chr 7:65,705,348...65,733,143
Ensembl chr 7:65,705,368...65,733,141

G

POU class 1 homeobox 1

increases expression

Thimerosal results in increased expression of POU1F1 mRNA

NCBI chr11:3,316,818...3,334,804
Ensembl chr11:3,317,058...3,334,801

G

PTPRF interacting protein alpha 4

decreases expression

Thimerosal results in decreased expression of PPFIA4 mRNA

NCBI chr13:45,753,827...45,802,305
Ensembl chr13:45,753,827...45,802,261

G

PPFIA binding protein 1

decreases expression

Thimerosal results in decreased expression of PPFIBP1 mRNA

NCBI chr 4:179,807,579...179,951,428
Ensembl chr 4:179,808,794...179,951,428

G

peptidylprolyl isomerase A

decreases expression

Thimerosal results in decreased expression of PPIA mRNA

NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601

G

peptidylprolyl isomerase like 2

decreases expression

Thimerosal results in decreased expression of PPIL2 mRNA

NCBI chr11:83,897,719...83,920,970
Ensembl chr11:83,897,764...83,922,144

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

decreases expression

Thimerosal results in decreased expression of PPP1R14A mRNA

NCBI chr 1:84,583,127...84,590,743
Ensembl chr 1:84,586,627...84,590,671

G

protein phosphatase 1, regulatory subunit 3B

decreases expression

Thimerosal results in decreased expression of PPP1R3B mRNA

NCBI chr16:56,830,011...56,842,395
Ensembl chr16:56,829,660...56,842,406

G

protein phosphatase 1, regulatory subunit 3E

decreases expression

Thimerosal results in decreased expression of PPP1R3E mRNA

NCBI chr15:28,348,443...28,349,603
Ensembl chr15:28,347,854...28,349,603

G

PR/SET domain 2

decreases expression

Thimerosal results in decreased expression of PRDM2 mRNA

NCBI chr 5:155,421,066...155,531,884
Ensembl chr 5:155,422,134...155,531,825

G

PRELI domain containing 2

decreases expression

Thimerosal results in decreased expression of PRELID2 mRNA

NCBI chr18:33,869,934...33,961,320
Ensembl chr18:33,873,599...33,961,225

G

prolyl endopeptidase-like

increases expression

Thimerosal results in increased expression of PREPL mRNA

NCBI chr 6:9,580,367...9,609,957
Ensembl chr 6:9,580,217...9,607,772

G

phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2

increases expression

Thimerosal results in increased expression of PREX2 mRNA

NCBI chr 5:7,937,692...8,253,112
Ensembl chr 5:7,942,573...8,253,068

G

DNA primase subunit 2

increases expression

Thimerosal results in increased expression of PRIM2 mRNA

NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030

G

proline rich membrane anchor 1

decreases expression

Thimerosal results in decreased expression of PRIMA1 mRNA

NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921

G

protein kinase AMP-activated non-catalytic subunit beta 2

decreases expression

Thimerosal results in decreased expression of PRKAB2 mRNA

NCBI chr 2:185,257,218...185,272,846
Ensembl chr 2:185,257,213...185,269,872

G

protein kinase D2

decreases expression

Thimerosal results in decreased expression of PRKD2 mRNA

NCBI chr 1:77,513,625...77,542,386
Ensembl chr 1:77,513,986...77,542,376

G

protein kinase D3

increases expression

Thimerosal results in increased expression of PRKD3 mRNA

NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443

G

PRKR interacting protein 1

decreases expression

Thimerosal results in decreased expression of PRKRIP1 mRNA

NCBI chr12:20,470,802...20,491,789
Ensembl chr12:20,470,820...20,489,115

G

prolactin

increases expression

Thimerosal results in increased expression of PRL mRNA; Thimerosal results in increased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

prolactin receptor

increases expression

Thimerosal results in increased expression of PRLR mRNA

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718

G

pre-mRNA processing factor 6

decreases expression

Thimerosal results in decreased expression of PRPF6 mRNA

NCBI chr 3:168,706,952...168,771,191
Ensembl chr 3:168,704,299...168,774,991

G

proline rich 14-like

decreases expression

Thimerosal results in decreased expression of PRR14L mRNA

NCBI chr14:77,869,848...77,937,141
Ensembl chr14:77,869,799...77,936,521

G

proline rich 5 like

decreases expression

Thimerosal results in decreased expression of PRR5L mRNA

NCBI chr 3:88,001,951...88,173,532
Ensembl chr 3:88,003,617...88,082,763

G

proline-rich coiled-coil 2C

decreases expression

Thimerosal results in decreased expression of PRRC2C mRNA

NCBI chr13:75,003,995...75,073,701
Ensembl chr13:75,004,010...75,073,643

G

proline-rich transmembrane protein 1

decreases expression

Thimerosal results in decreased expression of PRRT1 mRNA

NCBI chr20:4,117,957...4,121,643
Ensembl chr20:4,117,957...4,121,600

G

proteasome activator subunit 4

decreases expression

Thimerosal results in decreased expression of PSME4 mRNA

NCBI chr14:104,505,716...104,609,410
Ensembl chr14:104,505,716...104,609,408

G

proteasome inhibitor subunit 1

decreases expression

Thimerosal results in decreased expression of PSMF1 mRNA

NCBI chr 3:140,235,371...140,260,546
Ensembl chr 3:140,235,373...140,260,546

G

polypyrimidine tract binding protein 2

increases expression

Thimerosal results in increased expression of PTBP2 mRNA

NCBI chr 2:207,812,659...207,874,019
Ensembl chr 2:207,812,920...207,873,506

G

patched domain containing 4

increases expression

Thimerosal results in increased expression of PTCHD4 mRNA

NCBI chr 9:18,462,934...18,666,272
Ensembl chr 9:18,463,737...18,665,705

G

protein tyrosine kinase 2

multiple interactions
increases response to substance

[[Thimerosal results in increased abundance of Reactive Oxygen Species] which results in increased activity of CASP3 protein] which results in increased cleavage of PTK2 protein; Acetylcysteine inhibits the reaction [[[Thimerosal results in increased abundance of Reactive Oxygen Species] which results in increased activity of CASP3 protein] which results in increased cleavage of PTK2 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[[Thimerosal results in increased abundance of Reactive Oxygen Species] which results in increased activity of CASP3 protein] which results in increased cleavage of PTK2 protein]
PTK2 protein results in increased susceptibility to Thimerosal

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

parathymosin

decreases expression

Thimerosal results in decreased expression of PTMS mRNA

NCBI chr 4:157,722,384...157,726,575
Ensembl chr 4:157,722,386...157,727,009

G

PTOV1, extended AT-hook containing adaptor protein

decreases expression

Thimerosal results in decreased expression of PTOV1 mRNA

NCBI chr 1:95,347,065...95,354,514
Ensembl chr 1:95,347,068...95,353,613

G

protein tyrosine phosphatase 4A3

decreases expression

Thimerosal results in decreased expression of PTP4A3 mRNA

NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:105,628,029...105,660,919

G

protein tyrosine phosphatase, non-receptor type 12

decreases expression

Thimerosal results in decreased expression of PTPN12 mRNA

NCBI chr 4:14,020,997...14,092,931
Ensembl chr 4:14,021,052...14,092,927

G

protein tyrosine phosphatase, non-receptor type 4

increases expression

Thimerosal results in increased expression of PTPN4 mRNA

NCBI chr13:30,772,012...30,952,340
Ensembl chr13:30,776,682...30,952,170

G

protein tyrosine phosphatase, receptor type, A

decreases expression

Thimerosal results in decreased expression of PTPRA mRNA

NCBI chr 3:117,650,146...117,759,744
Ensembl chr 3:117,650,183...117,759,728

G

protein tyrosine phosphatase, receptor type, K

increases expression

Thimerosal results in increased expression of PTPRK mRNA

NCBI chr 1:16,738,896...17,236,687
Ensembl chr 1:16,850,576...17,103,605

G

purine rich element binding protein B

decreases expression

Thimerosal results in decreased expression of PURB mRNA

NCBI chr14:81,342,374...81,344,857
Ensembl chr14:81,336,448...81,351,432

G

peroxisomal membrane protein 4

decreases expression

Thimerosal results in decreased expression of PXMP4 mRNA

NCBI chr 3:143,093,371...143,110,620
Ensembl chr 3:143,093,018...143,110,651

G

glycogen phosphorylase L

decreases expression

Thimerosal results in decreased expression of PYGL mRNA

NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310

G

pyridine nucleotide-disulphide oxidoreductase domain 1

increases expression

Thimerosal results in increased expression of PYROXD1 mRNA

NCBI chr 4:175,292,124...175,311,143
Ensembl chr 4:175,292,177...175,308,689

G

quinolinate phosphoribosyltransferase

decreases expression

Thimerosal results in decreased expression of QPRT mRNA

NCBI chr 1:181,718,189...181,733,486
Ensembl chr 1:181,718,190...181,733,486

G

RAB29, member RAS oncogene family

decreases expression

Thimerosal results in decreased expression of RAB29 mRNA

NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417

G

RAB30, member RAS oncogene family

increases expression

Thimerosal results in increased expression of RAB30 mRNA

NCBI chr 1:146,803,719...146,898,369
Ensembl chr 1:146,803,714...146,892,181

G

RAB3B, member RAS oncogene family

affects expression

Thimerosal affects the expression of RAB3B mRNA

NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401

G

RAB3 GTPase activating protein catalytic subunit 1

increases expression

Thimerosal results in increased expression of RAB3GAP1 mRNA

NCBI chr13:39,355,698...39,429,154
Ensembl chr13:39,352,247...39,429,169

G

RAB, member of RAS oncogene family-like 3

increases expression

Thimerosal results in increased expression of RABL3 mRNA

NCBI chr11:63,153,281...63,182,240
Ensembl chr11:63,152,792...63,182,671

G

RAD18 E3 ubiquitin protein ligase

increases expression

Thimerosal results in increased expression of RAD18 mRNA

NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069

G

RAD23 homolog A, nucleotide excision repair protein

decreases expression

Thimerosal results in decreased expression of RAD23A mRNA

NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695

G

Ral GTPase activating protein catalytic subunit alpha 2

increases expression

Thimerosal results in increased expression of RALGAPA2 mRNA

NCBI chr 3:133,658,725...133,938,821
Ensembl chr 3:133,659,761...133,938,916

G

Rap guanine nucleotide exchange factor 2

increases expression

Thimerosal results in increased expression of RAPGEF2 mRNA

NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247

G

Rap guanine nucleotide exchange factor 5

decreases expression

Thimerosal results in decreased expression of RAPGEF5 mRNA

NCBI chr 6:138,445,184...138,679,943
Ensembl chr 6:138,437,991...138,679,936

G

Rap guanine nucleotide exchange factor like 1

decreases expression

Thimerosal results in decreased expression of RAPGEFL1 mRNA

NCBI chr10:83,793,711...83,810,373
Ensembl chr10:83,793,694...83,810,371

G

retinoic acid receptor responder 1

increases expression

Thimerosal results in increased expression of RARRES1 mRNA

NCBI chr 2:151,749,715...151,783,975
Ensembl chr 2:151,749,715...151,783,978

G

RAS p21 protein activator 2

increases expression

Thimerosal results in increased expression of RASA2 mRNA

NCBI chr 8:97,119,983...97,236,687
Ensembl chr 8:97,118,802...97,236,671

G

RasGEF domain family, member 1A

increases expression
decreases expression

Thimerosal results in increased expression of RASGEF1A mRNA
Thimerosal results in decreased expression of RASGEF1A mRNA

PMID:24675092 PMID:27188386

NCBI chr 4:151,187,533...151,267,982
Ensembl chr 4:151,225,856...151,267,995

G

Ras association domain family member 4

decreases expression

Thimerosal results in decreased expression of RASSF4 mRNA

NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411

G

Ras association domain family member 8

decreases expression

Thimerosal results in decreased expression of RASSF8 mRNA

NCBI chr 4:178,716,110...178,798,042
Ensembl chr 4:178,719,992...178,796,690

G

RB-associated KRAB zinc finger

decreases expression

Thimerosal results in decreased expression of RBAK mRNA

NCBI chr12:11,375,314...11,388,937
Ensembl chr12:11,375,318...11,388,934

G

RNA binding fox-1 homolog 3

decreases expression

Thimerosal results in decreased expression of RBFOX3 mRNA

NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935

G

RNA binding motif protein 22

decreases expression

Thimerosal results in decreased expression of RBM22 mRNA

NCBI chr18:54,013,374...54,024,182
Ensembl chr18:54,013,351...54,024,569

G

RNA binding motif protein 26

decreases expression

Thimerosal results in decreased expression of RBM26 mRNA

NCBI chr15:81,884,783...81,964,245
Ensembl chr15:81,887,219...81,964,118

G

RNA binding motif protein 7

decreases expression

Thimerosal results in decreased expression of RBM7 mRNA

NCBI chr 8:48,831,894...48,838,399
Ensembl chr 8:48,831,894...48,838,411

G

RNA binding motif protein 8A

decreases expression

Thimerosal results in decreased expression of RBM8A mRNA

NCBI chr 2:184,165,189...184,167,959
Ensembl chr 2:184,165,193...184,167,959

G

recombination signal binding protein for immunoglobulin kappa J region

decreases expression

Thimerosal results in decreased expression of RBPJ mRNA

NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353

G

RNA binding protein, mRNA processing factor 2

decreases expression

Thimerosal results in decreased expression of RBPMS2 mRNA

NCBI chr 8:66,153,169...66,184,278
Ensembl chr 8:66,153,593...66,184,268

G

RCAN family member 3

decreases expression

Thimerosal results in decreased expression of RCAN3 mRNA

NCBI chr 5:147,650,935...147,671,881
Ensembl chr 5:147,655,085...147,671,937

G

REST corepressor 2

decreases expression

Thimerosal results in decreased expression of RCOR2 mRNA

NCBI chr 1:204,453,403...204,461,403
Ensembl chr 1:204,454,360...204,460,838

G

receptor accessory protein 6

decreases expression

Thimerosal results in decreased expression of REEP6 mRNA

NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597

G

RELT-like 1

decreases expression

Thimerosal results in decreased expression of RELL1 mRNA

NCBI chr14:44,318,640...44,378,541
Ensembl chr14:44,303,009...44,378,500

G

RALBP1 associated Eps domain containing 1

increases expression

Thimerosal results in increased expression of REPS1 mRNA

NCBI chr 1:12,697,742...12,775,562
Ensembl chr 1:12,697,747...12,775,561

G

replication factor C subunit 1

increases expression

Thimerosal results in increased expression of RFC1 mRNA

NCBI chr14:42,966,279...43,041,372
Ensembl chr14:42,966,324...43,041,370

G

regulatory factor X, 7

decreases expression

Thimerosal results in decreased expression of RFX7 mRNA

NCBI chr 8:73,254,051...73,339,209
Ensembl chr 8:73,254,051...73,339,209

G

Rho-related BTB domain containing 2

decreases expression

Thimerosal results in decreased expression of RHOBTB2 mRNA

NCBI chr15:44,868,251...44,888,436
Ensembl chr15:44,870,376...44,888,651

G

Rho-related BTB domain containing 3

decreases expression

Thimerosal results in decreased expression of RHOBTB3 mRNA

NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041

G

ras homolog family member U

decreases expression

Thimerosal results in decreased expression of RHOU mRNA

NCBI chr19:51,641,476...51,651,249
Ensembl chr19:51,641,227...51,650,552

G

ribosomal modification protein rimK-like family member A

decreases expression

Thimerosal results in decreased expression of RIMKLA mRNA

NCBI chr 5:133,072,179...133,098,840
Ensembl chr 5:133,073,960...133,098,792

G

regulating synaptic membrane exocytosis 1

increases expression

Thimerosal results in increased expression of RIMS1 mRNA

NCBI chr 9:24,696,959...25,196,404
Ensembl chr 9:24,698,854...25,196,631

G

RNA 5'-phosphate and 3'-OH ligase 1

increases expression

Thimerosal results in increased expression of RLIG1 mRNA

NCBI chr 7:35,396,876...35,408,633
Ensembl chr 7:35,397,995...35,409,600

G

ribonuclease A family member 4

decreases expression

Thimerosal results in decreased expression of RNASE4 mRNA

NCBI chr15:24,312,765...24,330,112
Ensembl chr15:24,312,464...24,330,117

G

ribonuclease T2

decreases expression

Thimerosal results in decreased expression of RNASET2 mRNA

NCBI chr 1:52,576,344...52,603,151
Ensembl chr 1:52,585,929...52,603,147

G

ring finger protein 130

decreases expression

Thimerosal results in decreased expression of RNF130 mRNA

NCBI chr10:34,342,835...34,456,048
Ensembl chr10:34,342,830...34,456,062

G

ring finger protein 43

decreases expression

Thimerosal results in decreased expression of RNF43 mRNA

NCBI chr10:72,461,508...72,537,301
Ensembl chr10:72,464,348...72,536,977

G

RNA (guanine-7-) methyltransferase

increases expression

Thimerosal results in increased expression of RNMT mRNA

NCBI chr18:61,886,230...61,909,775
Ensembl chr18:61,886,292...61,909,775

G

RAR-related orphan receptor A

decreases expression

Thimerosal results in decreased expression of RORA mRNA

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

ribosomal protein L7

increases expression

Thimerosal results in increased expression of RPL7 mRNA

NCBI chr 5:3,217,184...3,220,192

G

ribosomal protein S23

decreases expression

Thimerosal results in decreased expression of RPS23 mRNA

NCBI chr 2:22,079,339...22,080,909
Ensembl chr 2:22,079,302...22,080,918

G

ribosomal protein S27-like

increases expression

Thimerosal results in increased expression of RPS27L mRNA

NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418

G

RRAD, Ras related glycolysis inhibitor and calcium channel regulator

increases expression

Thimerosal results in increased expression of RRAD mRNA

NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417

G

radial spoke head component 9

decreases expression

Thimerosal results in decreased expression of RSPH9 mRNA

NCBI chr 9:14,840,115...14,852,950
Ensembl chr 9:14,840,115...14,860,062

G

RT1 class Ia, locus A2

decreases expression

Thimerosal results in decreased expression of HLA-E mRNA

NCBI chr20:4,870,939...4,910,183

G

RT1 class I, locus CE16

decreases expression

Thimerosal results in decreased expression of HLA-A mRNA

NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563

G

RT1 class II, locus Hb, pseudogene 1

decreases expression

Thimerosal results in decreased expression of HLA-DPB1 mRNA

NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618

G

retrotransposon Gag like 8A

decreases expression

Thimerosal results in decreased expression of RTL8A mRNA

NCBI chr X:133,414,027...133,415,240
Ensembl chr X:133,414,030...133,415,240

G

reticulon 4 receptor

decreases expression

Thimerosal results in decreased expression of RTN4R mRNA

NCBI chr11:82,844,309...82,869,251
Ensembl chr11:82,844,309...82,869,466

G

RUN and FYVE domain containing 2

increases expression

Thimerosal results in increased expression of RUFY2 mRNA

NCBI chr20:25,626,958...25,658,157
Ensembl chr20:25,621,999...25,658,186

G

RUN and SH3 domain containing 2

decreases expression

Thimerosal results in decreased expression of RUSC2 mRNA

NCBI chr 5:57,628,397...57,675,524
Ensembl chr 5:57,629,904...57,675,524

G

ryanodine receptor 3

increases expression

Thimerosal results in increased expression of RYR3 mRNA

NCBI chr 3:99,431,755...99,979,125
Ensembl chr 3:99,432,505...99,704,961

G

spalt-like transcription factor 4

decreases expression

Thimerosal results in decreased expression of SALL4 mRNA

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1

decreases expression

Thimerosal results in decreased expression of SAMHD1 mRNA

NCBI chr 3:145,761,549...145,794,420
Ensembl chr 3:145,761,558...145,794,386

G

suppressor APC domain containing 2

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAPCD2 mRNA

NCBI chr 3:8,186,089...8,195,119
Ensembl chr 3:8,187,266...8,192,546

G

secretion associated, Ras related GTPase 1B

increases expression

Thimerosal results in increased expression of SAR1B mRNA

NCBI chr10:36,024,415...36,054,069
Ensembl chr10:36,024,382...36,054,066

G

salvador family WW domain containing protein 1

decreases expression

Thimerosal results in decreased expression of SAV1 mRNA

NCBI chr 6:88,478,536...88,500,121
Ensembl chr 6:88,478,539...88,499,968

G

stabilizer of axonemal microtubules 2

increases expression

Thimerosal results in increased expression of SAXO2 mRNA

NCBI chr 1:136,596,445...136,638,444
Ensembl chr 1:136,623,493...136,638,454

G

stearoyl-CoA desaturase

decreases expression

Thimerosal results in decreased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

short coiled-coil protein

increases expression

Thimerosal results in increased expression of SCOC mRNA

NCBI chr19:24,659,651...24,689,237
Ensembl chr19:24,659,651...24,693,217

G

secernin 3

decreases expression

Thimerosal results in decreased expression of SCRN3 mRNA

NCBI chr 3:58,188,820...58,213,623
Ensembl chr 3:58,188,889...58,213,623

G

scratch family transcriptional repressor 1

increases expression

Thimerosal results in increased expression of SCRT1 mRNA

NCBI chr 7:108,240,986...108,244,636
Ensembl chr 7:108,240,986...108,244,636

G

SCY1 like pseudokinase 2

decreases expression

Thimerosal results in decreased expression of SCYL2 mRNA

NCBI chr 7:24,064,404...24,117,338
Ensembl chr 7:24,064,404...24,117,305

G

syndecan 1

decreases expression

Thimerosal results in decreased expression of SDC1 mRNA

NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264

G

SECIS binding protein 2-like

decreases expression

Thimerosal results in decreased expression of SECISBP2L mRNA

NCBI chr 3:112,989,613...113,036,060
Ensembl chr 3:112,991,908...113,035,884

G

SEL1L adaptor subunit of SYVN1 ubiquitin ligase

decreases expression

Thimerosal results in decreased expression of SEL1L mRNA

NCBI chr 6:110,735,450...110,779,695
Ensembl chr 6:110,735,450...110,779,648

G

semaphorin 3F

decreases expression

Thimerosal results in decreased expression of SEMA3F mRNA

NCBI chr 8:108,357,629...108,386,569
Ensembl chr 8:108,357,629...108,387,083

G

ssemaphorin 4F

decreases expression

Thimerosal results in decreased expression of SEMA4F mRNA

NCBI chr 4:115,411,411...115,437,721
Ensembl chr 4:115,411,417...115,437,721

G

semaphorin 6A

decreases expression

Thimerosal results in decreased expression of SEMA6A mRNA

NCBI chr18:40,050,623...40,171,954
Ensembl chr18:40,050,624...40,171,954

G

SUMO specific peptidase 7

increases expression

Thimerosal results in increased expression of SENP7 mRNA

NCBI chr11:44,423,733...44,584,129
Ensembl chr11:44,423,735...44,564,711

G

Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase

increases expression
multiple interactions

Thimerosal results in increased expression of SEPSECS mRNA
[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEPSECS mRNA

NCBI chr14:58,311,484...58,341,745
Ensembl chr14:58,311,499...58,341,740

G

septin 9

decreases expression

Thimerosal results in decreased expression of SEPTIN9 mRNA

NCBI chr10:102,409,798...102,579,056
Ensembl chr10:102,409,711...102,579,055

G

serine incorporator 2

decreases expression

Thimerosal results in decreased expression of SERINC2 mRNA

NCBI chr 5:142,592,308...142,614,628
Ensembl chr 5:142,592,309...142,618,364

G

serpin family E member 1

increases expression

Thimerosal results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

serpin family H member 1

increases expression

Thimerosal results in increased expression of SERPINH1 mRNA

NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801

G

SET domain containing 2, histone lysine methyltransferase

decreases expression

Thimerosal results in decreased expression of SETD2 mRNA

NCBI chr 8:110,511,808...110,597,475
Ensembl chr 8:110,511,772...110,597,489

G

SET domain containing, pseudogene 1

increases expression

Thimerosal results in increased expression of SETD9 mRNA

NCBI chr 2:43,319,359...43,322,764

G

senataxin

decreases expression

Thimerosal results in decreased expression of SETX mRNA

NCBI chr 3:12,428,091...12,480,801
Ensembl chr 3:12,427,635...12,480,803

G

seizure related 6 homolog like 2

decreases expression

Thimerosal results in decreased expression of SEZ6L2 mRNA

NCBI chr 1:181,557,109...181,577,456
Ensembl chr 1:181,557,109...181,577,456

G

splicing factor 3A subunit 2

decreases expression

Thimerosal results in decreased expression of SF3A2 mRNA

NCBI chr 7:8,909,507...8,916,104
Ensembl chr 7:8,909,507...8,915,530

G

splicing factor 3b, subunit 1

decreases expression

Thimerosal results in decreased expression of SF3B1 mRNA

NCBI chr 9:56,492,403...56,532,300
Ensembl chr 9:56,492,403...56,532,300

G

splicing factor 3B subunit 4

decreases expression

Thimerosal results in decreased expression of SF3B4 mRNA

NCBI chr 2:183,732,791...183,737,545
Ensembl chr 2:183,732,754...183,737,959

G

splicing factor proline and glutamine rich

decreases expression

Thimerosal results in decreased expression of SFPQ mRNA

NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472

G

SWI5-dependent homologous recombination repair protein 1

increases expression

Thimerosal results in increased expression of SFR1 mRNA

NCBI chr 1:246,619,235...246,623,250
Ensembl chr 1:246,597,044...246,623,250

G

secreted frizzled-related protein 1

decreases expression

Thimerosal results in decreased expression of SFRP1 mRNA

NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286

G

sphingosine-1-phosphate lyase 1

increases expression

Thimerosal results in increased expression of SGPL1 mRNA

NCBI chr20:29,047,793...29,094,209
Ensembl chr20:29,047,796...29,094,084

G

SH3 domain binding glutamate-rich protein like 3

decreases expression

Thimerosal results in decreased expression of SH3BGRL3 mRNA

NCBI chr 5:146,354,152...146,355,525
Ensembl chr 5:146,354,152...146,355,331

G

shiftless antiviral inhibitor of ribosomal frameshifting

decreases expression

Thimerosal results in decreased expression of SHFL mRNA

NCBI chr 8:19,408,298...19,414,084
Ensembl chr 8:19,408,333...19,413,971

G

shisa family member 5

decreases expression

Thimerosal results in decreased expression of SHISA5 mRNA

NCBI chr 8:109,691,504...109,706,411
Ensembl chr 8:109,691,522...109,706,408

G

SHOC2 leucine-rich repeat scaffold protein

increases expression

Thimerosal results in increased expression of SHOC2 mRNA

NCBI chr 1:252,958,939...253,048,820
Ensembl chr 1:252,959,723...253,047,337

G

siah E3 ubiquitin protein ligase 1

increases expression

Thimerosal results in increased expression of SIAH1 mRNA

NCBI chr19:20,378,908...20,402,512
Ensembl chr19:20,378,439...20,403,808

G

suppressor of IKBKE 1

decreases expression

Thimerosal results in decreased expression of SIKE1 mRNA

NCBI chr 2:190,518,002...190,525,833
Ensembl chr 2:190,518,002...190,525,832

G

signal-induced proliferation-associated 1

decreases expression

Thimerosal results in decreased expression of SIPA1 mRNA

NCBI chr 1:202,938,532...202,950,672
Ensembl chr 1:202,938,580...202,950,591

G

signal-regulatory protein alpha

decreases expression

Thimerosal results in decreased expression of SIRPA mRNA

NCBI chr 3:116,819,730...116,858,099
Ensembl chr 3:116,819,726...116,858,098

G

sirtuin 1

multiple interactions

SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

SIX homeobox 5

decreases expression

Thimerosal results in decreased expression of SIX5 mRNA

NCBI chr 1:78,740,812...78,745,890
Ensembl chr 1:78,741,367...78,745,890

G

SIX homeobox 6

increases expression

Thimerosal results in increased expression of SIX6 mRNA

NCBI chr 6:91,634,568...91,639,548
Ensembl chr 6:91,634,568...91,639,548

G

spindle and kinetochore associated complex subunit 2

increases expression

Thimerosal results in increased expression of SKA2 mRNA

NCBI chr10:71,921,474...71,939,461
Ensembl chr10:71,921,582...71,939,458

G

SKI3 subunit of superkiller complex

decreases expression

Thimerosal results in decreased expression of SKIC3 mRNA

NCBI chr 2:5,631,544...5,783,643
Ensembl chr 2:5,631,635...5,751,626

G

solute carrier family 10, member 7

increases expression

Thimerosal results in increased expression of SLC10A7 mRNA

NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464

G

solute carrier family 12 member 2

increases expression

Thimerosal results in increased expression of SLC12A2 mRNA

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 16 member 1

decreases expression

Thimerosal results in decreased expression of SLC16A1 mRNA

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 16, member 14

increases expression

Thimerosal results in increased expression of SLC16A14 mRNA

NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:86,112,894...86,137,318

G

solute carrier family 16, member 6

increases expression

Thimerosal results in increased expression of SLC16A6 mRNA

NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779

G

solute carrier family 16, member 9

increases expression

Thimerosal results in increased expression of SLC16A9 mRNA

NCBI chr20:18,335,862...18,377,125
Ensembl chr20:18,335,862...18,377,022

G

solute carrier family 18 member B1

decreases expression

Thimerosal results in decreased expression of SLC18B1 mRNA

NCBI chr 1:21,628,235...21,670,807
Ensembl chr 1:21,628,237...21,670,684

G

solute carrier family 1 member 1

increases expression

Thimerosal results in increased expression of SLC1A1 protein

NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402

G

solute carrier family 22 member 4

decreases activity

Thimerosal results in decreased activity of SLC22A4 protein

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720

G

solute carrier family 25 member 1

decreases expression

Thimerosal results in decreased expression of SLC25A1 mRNA

NCBI chr11:83,055,764...83,058,781
Ensembl chr11:83,055,748...83,058,781

G

solute carrier family 25 member 21

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A21 mRNA

NCBI chr 6:74,203,439...74,702,902
Ensembl chr 6:74,203,440...74,702,680

G

solute carrier family 25 member 23

decreases expression

Thimerosal results in decreased expression of SLC25A23 mRNA

NCBI chr 9:1,882,636...1,898,369
Ensembl chr 9:1,882,621...1,898,561

G

solute carrier family 25, member 44

increases expression

Thimerosal results in increased expression of SLC25A44 mRNA

NCBI chr 2:173,868,317...173,883,137
Ensembl chr 2:173,868,320...173,883,020

G

solute carrier family 29 member 2

decreases expression

Thimerosal results in decreased expression of SLC29A2 mRNA

NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171

G

solute carrier family 2 member 1

decreases expression

Thimerosal results in decreased expression of SLC2A1 mRNA

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 2 member 12

decreases expression

Thimerosal results in decreased expression of SLC2A12 mRNA

NCBI chr 1:22,803,068...22,862,204
Ensembl chr 1:22,804,418...22,860,971

G

solute carrier family 2 member 3

decreases expression

Thimerosal results in decreased expression of SLC2A3 mRNA

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

solute carrier family 30 member 5

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A5 mRNA

NCBI chr 2:31,945,745...31,975,969
Ensembl chr 2:31,945,729...31,975,934

G

solute carrier family 38, member 1

decreases expression

Thimerosal results in decreased expression of SLC38A1 mRNA

NCBI chr 7:127,733,230...127,802,541
Ensembl chr 7:127,738,226...127,802,218

G

solute carrier family 5 member 3

increases expression

Thimerosal results in increased expression of SLC5A3 mRNA

NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883

G

solute carrier family 5 member 7

decreases expression

Thimerosal results in decreased expression of SLC5A7 mRNA

NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258

G

solute carrier family 7 member 1

decreases expression

Thimerosal results in decreased expression of SLC7A1 mRNA

NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849

G

solute carrier family 7 member 3

decreases expression

Thimerosal results in decreased expression of SLC7A3 mRNA

NCBI chr X:66,210,071...66,216,482
Ensembl chr X:66,210,081...66,215,708

G

solute carrier family 8 member A1

increases expression

Thimerosal results in increased expression of SLC8A1 mRNA

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2

affects expression

Thimerosal affects the expression of SMARCC2 mRNA

NCBI chr 7:881,844...910,090
Ensembl chr 7:881,421...909,978

G

structural maintenance of chromosomes 1A

decreases expression

Thimerosal results in decreased expression of SMC1A mRNA

NCBI chr X:21,103,323...21,148,053
Ensembl chr X:21,103,282...21,148,056

G

structural maintenance of chromosomes flexible hinge domain containing 1

decreases expression

Thimerosal results in decreased expression of SMCHD1 mRNA

NCBI chr 9:111,243,445...111,387,272
Ensembl chr 9:111,247,702...111,349,665

G

small integral membrane protein 3

decreases expression

Thimerosal results in decreased expression of SMIM3 mRNA

NCBI chr18:53,930,019...53,982,339
Ensembl chr18:53,930,020...53,957,416

G

spermine oxidase

decreases expression

Thimerosal results in decreased expression of SMOX mRNA

NCBI chr 3:118,731,814...118,767,242
Ensembl chr 3:118,731,900...118,765,710

G

synaptosome associated protein 25

decreases expression

Thimerosal results in decreased expression of SNAP25 protein

NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760

G

synuclein, alpha interacting protein

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA

NCBI chr18:46,205,846...46,343,932
Ensembl chr18:46,207,152...46,343,929

G

small nuclear ribonucleoprotein polypeptide A

decreases expression

Thimerosal results in decreased expression of SNRPA mRNA

NCBI chr 1:82,481,770...82,490,540
Ensembl chr 1:82,481,770...82,490,538

G

sorting nexin 2

increases expression

Thimerosal results in increased expression of SNX2 mRNA

NCBI chr18:46,602,223...46,643,870
Ensembl chr18:46,602,284...46,643,865

G

sorting nexin family member 21

decreases expression

Thimerosal results in decreased expression of SNX21 mRNA

NCBI chr 3:153,522,474...153,532,235
Ensembl chr 3:153,522,486...153,532,221

G

sorting nexin 4

increases expression

Thimerosal results in increased expression of SNX4 mRNA

NCBI chr11:67,460,872...67,518,143
Ensembl chr11:67,460,870...67,518,174

G

sorting nexin 9

decreases expression

Thimerosal results in decreased expression of SNX9 mRNA

NCBI chr 1:46,424,897...46,510,096
Ensembl chr 1:46,423,553...46,509,036

G

superoxide dismutase 1

multiple interactions
increases response to substance

[SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased acetylation of and results in increased ubiquitination of KCNIP3 protein; [SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased expression of PDYN mRNA; [SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein; [SOD1 protein results in increased susceptibility to Thimerosal] which results in increased cleavage of CASP3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]; Resveratrol inhibits the reaction [[SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased acetylation of and results in increased ubiquitination of KCNIP3 protein]; Resveratrol inhibits the reaction [[SOD1 protein mutant form results in increased susceptibility to Thimerosal] which results in increased expression of PDYN mRNA]; Resveratrol inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]; Resveratrol inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in increased cleavage of CASP3 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

SON DNA and RNA binding protein

decreases expression

Thimerosal results in decreased expression of SON mRNA

NCBI chr11:30,850,890...30,923,167
Ensembl chr11:30,892,005...30,923,167

G

sorbin and SH3 domain containing 2

increases expression

Thimerosal results in increased expression of SORBS2 mRNA

NCBI chr16:46,435,220...46,748,743
Ensembl chr16:46,435,237...46,626,514

G

sorbin and SH3 domain containing 3

decreases expression

Thimerosal results in decreased expression of SORBS3 mRNA

NCBI chr15:45,252,921...45,284,758
Ensembl chr15:45,253,379...45,284,758

G

sortilin related receptor 1

decreases expression

Thimerosal results in decreased expression of SORL1 mRNA

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

SRY-box transcription factor 18

decreases expression

Thimerosal results in decreased expression of SOX18 mRNA

NCBI chr 3:168,785,488...168,787,290
Ensembl chr 3:168,785,490...168,787,290

G

SRY-box transcription factor 7

decreases expression

Thimerosal results in decreased expression of SOX7 mRNA

NCBI chr15:38,180,503...38,187,264
Ensembl chr15:38,180,503...38,187,264

G

SRY-box transcription factor 8

decreases expression

Thimerosal results in decreased expression of SOX8 mRNA

NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818

G

SRY-box transcription factor 9

increases expression

Thimerosal results in increased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

Sp4 transcription factor

decreases expression

Thimerosal results in decreased expression of SP4 mRNA

NCBI chr 6:139,187,458...139,252,741
Ensembl chr 6:139,192,147...139,252,126

G

Sp5 transcription factor

decreases expression

Thimerosal results in decreased expression of SP5 mRNA

NCBI chr 3:55,274,931...55,277,733
Ensembl chr 3:55,274,931...55,277,733

G

Sp8 transcription factor

increases expression

Thimerosal results in increased expression of SP8 mRNA

NCBI chr 6:139,816,258...139,818,865
Ensembl chr 6:139,814,819...139,823,168
Ensembl chr 6:139,814,819...139,823,168

G

sperm associated antigen 4

decreases expression

Thimerosal results in decreased expression of SPAG4 mRNA

NCBI chr 3:144,581,006...144,587,879
Ensembl chr 3:144,581,095...144,585,435

G

sperm associated antigen 9

increases expression

Thimerosal results in increased expression of SPAG9 mRNA

NCBI chr10:78,943,439...79,077,797
Ensembl chr10:78,943,479...79,077,797

G

spermatogenesis associated 18

increases expression

Thimerosal results in increased expression of SPATA18 mRNA

NCBI chr14:34,531,931...34,558,671
Ensembl chr14:34,531,061...34,558,687

G

spermatogenesis associated 2

decreases expression

Thimerosal results in decreased expression of SPATA2 mRNA

NCBI chr 3:156,202,962...156,213,283
Ensembl chr 3:156,202,967...156,211,705

G

spermatogenesis and centriole associated 1-like

decreases expression

Thimerosal results in decreased expression of SPATC1L mRNA

NCBI chr20:12,074,040...12,083,873
Ensembl chr20:12,074,047...12,083,301

G

sperm antigen with calponin homology and coiled-coil domains 1

increases expression

Thimerosal results in increased expression of SPECC1 mRNA

NCBI chr10:46,638,947...46,912,989
Ensembl chr10:46,638,809...46,912,802

G

spen family transcriptional repressor

decreases expression

Thimerosal results in decreased expression of SPEN mRNA

NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811

G

sperm microtubule inner protein 4

decreases expression

Thimerosal results in decreased expression of SPMIP4 mRNA

NCBI chr 4:79,663,375...79,688,291
Ensembl chr 4:79,663,376...79,689,072

G

signal peptide peptidase-like 2B

decreases expression

Thimerosal results in decreased expression of SPPL2B mRNA

NCBI chr 7:8,843,918...8,856,642
Ensembl chr 7:8,843,918...8,856,608

G

spectrin, beta, non-erythrocytic 1

decreases expression

Thimerosal results in decreased expression of SPTBN1 mRNA

NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507

G

squalene epoxidase

decreases expression

Thimerosal results in decreased expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

steroid 5 alpha-reductase 3

decreases expression

Thimerosal results in decreased expression of SRD5A3 mRNA

NCBI chr14:32,046,408...32,060,796
Ensembl chr14:32,046,408...32,060,747

G

sarcalumenin

decreases expression

Thimerosal results in decreased expression of SRL mRNA

NCBI chr10:11,033,976...11,078,103
Ensembl chr10:11,034,035...11,078,101

G

SRP receptor subunit alpha

decreases expression

Thimerosal results in decreased expression of SRPRA mRNA

NCBI chr 8:33,560,365...33,566,458
Ensembl chr 8:33,560,348...33,566,470

G

serine and arginine repetitive matrix 1

decreases expression

Thimerosal results in decreased expression of SRRM1 mRNA

NCBI chr 5:147,559,515...147,591,895
Ensembl chr 5:147,559,514...147,591,849

G

serine/arginine repetitive matrix 2

decreases expression

Thimerosal results in decreased expression of SRRM2 mRNA

NCBI chr10:12,815,471...12,848,750
Ensembl chr10:12,815,471...12,848,751

G

serine and arginine rich splicing factor 4

increases expression

Thimerosal results in increased expression of SRSF4 mRNA

NCBI chr 5:144,060,981...144,090,798
Ensembl chr 5:144,061,463...144,089,229

G

structure specific recognition protein 1

decreases expression

Thimerosal results in decreased expression of SSRP1 mRNA

NCBI chr 3:70,124,371...70,134,481
Ensembl chr 3:70,118,655...70,134,482

G

STAG1 cohesin complex component

increases expression

Thimerosal results in increased expression of STAG1 mRNA

NCBI chr 8:101,179,039...101,564,684
Ensembl chr 8:101,179,039...101,564,677

G

STAG2 cohesin complex component

increases expression

Thimerosal results in increased expression of STAG2 mRNA

NCBI chr X:120,974,687...121,105,677
Ensembl chr X:120,974,857...121,105,677

G

stanniocalcin 1

decreases expression

Thimerosal results in decreased expression of STC1 mRNA

NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264

G

stanniocalcin 2

decreases expression

Thimerosal results in decreased expression of STC2 mRNA

NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973

G

stromal interaction molecule 2

increases expression

Thimerosal results in increased expression of STIM2 mRNA

NCBI chr14:56,878,428...57,004,405
Ensembl chr14:56,878,645...57,004,179

G

serine/threonine kinase 35

increases expression

Thimerosal results in increased expression of STK35 mRNA

NCBI chr 3:117,016,819...117,049,131
Ensembl chr 3:117,016,950...117,048,066

G

stonin 2

decreases expression

Thimerosal results in decreased expression of STON2 mRNA

NCBI chr 6:110,567,485...110,676,376
Ensembl chr 6:110,567,485...110,676,376

G

sperm-tail PG-rich repeat containing 1

decreases expression

Thimerosal results in decreased expression of STPG1 mRNA

NCBI chr 5:147,717,084...147,769,792
Ensembl chr 5:147,726,646...147,769,788

G

syntaxin 2

decreases expression

Thimerosal results in decreased expression of STX2 mRNA

NCBI chr12:27,678,744...27,714,751
Ensembl chr12:27,689,819...27,714,751

G

syntaxin 4

increases expression

Thimerosal results in increased expression of STX4 mRNA

NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979

G

serine/threonine/tyrosine interacting protein

decreases expression

Thimerosal results in decreased expression of STYX mRNA

NCBI chr15:18,565,214...18,595,797
Ensembl chr15:18,564,633...18,593,524

G

Sad1 and UNC84 domain containing 2

increases expression

Thimerosal results in increased expression of SUN2 mRNA

NCBI chr 7:111,275,374...111,292,565
Ensembl chr 7:111,275,380...111,292,553

G

SPT16 homolog, facilitates chromatin remodeling subunit

decreases expression

Thimerosal results in decreased expression of SUPT16H mRNA

NCBI chr15:24,867,697...24,904,818
Ensembl chr15:24,866,489...24,904,846

G

synaptonemal complex protein 2

increases expression

Thimerosal results in increased expression of SYCP2 mRNA

NCBI chr 3:165,431,715...165,502,134
Ensembl chr 3:165,436,331...165,498,789

G

synaptonemal complex protein 3

increases expression

Thimerosal results in increased expression of SYCP3 mRNA

NCBI chr 7:22,874,055...22,888,512
Ensembl chr 7:22,874,055...22,888,511

G

synaptotagmin binding, cytoplasmic RNA interacting protein

decreases expression

Thimerosal results in decreased expression of SYNCRIP mRNA

NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515

G

spectrin repeat containing nuclear envelope protein 2

decreases expression

Thimerosal results in decreased expression of SYNE2 mRNA

NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064

G

synaptogyrin 3

decreases expression

Thimerosal results in decreased expression of SYNGR3 mRNA

NCBI chr10:13,710,553...13,715,309
Ensembl chr10:13,704,998...13,715,669

G

synaptojanin 2 binding protein

decreases expression

Thimerosal results in decreased expression of SYNJ2BP mRNA

NCBI chr 6:101,189,714...101,227,400
Ensembl chr 6:101,189,714...101,227,406

G

synaptotagmin 6

decreases expression

Thimerosal results in decreased expression of SYT6 mRNA

NCBI chr 2:191,093,009...191,152,283
Ensembl chr 2:191,093,007...191,149,956

G

synaptotagmin-like 4

decreases expression

Thimerosal results in decreased expression of SYTL4 mRNA

NCBI chr X:97,135,496...97,185,867
Ensembl chr X:97,135,500...97,185,854

G

TATA-box binding protein associated factor 9

increases expression

Thimerosal results in increased expression of TAF9 mRNA

NCBI chr 2:31,794,316...31,798,324
Ensembl chr 2:31,794,142...31,798,769

G

TATA-box binding protein associated factor 9b

affects expression

Thimerosal affects the expression of TAF9B mRNA

NCBI chr X:71,289,290...71,300,142
Ensembl chr X:71,289,290...71,300,604

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2

decreases expression

Thimerosal results in decreased expression of TANC2 mRNA

NCBI chr10:90,553,124...90,873,477
Ensembl chr10:90,553,002...90,868,756

G

TAO kinase 1

decreases expression

Thimerosal results in decreased expression of TAOK1 mRNA

NCBI chr10:62,373,072...62,465,295
Ensembl chr10:62,381,404...62,465,766

G

transporter 2, ATP binding cassette subfamily B member

decreases expression

Thimerosal results in decreased expression of TAP2 mRNA

NCBI chr20:4,636,347...4,650,387
Ensembl chr20:4,636,357...4,650,407

G

transcription activation suppressor family member 2

increases expression

Thimerosal results in increased expression of TASOR2 mRNA

NCBI chr17:66,583,554...66,650,127
Ensembl chr17:66,594,908...66,649,135

G

Tax1 binding protein 1

increases expression

Thimerosal results in increased expression of TAX1BP1 mRNA

NCBI chr 4:81,821,991...81,877,906
Ensembl chr 4:81,821,989...81,879,100

G

TBC1 domain family, member 16

decreases expression

Thimerosal results in decreased expression of TBC1D16 mRNA

NCBI chr10:104,400,963...104,486,698
Ensembl chr10:104,402,398...104,486,670

G

TBC1 domain family member 8B

decreases expression

Thimerosal results in decreased expression of TBC1D8B mRNA

NCBI chr X:103,319,181...103,407,137
Ensembl chr X:103,319,340...103,407,133

G

transducin (beta)-like 1 X-linked

decreases expression

Thimerosal results in decreased expression of TBL1X mRNA

NCBI chr X:41,574,558...41,731,117
Ensembl chr X:41,576,047...41,731,101

G

TBL1X/Y related 1

increases expression

Thimerosal results in increased expression of TBL1XR1 mRNA

NCBI chr 2:104,788,950...104,929,055
Ensembl chr 2:104,801,721...104,929,055

G

transforming growth factor beta regulator 4

decreases expression

Thimerosal results in decreased expression of TBRG4 mRNA

NCBI chr14:81,481,977...81,490,781
Ensembl chr14:81,481,981...81,490,756

G

transcription factor 7 like 1

decreases expression

Thimerosal results in decreased expression of TCF7L1 mRNA

NCBI chr 4:104,680,734...104,846,086
Ensembl chr 4:104,680,739...104,845,287

G

tudor domain containing 6

increases expression

Thimerosal results in increased expression of TDRD6 mRNA

NCBI chr 9:17,344,033...17,359,348
Ensembl chr 9:17,344,026...17,359,344

G

tudor domain containing 7

decreases expression

Thimerosal results in decreased expression of TDRD7 mRNA

NCBI chr 5:60,238,742...60,312,548
Ensembl chr 5:60,238,678...60,312,544

G

tudor and KH domain containing

decreases expression

Thimerosal results in decreased expression of TDRKH mRNA

NCBI chr 2:182,049,175...182,071,516
Ensembl chr 2:182,049,215...182,070,755

G

TEA domain transcription factor 1

decreases expression

Thimerosal results in decreased expression of TEAD1 mRNA

NCBI chr 1:166,791,900...167,010,591
Ensembl chr 1:166,792,628...167,003,369

G

trans-2,3-enoyl-CoA reductase

decreases expression

Thimerosal results in decreased expression of TECR mRNA

NCBI chr19:24,526,700...24,568,168
Ensembl chr19:24,541,615...24,568,168

G

tet methylcytosine dioxygenase 1

decreases expression

Thimerosal results in decreased expression of TET1 mRNA

NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052

G

tet methylcytosine dioxygenase 2

decreases expression

Thimerosal results in decreased expression of TET2 mRNA

NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534

G

tet methylcytosine dioxygenase 3

decreases expression

Thimerosal results in decreased expression of TET3 mRNA

NCBI chr 4:115,867,412...115,964,433
Ensembl chr 4:115,871,265...115,964,193

G

testis expressed 10

decreases expression

Thimerosal results in decreased expression of TEX10 mRNA

NCBI chr 5:62,762,230...62,808,373
Ensembl chr 5:62,762,230...62,808,373

G

transforming growth factor, beta 1

increases expression

Thimerosal results in increased expression of TGFB1

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

thioesterase superfamily member 4

increases expression

Thimerosal results in increased expression of THEM4 mRNA

NCBI chr 2:181,953,550...181,974,708
Ensembl chr 2:181,953,550...181,974,708

G

thymocyte selection associated family member 2

decreases expression

Thimerosal results in decreased expression of THEMIS2 mRNA

NCBI chr 5:144,991,110...145,006,362
Ensembl chr 5:144,991,112...145,006,400

G

thrombopoietin

decreases expression

Thimerosal results in decreased expression of THPO mRNA

Ensembl chr11:80,182,820...80,188,167

G

thyroid hormone receptor associated protein 3

decreases expression

Thimerosal results in decreased expression of THRAP3 mRNA

NCBI chr 5:138,445,284...138,487,544
Ensembl chr 5:138,445,295...138,487,477

G

Thy-1 cell surface antigen

decreases expression

Thimerosal results in decreased expression of THY1 mRNA

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

transketolase

decreases expression

Thimerosal results in decreased expression of TKT mRNA

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

TLE family member 4, transcriptional corepressor

decreases expression

Thimerosal results in decreased expression of TLE4 mRNA

NCBI chr 1:211,661,738...211,798,458
Ensembl chr 1:211,661,746...211,797,862

G

transmembrane channel-like 5

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMC5 mRNA

NCBI chr 1:172,914,915...172,999,478
Ensembl chr 1:172,914,457...172,999,474

G

transmembrane channel like 6

decreases expression

Thimerosal results in decreased expression of TMC6 mRNA

NCBI chr10:102,982,059...102,999,509
Ensembl chr10:102,971,229...102,998,960

G

transmembrane protein with EGF-like and two follistatin-like domains 2

increases expression

Thimerosal results in increased expression of TMEFF2 mRNA

NCBI chr 9:50,445,947...50,733,473
Ensembl chr 9:50,436,079...50,733,475

G

transmembrane protein 240

decreases expression

Thimerosal results in decreased expression of TMEM240 mRNA

NCBI chr 5:166,344,000...166,350,210
Ensembl chr 5:166,344,386...166,350,636

G

transmembrane protein 33

decreases expression

Thimerosal results in decreased expression of TMEM33 mRNA

NCBI chr14:40,888,485...40,910,715
Ensembl chr14:40,885,712...40,910,715

G

transmembrane protein 74B

decreases expression

Thimerosal results in decreased expression of TMEM74B mRNA

NCBI chr 3:140,219,592...140,224,208
Ensembl chr 3:140,219,412...140,235,872

G

transmembrane protein 97

decreases expression

Thimerosal results in decreased expression of TMEM97 mRNA

NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730

G

tropomodulin 2

increases expression

Thimerosal results in increased expression of TMOD2 mRNA

NCBI chr 8:76,316,736...76,366,003
Ensembl chr 8:76,325,667...76,365,720

G

transmembrane O-mannosyltransferase targeting cadherins 3

decreases expression

Thimerosal results in decreased expression of TMTC3 mRNA

NCBI chr 7:35,264,886...35,310,010
Ensembl chr 7:35,264,892...35,310,385

G

tumor necrosis factor

increases secretion
multiple interactions

Thimerosal results in increased secretion of TNF protein
Glutathione inhibits the reaction [Thimerosal inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Thimerosal inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

PMID:17079650 PMID:18495191 PMID:20417223

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 13b

increases expression

Thimerosal results in increased expression of TNFSF13B mRNA

NCBI chr16:79,462,406...79,492,888
Ensembl chr16:79,462,402...79,492,693

G

TNFAIP3 interacting protein 1

decreases expression

Thimerosal results in decreased expression of TNIP1 mRNA

NCBI chr10:39,037,048...39,084,328
Ensembl chr10:39,037,058...39,077,625

G

troponin I3, cardiac type

decreases expression

Thimerosal results in decreased expression of TNNI3 mRNA

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

G

transducer of ERBB2, 2

decreases expression

Thimerosal results in decreased expression of TOB2 mRNA

NCBI chr 7:113,362,703...113,371,423
Ensembl chr 7:113,361,148...113,372,688

G

DNA topoisomerase II alpha

decreases activity

Thimerosal results in decreased activity of TOP2A protein

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

TOX high mobility group box family member 2

decreases expression

Thimerosal results in decreased expression of TOX2 mRNA

NCBI chr 3:151,853,294...151,980,086
Ensembl chr 3:151,853,294...151,980,749

G

tumor protein p53

affects activity

Thimerosal affects the activity of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 binding protein 1

decreases expression

Thimerosal results in decreased expression of TP53BP1 mRNA

NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822

G

two pore segment channel 1

decreases expression

Thimerosal results in decreased expression of TPCN1 mRNA

NCBI chr12:35,972,813...36,029,632
Ensembl chr12:35,972,846...36,029,626

G

tumor protein D52

decreases expression

Thimerosal results in decreased expression of TPD52 mRNA

NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622

G

triosephosphate isomerase 1

decreases expression

Thimerosal results in decreased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

tropomyosin 4

decreases expression

Thimerosal results in decreased expression of TPM4 mRNA

NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984

G

tripeptidyl peptidase 1

decreases expression

Thimerosal results in decreased expression of TPP1 mRNA

NCBI chr 1:160,097,984...160,104,108
Ensembl chr 1:160,096,833...160,104,129

G

tripeptidyl peptidase 2

decreases expression

Thimerosal results in decreased expression of TPP2 mRNA

NCBI chr 9:46,046,712...46,128,157
Ensembl chr 9:46,046,632...46,128,157

G

translocated promoter region, nuclear basket protein

decreases expression

Thimerosal results in decreased expression of TPR mRNA

NCBI chr13:62,424,312...62,487,502
Ensembl chr13:62,424,312...62,487,496

G

Tp53rk binding protein

increases expression

Thimerosal results in increased expression of TPRKB mRNA

NCBI chr 4:118,342,910...118,357,908
Ensembl chr 4:118,342,945...118,357,901

G

TNF receptor-associated factor 5

decreases expression

Thimerosal results in decreased expression of TRAF5 mRNA

NCBI chr13:103,569,944...103,618,747
Ensembl chr13:103,572,314...103,618,709

G

translocation associated membrane protein 1

increases expression

Thimerosal results in increased expression of TRAM1 mRNA

NCBI chr 5:5,642,579...5,667,666
Ensembl chr 5:5,642,546...5,686,971

G

trafficking protein particle complex subunit 13

increases expression

Thimerosal results in increased expression of TRAPPC13 mRNA

NCBI chr 2:35,270,495...35,302,049
Ensembl chr 2:35,269,183...35,302,048

G

tRNA aspartic acid methyltransferase 1

decreases expression

Thimerosal results in decreased expression of TRDMT1 mRNA

NCBI chr17:76,601,966...76,646,104
Ensembl chr17:76,610,543...76,645,439

G

transcriptional regulating factor 1

decreases expression

Thimerosal results in decreased expression of TRERF1 mRNA

NCBI chr 9:13,631,619...13,858,326
Ensembl chr 9:13,634,126...13,857,029

G

tribbles pseudokinase 3

decreases expression

Thimerosal results in decreased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

tripartite motif-containing 13

increases expression

Thimerosal results in increased expression of TRIM13 mRNA

NCBI chr15:35,733,548...35,772,676
Ensembl chr15:35,734,107...35,772,677

G

tripartite motif-containing 14

decreases expression

Thimerosal results in decreased expression of TRIM14 mRNA

NCBI chr 5:60,800,568...60,824,858
Ensembl chr 5:60,800,032...60,824,858

G

tripartite motif-containing 23

increases expression

Thimerosal results in increased expression of TRIM23 mRNA

NCBI chr 2:35,302,405...35,335,746
Ensembl chr 2:35,302,409...35,335,743

G

tripartite motif-containing 28

decreases expression

Thimerosal results in decreased expression of TRIM28 mRNA

NCBI chr 1:73,652,441...73,659,388
Ensembl chr 1:73,652,709...73,659,380

G

tripartite motif-containing 59

decreases expression

Thimerosal results in decreased expression of TRIM59 mRNA

NCBI chr 2:153,269,210...153,281,185
Ensembl chr 2:153,268,584...153,281,031

G

tripartite motif-containing 9

decreases expression

Thimerosal results in decreased expression of TRIM9 mRNA

NCBI chr 6:88,756,824...88,856,588
Ensembl chr 6:88,757,303...88,856,542

G

tRNA methyltransferase 10A

increases expression

Thimerosal results in increased expression of TRMT10A mRNA

NCBI chr 2:226,669,445...226,684,166
Ensembl chr 2:226,669,832...226,684,151

G

transient receptor potential cation channel, subfamily M, member 3

increases expression

Thimerosal results in increased expression of TRPM3 mRNA

NCBI chr 1:219,673,200...220,557,610
Ensembl chr 1:219,672,892...220,560,717

G

thyroid stimulating hormone subunit beta

increases expression

Thimerosal results in increased expression of TSHB mRNA; Thimerosal results in increased expression of TSHB protein

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

tetraspanin 33

decreases expression

Thimerosal results in decreased expression of TSPAN33 mRNA

NCBI chr 4:58,305,378...58,330,013
Ensembl chr 4:58,305,437...58,328,940

G

tetratricopeptide repeat domain 39C

multiple interactions

[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC39C mRNA

NCBI chr18:3,768,802...3,887,932
Ensembl chr18:3,805,183...3,887,930

G

tweety family member 2

decreases expression

Thimerosal results in decreased expression of TTYH2 mRNA

NCBI chr10:99,709,063...99,753,449
Ensembl chr10:99,709,007...99,753,444

G

tubulin, beta 2A class IIa

decreases expression

Thimerosal results in decreased expression of TUBB2A mRNA

NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714

G

tubulin, beta 4B class IVb

decreases expression

Thimerosal results in decreased expression of TUBB4B mRNA

NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296

G

tubulin gamma complex component 3

increases expression

Thimerosal results in increased expression of TUBGCP3 mRNA

NCBI chr16:76,851,859...76,912,499
Ensembl chr16:76,851,810...76,912,499

G

thioredoxin domain containing 9

increases expression

Thimerosal results in increased expression of TXNDC9 mRNA

NCBI chr 9:40,211,818...40,221,953
Ensembl chr 9:40,211,412...40,384,279
Ensembl chr 9:40,211,412...40,384,279

G

thioredoxin interacting protein

decreases expression

Thimerosal results in decreased expression of TXNIP mRNA

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

ubiquitin-conjugating enzyme E2L 3

decreases expression

Thimerosal results in decreased expression of UBE2L3 mRNA

NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862

G

ubinuclein 1

decreases expression

Thimerosal results in decreased expression of UBN1 mRNA

NCBI chr10:10,496,576...10,532,010
Ensembl chr10:10,496,576...10,532,010

G

ubinuclein 2

decreases expression

Thimerosal results in decreased expression of UBN2 mRNA

NCBI chr 4:67,165,278...67,251,562
Ensembl chr 4:67,166,346...67,230,491

G

ubiquitin protein ligase E3 component n-recognin 1

increases expression

Thimerosal results in increased expression of UBR1 mRNA

NCBI chr 3:107,813,721...107,921,701
Ensembl chr 3:107,811,392...107,922,204

G

uncoupling protein 2

decreases expression

Thimerosal results in decreased expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

UDP-glucose ceramide glucosyltransferase

decreases expression

Thimerosal results in decreased expression of UGCG mRNA

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

UDP-glucose glycoprotein glucosyltransferase 1

decreases expression

Thimerosal results in decreased expression of UGGT1 mRNA

NCBI chr 9:38,355,229...38,468,473
Ensembl chr 9:38,359,089...38,468,467

G

UDP glycosyltransferase 8

decreases expression

Thimerosal results in decreased expression of UGT8 mRNA

NCBI chr 2:214,264,483...214,332,769
Ensembl chr 2:214,264,483...214,332,660

G

U2AF homology motif kinase 1

decreases expression

Thimerosal results in decreased expression of UHMK1 mRNA

NCBI chr13:82,396,646...82,416,292
Ensembl chr13:82,401,187...82,416,292

G

UPF1, RNA helicase and ATPase

decreases expression

Thimerosal results in decreased expression of UPF1 mRNA

NCBI chr16:19,076,594...19,097,365
Ensembl chr16:19,076,322...19,096,568

G

uridine phosphorylase 1

increases expression

Thimerosal results in increased expression of UPP1 mRNA

NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462

G

ubiquitin specific peptidase 1

decreases expression

Thimerosal results in decreased expression of USP1 mRNA

NCBI chr 5:113,587,564...113,598,934
Ensembl chr 5:113,587,564...113,598,932

G

ubiquitin specific peptidase 10

decreases expression

Thimerosal results in decreased expression of USP10 mRNA

NCBI chr19:47,972,858...48,014,900
Ensembl chr19:47,972,611...48,014,897

G

ubiquitin specific peptidase 16

increases expression

Thimerosal results in increased expression of USP16 mRNA

NCBI chr11:26,681,359...26,711,313
Ensembl chr11:26,681,414...26,710,539

G

ubiquitin specific peptidase 25

affects expression

Thimerosal affects the expression of USP25 mRNA

NCBI chr11:15,603,654...15,711,356
Ensembl chr11:15,603,881...15,711,348

G

ubiquitin specific peptidase 29

decreases expression

Thimerosal results in decreased expression of USP29 mRNA

NCBI chr 1:66,874,216...67,097,731
Ensembl chr 1:66,874,017...67,097,686

G

ubiquitin specific peptidase 34

affects expression

Thimerosal affects the expression of USP34 mRNA

NCBI chr14:97,285,799...97,476,376
Ensembl chr14:97,286,018...97,476,376

G

ubiquitin specific peptidase 49

decreases expression

Thimerosal results in decreased expression of USP49 mRNA

NCBI chr 9:13,305,640...13,366,132
Ensembl chr 9:13,308,178...13,366,132

G

ubiquitin specific peptidase 51

decreases expression

Thimerosal results in decreased expression of USP51 mRNA

NCBI chr X:18,374,940...18,381,472
Ensembl chr X:18,376,930...18,379,888

G

VANGL planar cell polarity protein 1

decreases expression

Thimerosal results in decreased expression of VANGL1 mRNA

NCBI chr 2:189,586,681...189,637,609
Ensembl chr 2:189,589,229...189,637,619

G

VAMP associated protein B and C

decreases expression

Thimerosal results in decreased expression of VAPB mRNA

NCBI chr 3:162,535,974...162,578,747
Ensembl chr 3:162,535,905...162,573,763

G

vasodilator-stimulated phosphoprotein

decreases expression

Thimerosal results in decreased expression of VASP mRNA

NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061

G

vesicle amine transport 1

decreases expression

Thimerosal results in decreased expression of VAT1 mRNA

NCBI chr10:86,389,549...86,397,167
Ensembl chr10:86,389,545...86,397,224

G

valosin-containing protein

decreases expression

Thimerosal results in decreased expression of VCP mRNA

NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571

G

vascular endothelial growth factor A

decreases expression

Thimerosal results in decreased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor B

decreases expression

Thimerosal results in decreased expression of VEGFB mRNA

NCBI chr 1:204,172,297...204,178,046
Ensembl chr 1:204,172,225...204,177,944

G

VPS37B subunit of ESCRT-I

decreases expression

Thimerosal results in decreased expression of VPS37B mRNA

NCBI chr12:32,560,047...32,589,015
Ensembl chr12:32,560,047...32,589,014

G

VPS53 subunit of GARP complex

decreases expression

Thimerosal results in decreased expression of VPS53 mRNA

NCBI chr10:60,919,820...61,038,674
Ensembl chr10:60,919,820...61,038,676

G

V-set and immunoglobulin domain containing 10 like

decreases expression

Thimerosal results in decreased expression of VSIG10L mRNA

NCBI chr 1:93,871,487...93,880,157
Ensembl chr 1:93,851,774...93,879,566

G

WAPL cohesin release factor

decreases expression

Thimerosal results in decreased expression of WAPL mRNA

NCBI chr16:10,005,520...10,075,270
Ensembl chr16:10,004,941...10,073,510

G

WASP family member 2

decreases expression

Thimerosal results in decreased expression of WASF2 mRNA

NCBI chr 5:145,336,817...145,402,041
Ensembl chr 5:145,336,842...145,399,242

G

WASP like actin nucleation promoting factor

decreases expression

Thimerosal results in decreased expression of WASL mRNA

NCBI chr 4:53,083,536...53,132,061
Ensembl chr 4:53,083,536...53,132,022

G

WD repeat and FYVE domain containing 3

increases expression

Thimerosal results in increased expression of WDFY3 mRNA

NCBI chr14:7,578,245...7,810,491
Ensembl chr14:7,606,628...7,810,482

G

WD repeat domain 49

increases expression

Thimerosal results in increased expression of WDR49 mRNA

NCBI chr 2:160,049,478...160,264,581
Ensembl chr 2:160,051,458...160,264,511

G

WD repeat domain 54

decreases expression

Thimerosal results in decreased expression of WDR54 mRNA

NCBI chr 4:115,654,968...115,677,979
Ensembl chr 4:115,654,968...115,661,562

G

WD repeat domain 59

decreases expression

Thimerosal results in decreased expression of WDR59 mRNA

NCBI chr19:39,416,432...39,483,773
Ensembl chr19:39,416,429...39,483,698

G

WD repeat domain 86

decreases expression

Thimerosal results in decreased expression of WDR86 mRNA

NCBI chr 4:10,423,496...10,443,473
Ensembl chr 4:10,424,008...10,441,465

G

WAS/WASL interacting protein family, member 3

decreases expression

Thimerosal results in decreased expression of WIPF3 mRNA

NCBI chr 4:83,550,075...83,629,929
Ensembl chr 4:83,550,468...83,629,386

G

WNK lysine deficient protein kinase 1

decreases expression

Thimerosal results in decreased expression of WNK1 mRNA

NCBI chr 4:153,128,334...153,253,905
Ensembl chr 4:153,128,334...153,253,905

G

Wnt family member 3

decreases expression

Thimerosal results in decreased expression of WNT3 mRNA

NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099

G

X-linked inhibitor of apoptosis

affects expression
multiple interactions
decreases expression

Thimerosal affects the expression of XIAP protein
Glutathione inhibits the reaction [Thimerosal results in decreased expression of XIAP protein]

PMID:12140745 PMID:16649253

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

G

zinc finger CCCH type containing 12C

increases expression

Thimerosal results in increased expression of ZC3H12C mRNA

NCBI chr 8:52,443,791...52,508,643
Ensembl chr 8:52,448,320...52,504,315

G

zinc finger protein 382

decreases expression

Thimerosal results in decreased expression of ZFP382 mRNA

NCBI chr 1:85,377,614...85,400,832
Ensembl chr 1:85,377,484...85,399,667

G

zinc finger protein 655

increases expression

Thimerosal results in increased expression of ZFP655 mRNA

NCBI chr12:9,349,985...9,375,449
Ensembl chr12:9,357,639...9,374,569

G

zinc finger protein 958

decreases expression

Thimerosal results in decreased expression of ZFP958 mRNA

NCBI chr12:3,953,442...3,975,328
Ensembl chr12:3,953,455...3,975,514
Ensembl chr12:3,953,455...3,975,514

triarachidonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

stearoyl-CoA desaturase

decreases expression
multiple interactions

Triarachidonin results in decreased expression of SCD1 mRNA
Clofibrate inhibits the reaction [Triarachidonin results in decreased expression of SCD1 mRNA]

PMID:8729090 PMID:8790349

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19841
chemical entity	19839
molecular entity	19839
ion	16708
anion	16088
organic anion	3616
carboxylic acid anion	2480
monocarboxylic acid anion	1591
(+)-DCA-CL(1-)	0
(+)-artemisinate	0
(+)-pisiferate	0
(-)-DCA-CL(1-)	0
(-)-phomoidride B(1-)	0
(10aS)-10,10a-dihydrophenazine-1-carboxylate	0
(11R)-carlactonoate +	0
(1R)-1,4,5,10-tetrahydrophenazine-1-carboxylate	0
(1R,10aS)-1,4,10,10a-tetrahydrophenazine-1-carboxylate	0
(1S,3R)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate	0
(2-chloro-5-oxo-2,5-dihydro-2-furyl)acetate +	0
(2-hydroxyphenyl)acetate	0
(2E,6E,10R,11S)-10,11-epoxy-3,7,11-trimethyltrideca-2,6-dienoate	0
(2R,3R,5S)-2-(S-pantetheinyl)-carbapenam-3-carboxylate	0
(2R,3R,5S,6R)-6-(ethyl)-2-(S-pantetheinyl)-carbapenam-3-carboxylate	0
(2R,3R,5S,6R)-6-(methyl)-2-(S-pantetheinyl)-carbapenam-3-carboxylate	0
(2S)-3-(4-hydroxyphenyl)-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]propanoate	0
(2S)-3-methyl-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]butanoate	0
(2S)-3-phenyl-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]propanoate	0
(2S)-4-methyl-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]pentanoate	0
(2Z,4Z)-2-hydroxyhexa-2,4-dienoate	0
(2xi)-3-deoxy-7-O-phosphonato-beta-D-threo-hept-6-ulopyranosonate +	0
(2xi)-D-gluco-heptonate +	0
(3,5-dichlorophenyl)ureidoformate	0
(3-nitro-4-oxidophenyl)acetate	0
(3R)-7,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate	0
(3R,5S)-fluvastatin(1-) +	0
(3S)-1,2-diazinane-3-carboxylate	0
(3S)-3-(\{(2S)-2-[5-tert-butyl-3-\{[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]amino\}-2-oxopyrazin-1(2H)-yl]butanoyl\}amino)-5-[hexyl(methyl)amino]-4-oxopentanoate	0
(3S)-7,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate	0
(3S,5R)-fluvastatin(1-) +	0
(3S,5S)-carbapenam-3-carboxylate	0
(4-hydroxy-3-nitrophenyl)acetate	0
(4-hydroxy-5-iodo-3-nitrophenyl)acetate	0
(4-nitrophenyl)acetate	0
(4-octa-1-enyl-2,5-dioxo-2,5-dihydro-3-furanyl)acetate	0
(4R,5S)-dethiobiotin(1-)	0
(4S)-4,16-dihydroxyretinoate	0
(5R)-carbapenem-3-carboxylate	0
(7R)-6-deoxy-D-manno-oct-7-ulosuronate	0
(8E,10S,12Z,15Z)-10-hydroperoxyoctadec-8,12,15-trienoate	0
(9E)-12-(phosphonooxy)octadecenoate(3-)	0
(9Z)-18-hydroxyoctadec-9-enoate 18-O-beta-D-glucoside	0
(9Z,11E,13S,14Z)-13-hydroperoxyoctadeca-9,11,14-trienoate	0
(E)-3-(indol-3-yl)acrylate(1-)	0
(R)-2-(4-chloro-2-methylphenoxy)propanoate	0
(R)-2-O-sulfonatolactate(2-)	0
(R)-3,5-bisphosphonatomevalonate(5-)	0
(R)-3-sulfolactate	0
(R)-5-diphosphonatomevalonate(4-)	0
(R)-dichlorprop(1-)	0
(R)-dihydrocamalexate	0
(R)-imazamox(1-) +	0
(R)-imazapic(1-) +	0
(R)-imazapyr(1-) +	0
(R)-imazaquin(1-) +	0
(R)-lorglumide(1-) +	0
(R,R)-chrysanthemate	0
(S)-2-(4-chloro-2-methylphenoxy)propanoate	0
(S)-2-O-sulfonatolactate(2-)	0
(S)-2-chloropropanoate	0
(S)-4-amino-5-oxopentanoate	0
(S)-5-carboxymethyl-tetronate(1-)	0
(S)-alpha-hydroxyglutarate-gamma-lactone	0
(S)-dichlorprop(1-)	0
(S)-dihydrocamalexate	0
(S)-haloxyfop(1-)	0
(S)-imazamox(1-) +	0
(S)-imazapic(1-) +	0
(S)-imazapyr(1-) +	0
(S)-imazaquin(1-) +	0
(S)-lorglumide(1-) +	0
(Z)-2-methylureidoacrylate	0
(Z)-3-amino-2-methylacrylate	0
(Z)-3-aminoacrylate	0
(aminooxy)acetate +	0
(methylthio)acetate	0
1,2-diacyl-3-[3-(alpha-D-N-acetylneuraminyl)-beta-D-galactosyl]-sn-glycerol(1-)	0
1,4-dihydroxy-6-naphthoate	0
1,6-anhydro-N-acetyl-beta-muramate	0
1,6-dihydroxy-2-methylcyclohexa-2,4-diene-1-carboxylate	0
1-(2-carboxylatophenylamino)-1-deoxy-D-ribulose 5-phosphate(3-)	0
1-O-hexadecyl-2-(8-carboxyoctanoyl)-sn-glycero-3-phosphocholine(1-)	0
1-deoxypentalenate	0
1-hexadecyl-2-glutaryl-sn-glycero-3-phosphocholine(1-)	0
1-hexadecyl-2-succinyl-sn-glycero-3-phosphocholine(1-)	0
1-methyl-4-imidazoleacetate	0
1-naphthaleneacetate	0
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine(1-)	0
1-phosphonato-alpha-D-galacturonate(3-)	0
1-phosphonato-alpha-D-glucuronate(3-)	0
1-piperideine-6-carboxylate +	0
1-pyrrolinecarboxylate +	0
12-(octadecanoyloxy)octadecanoate	0
12-(phosphonooxy)octadecanoate(3-)	0
12-[(9Z)-hexadecenoyloxy]octadecanoate	0
12-[(9Z)-octadecenoyloxy]octadecanoate	0
12-ethyl-8-isobutyl-3-vinylbacteriochlorophyllide d(1-)	0
12-ethyl-8-propyl-3-vinylbacteriochlorophyllide d(1-)	0
13-(beta-D-glucosyloxy)docosanoate	0
13-(octadecanoyloxy)octadecanoate	0
13-[(9Z)-hexadecenoyloxy]octadecanoate	0
13-[(9Z)-octadecenoyloxy]octadecanoate	0
16-epiestriol 16-O-(beta-D-glucuronide)(1-)	0
16-epiestriol 3-O-(beta-D-glucuronide)(1-)	0
16-feruloyloxypalmitate	0
16-sinapoyloxypalmitate	0
17-(4-hydroxyphenyl)heptadecanoate	0
17-epiestriol 16-O-(beta-D-glucuronide)(1-)	0
17-epiestriol 17-O-(beta-D-glucuronide)(1-)	0
17-epiestriol 3-O-(beta-D-glucuronide)(1-)	0
17alpha-(N-acetyl-D-glucosaminyl)estradiol 3-glucosiduronate	0
17alpha-estradiol 3-glucosiduronate	0
17beta-estradiol 17-glucosiduronate +	0
19-(4-hydroxyphenyl)nonadecanoate	0
2,3,6,8,9-pentahydroxy-1-oxo-3-(2-oxopropyl)-1,2,3,4-tetrahydroanthracene-2-carboxylate	0
2,3-bisphosphonato-D-glycerate(5-)	0
2,4,5-trihydroxyphenylacetate	0
2,4-dichloro-5-oxo-2,5-dihydro-2-furylacetate	0
2,4-divinyl protochlorophyllide a(1-)	0
2,6-dihydroxynicotinate	0
2-O-(4-deoxy-beta-L-threo-hex-4-enopyranuronosyl)-alpha-L-rhamnopyranose(1-)	0
2-O-(6-phospho-alpha-D-mannosyl)-D-glycerate	0
2-O-(alpha-D-glucopyranosyl)-3-O-phosphonato-D-glycerate(3-)	0
2-O-[alpha-D-mannopyranosyl-(1->2)-alpha-D-glucopyranosyl]-3-O-phosphonato-D-glycerate(3-)	0
2-O-[alpha-D-mannosyl-(1->2)-alpha-D-glucosyl]-D-glycerate	0
2-O-alpha-L-rhamnosyl-alpha-L-rhamnosyl-3-hydroxydecanoyl-3-hydroxydecanoate	0
2-[(1R,8S,14R,15R)-11-hydroxy-14,15-bis[(6E)-oct-6-en-1-yl]-3,5,9-trioxo-4,10-dioxatetracyclo[9.4.0.0(2,6).0(8,12)]pentadeca-2(6),12-dien-8-yl]acetate	0
2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]acetate	0
2-[1-(\{5-hydroxy-4-oxo-3-[2-(sulfonatooxy)phenyl]-4H-chromen-6-yl\}oxy)-2-oxoethoxy]-3-oxopropanoate	0
2-acetamido-2-deoxy-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronate)-4-O-sulfonato-D-galactopyranose(2-) +	0
2-acetamido-2-deoxy-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronate)-6-O-sulfonato-D-galactopyranose(2-) +	0
2-amino-2-deoxy-D-gluconate	0
2-amino-3-oxo-4-(phosphonatooxy)butanoate	0
2-carboxylato-D-arabinitol 1-phosphate(3-)	0
2-carboxylato-D-arabinitol(1-)	0
2-chloroacrylate	0
2-cis-abscisate +	0
2-dehydro-3,6-dideoxy-6-sulfo-D-gluconate(2-)	0
2-dehydro-3-deoxy-6-phosphonato-D-gluconate(3-)	0
2-ethylacrylate	0
2-hydroxy-17beta-estradiol 2-O-(beta-D-glucuronide)(1-)	0
2-hydroxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
2-hydroxyestrone 2-O-(beta-D-glucuronide)(1-)	0
2-hydroxyestrone 3-O-(beta-D-glucuronide)(1-)	0
2-imino-3-(7-chloroindol-3-yl)propionate(1-)	0
2-imino-3-(indol-3-yl)propanoate	0
2-iminopropanoate	0
2-methoxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
2-methoxyestrone 3-O-(beta-D-glucuronide)(1-)	0
2-methylvalerate	0
2-oxindole-3-acetate	0
2-oxo-1,2-dihydroquinoline-4-carboxylate	0
2-oxo-4-phosphonobutanoate(2-)	0
2-phosphonatoglycolate(3-)	0
3'-dehydrocarminate(2-)	0
3,3',5-triiodo-L-thyroninate +	0
3,4,5-trimethoxybenzoate	0
3,4,5-trimethoxydihydrocinnamate	0
3,4-dehydrothiomorpholine-3-carboxylate	0
3,4-dimethylindole-2-carboxylate	0
3,5-dibromo-4-oxidobenzoate(2-)	0
3-(1-hydroxyethyl)bacteriochlorophyllide a(2-)	0
3-(1-hydroxyethyl)chlorophyllide a(2-)	0
3-(1H-indol-3-yl)propanoate	0
3-(2,3-dihydroxyphenyl)propanoate	0
3-(2-hydroxyphenyl)propanoate	0
3-(3,4-dihydroxyphenyl)propanoate	0
3-(3-hydroxyphenyl)propanoate	0
3-(3-sulfooxyphenyl)propanoate(2-)	0
3-(4-oxo-4,5-dihydro-1H-imidazol-5-yl)propanoate(1-)	0
3-(cis-5,6-dihydroxycyclohexa-1,3-dienyl)propanoate +	0
3-(dioxido-lambda(5)-azanylidene)propanoate(2-)	0
3-(trimethylsilyl)propionate +	0
3-ADP-2-phosphoglycerate(5-)	0
3-D-glucuronosyl-N(2),6-disulfonato-beta-D-glucosamine(3-)	0
3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronate)-D-galactosamine(1-)	0
3-acetylchlorophyllide a(2-)	0
3-aci-nitropropanoate	0
3-butynoate	0
3-carboxy-3-hydroxypropanoyl-CoA(5-) +	0
3-chloroacrylate	0
3-dehydro-L-gulonate 6-phosphate	0
3-dehydroshikimate	0
3-deoxy-D-glycero-beta-D-galacto-nonulosonate	0
3-deoxy-alpha-D-manno-2-octulosonate-8-phosphate(3-)	0
3-deoxy-alpha-D-manno-oct-2-ulosonate	0
3-hydroxy-2-isopropyl-4-methoxy-4-oxobutanoate	0
3-hydroxy-3-(4-O-beta-D-glucosyl-3-methoxyphenyl)propanoate	0
3-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propanoate	0
3-hydroxy-3-(4-hydroxyphenyl)propanoate	0
3-hydroxy-3-phenylpropionate	0
3-mercapto-2-mercaptomethylpropanoate(1-)	0
3-methylvalerate	0
3-nitroacrylate	0
3-nitropropanoate	0
3-phenylpropionate +	0
3-phosphonatopyruvate(2-)	0
3-phosphonatopyruvate(3-)	0
3-sulfinatopropionate	0
3-ureidoisobutyrate(1-)	0
3-vinyl-bacteriochlorophyllide d(1-)	0
3-vinylbacteriochlorophyllide a(1-)	0
3-vinylbacteriochlorophyllide a(2-)	0
3-vinylbacteriochlorophyllide d(1-)	0
3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oate(1-)	0
4'''-demalonylsalvianin(1-)	0
4,4'-diapolycopen-4-oate	0
4,4'-diaponeurosporenoate	0
4-(2,4-dichlorophenoxy)butanoate	0
4-O-beta-D-glucosyl-4-coumarate +	0
4-O-beta-D-glucosyl-trans-ferulate	0
4-O-beta-D-glucosyl-trans-sinapate	0
4-acetamidobutanoate	0
4-carboxylato-4'-sulfonatoazobenzene	0
4-carboxylatomethyl-3-methylbut-2-en-1,4-olide(1-)	0
4-carboxylatomethyl-4-methylbut-2-en-1,4-olide(1-)	0
4-carboxylatomethylenebut-2-en-4-olide	0
4-chlorophenylacetate	0
4-deoxy-Delta(4)-beta-D-GlcpA2S-(1->3)-beta-D-GalpNAc(2-)	0
4-deoxy-L-threo-hex-4-enopyranuronate +	0
4-deoxy-beta-L-threo-hex-4-enopyranuronate	0
4-guanidinobutanoate	0
4-hydroxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
4-hydroxy-17beta-estradiol 4-O-(beta-D-glucuronide)(1-)	0
4-hydroxyestrone 3-O-(beta-D-glucuronide)(1-)	0
4-hydroxyestrone 4-O-(beta-D-glucuronide)(1-)	0
4-hydroxyphenylacetate	0
4-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate	0
4-methoxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
4-methoxy-4-oxo-3-phenylbutanoate	0
4-methoxyestrone 3-O-(beta-D-glucuronide)(1-)	0
4-methyl-3-oxopentanoate	0
4-methylumbelliferone beta-D-glucuronide(1-)	0
4-sulfanylbutanoate	0
5(S),8(R)-DiHODE(1-)	0
5,10-dihydro-9-dimethylallylphenazine 1-carboxylate	0
5,10-dihydrophenazine-1-carboxylate	0
5,6,7,8-tetrahydropterin-6-carboxylate	0
5,6-epoxyretinoate	0
5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)-1,3-benzothiazol-6-yl beta-D-glucuronide(1-)	0
5-(2,3-dimethoxy-4-methylphenyl)pentanoate	0
5-(2-carboxylatoethyl)-4-oxo-4,5-dihydro-1H-imidazol-5-ide	0
5-[(9Z)-hexadecenoyloxy]octadecanoate	0
5-[(9Z)-octadecenoyloxy]octadecanoate	0
5-amino-4-chloro-2-(2-oxidomuconoyl)pyridazin-3(2H)-one(2-)	0
5-aminolevulinate	0
5-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium-3-carbonyl adenylate(3-)	0
5-chloromuconolactone(1-)	0
5-dehydro-4-deoxy-2-O-sulfo-D-glucuronic acid(2-)	0
5-dehydro-D-gluconate	0
5-dehydro-L-gluconate	0
5-deoxy-D-glucuronate	0
5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate	0
5-hydroxy-6-methylpyridine-3-carboxylate	0
5-hydroxyectoinate	0
5-hydroxyferulate +	0
5-hydroxyimidazole-4-acetate	0
5-oxo-2,5-dihydro-2-furylacetate	0
5-oxo-4,5-dihydro-2-furylacetate	0
5alpha-androstane-3alpha,17beta-diol 17-glucosiduronate	0
5alpha-androstane-3alpha,17beta-diol 3-glucosiduronate(1-)	0
5alpha-androstane-3beta,17beta-diol 17-O-(beta-D-glucuronide)(1-)	0
5alpha-dihydrotestosterone 17-O-(beta-D-glucuronide)(1-)	0
6-[(4-hydroxy-3-nitrophenyl)acetamido]caproate	0
6-deoxy-6-sulfo-D-gluconate(2-)	0
6-formamidopenicillanate	0
6-hydroxynicotinate(1-)	0
6-ketopiperidine-2-carboxylate	0
6-phospho-D-gluconate	0
6-phosphonato-2-dehydro-3-deoxy-D-galactate(3-)	0
6-phosphonatooxy-D-gluconate	0
6alpha-hydroxygermacra-1(10),4,11(13)-trien-12-oate	0
7(1),7(1)-dihydroxybacteriochlorophyllide d(1-)	0
7(1)-hydroxybacteriochlorophyllide d(1-)	0
7(1)-hydroxychlorophyllide a(2-)	0
7,7-dihydroxybacteriochlorophyllide c(1-)	0
7-carboxylato-7-deazaguanine	0
7-deoxyloganate	0
7-deoxyloganetate	0
7-hydroxybacteriochlorophyllide c(1-)	0
7-phospho-2-dehydro-3-deoxy-D-arabino-heptonate	0
8(R)-HPODE(1-)	0
8,12-diethyl-3-vinylbacteriochlorophyllide d(1-)	0
8-phosphonato-3-deoxy-D-manno-oct-2-ulosonate(3-)	0
9(R)-HPODE(1-)	0
9(S)-HPODE(1-)	0
9-(octadecanoyloxy)octadecanoate	0
9-[(10Z)-heptadecenoyloxy]-octadecanoate	0
9-[(9Z),(12Z)-octadecadienoyloxy]-octadecanoate	0
9-[(9Z)-hexadecenoyloxy]octadecanoate	0
9-[(9Z)-octadecenoyloxy]octadecanoate	0
9beta-pimara-7,15-dien-19-oate	0
ADP-5-ethyl-4-methylthiazole-2-carboxylate(3-)	0
CMP-5'-phosphonoformate(3-)	0
D-galactopyranuronate +	0
D-glucopyranuronate +	0
D-glucuronate 1-phosphate	0
F420-0(2-)	0
L-5-carboxylatomethylhydantoin(1-)	0
L-rhamnonate	0
L-rhamnosyl-3-hydroxydecanoyl-3-hydroxydecanoate	0
L-thyroxine(1-) +	0
N,N-dihydroxy-L-isoleucinate	0
N,N-dihydroxy-L-valinate	0
N-(1H-1,3-benzodiazol-2-yl)carbamate	0
N-(2-furoyl)glycinate	0
N-(2-hydroxy,5-methoxyphenyl)malonamate	0
N-(2-hydroxyphenyl)malonamate	0
N-(3,4-dichlorophenyl)malonamate	0
N-(3-carboxypropanoyl)-N-hydroxycadaverine zwitterion	0
N-(3-carboxypropanoyl)-N-hydroxyputrescine zwitterion	0
N-(indol-3-ylacetyl)glutaminate	0
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-gamma-aminobutanoate	0
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-gamma-aminobutyrate	0
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]glycinate	0
N-[(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]glycinate	0
N-[(R)-pantothenoyl]-L-cysteinate	0
N-acetyl-1-methyl-L-histidinate	0
N-acetyl-3-methyl-L-histidinate	0
N-acetyl-D-6-sulfogalactosamine(4-)	0
N-acetyl-D-glucosaminate	0
N-acetyl-D-muramoyl-L-alanyl-D-isoglutamine(1-)	0
N-acetyl-L-alaninate	0
N-acetyl-L-alpha-phenylglycinate	0
N-acetyl-L-cysteinate +	0
N-acetyl-L-isoleucinate	0
N-acetyl-L-threoninate	0
N-acetyl-L-tryptophanate	0
N-acetyl-L-tyrosinate	0
N-acetyl-L-valinate	0
N-acetyl-alpha-D-muramate 1-phosphate(3-)	0
N-acetyl-alpha-neuraminate +	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-6-sulfooxy-glucosaminide(2-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-Fuc-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-Fuc-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-6-sulfooxy-glucosaminide(2-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-N-acetyl-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminide(1-)	0
N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminide(1-)	0
N-acetyl-beta-D-6-sulfogalactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-D-6-sulfogalactosamine(3-)	0
N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-beta-D-4-sulfogalactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-D-4-sulfogalactosamine(4-)	0
N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide anion	0
N-acetyl-beta-D-muramoyl-L-alanyl-D-isoglutamine(1-)	0
N-acetyl-beta-neuraminate	0
N-acetylmethioninate +	0
N-acetylmuramate 6-phosphate +	0
N-acetylphosphinothricin(2-) +	0
N-acetyltryptophanate	0
N-acyl-gamma-aminobutyrate +	0
N-arachidonoyl-gamma-aminobutyrate	0
N-carbamoyl-D-phenylglycine(1-)	0
N-carbamoyl-beta-alaninate	0
N-carbamoylsarcosinate	0
N-cinnamoylglycinate	0
N-formylmaleamate	0
N-hexadecanoyl-O-(1-octadecanoyl-2-oleoyl-sn-glycero-3-phospho)-L-serine(2-)	0
N-hexanoylglycinate	0
N-hydroxy-L-isoleucinate	0
N-hydroxy-L-valinate	0
N-isobutyrylglycinate	0
N-isovalerylglycinate	0
O-formylcefamandole(1-) +	0
Photinus luciferin(1-)	0
[1-(5-phosphonatoribosyl)imidazol-4-yl]acetate(3-)	0
[2-methoxy-5-(\{[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl\}methyl)anilino]acetate	0
a carboxymycobactin(1-)	0
abietate	0
abscisates +	0
acetate +	41
acrylate +	2
adenin-9-yl riburonosate(1-)	0
aldehydic acid anion +	0
aldonate +	21
all-trans-13,14-dihydroretinoate +	0
all-trans-3,4-didehydroretinoate(1-)	0
allantoate	0
alpha-D-FucNAc4-(1->4)-beta-D-ManNAcA-(1->4)-D-GlcNAc-undecaprenyl diphosphate(3-)	0
alpha-D-mannopyranuronate	0
alpha-D-talopyranuronate	0
alpha-L-iduronyl-(1->3)-N-acetyl-D-6-sulfogalactosamine(3-)	0
alpha-L-iduronyl-(1->3)-N-acetyl-beta-D-4-sulfogalactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-D-4-sulfogalactosamine(4-)	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminide(1-) +	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide(1-) +	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminide(1-) +	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine(1-) +	0
alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide(1-)	0
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc(1-)	0
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc(1-) +	0
alpha-sulfophenylacetate	0
amidotrizoic acid anion +	16
aminocyclopyrachlor(1-) +	0
arsonoacetic acid anion	0
ascr#1(1-) +	0
ascr#10(1-) +	0
ascr#12(1-) +	0
ascr#14(1-)	0
ascr#16(1-)	0
ascr#9(1-) +	0
asnovolin I(1-)	0
asparagusate	0
asperaculane D(1-)	0
asperaculane E(1-)	0
asperaculane G(1-)	0
bacteriochlorophyllide a(2-) +	0
bacteriochlorophyllide c(1-)	0
bacteriochlorophyllide d(1-)	0
bacteriochlorophyllide e(1-)	0
bacteriochlorophyllide f(1-) +	0
bacteriochlorophyllide g(2-)	0
baicalin(1-)	0
benazolin(1-) +	0
benzoates +	1275
beraprost(1-) +	0
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-D-GlcpNAc(1-) +	0
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc(1-)	0
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc(1-)	0
beta-D-ManNAcA-(1->4)-alpha-D-GlcNAc-1-diphospho-ditrans,polycis-undecaprenol(3-)	0
beta-D-galactosyl-(1->3)-[N-acetyl-alpha-neuraminyl-(2->6)]-N-acetyl-alpha-D-galactosaminide(1-)	0
bile acid anion +	54
biotinate +	0
biotinate sulfoxide(1-)	0
bisorcic(1-)	0
bispyribac(1-) +	0
bromfenac(1-) +	0
bumadizone(1-) +	0
butyrylglycinate	0
calcitroate	0
candesartan(2-)	0
carbocyclic thromboxane A2(1-) +	0
carboprost(1-) +	0
carminate(2-)	0
carnosate	0
carumonam(1-) +	0
catechol beta-D-glucuronide(1-)	0
cefmenoxime(1-)	0
ceftizoxime(1-) +	0
cefuzonam(1-) +	0
chenodeoxycholic acid 24-O-(beta-D-glucuronide)(1-)	0
chlorfenac(1-) +	0
chlorogenate	0
chlorophenoxyacetate anion +	0
chlorophyllide a(2-)	0
chlorophyllide b(1-)	0
chlorophyllide b(2-)	0
chlorophyllide(2-) +	0
cholic acid 24-O-(beta-D-glucuronide)(1-)	0
chromenemonocarboxylate +	0
cinnamates +	0
cis-2-chloro-4-carboxylatomethylenebut-2-en-1,4-olide	0
cis-heme d hydroxychlorin gamma-spirolactone(1-)	0
clavaldehyde(1-)	0
clavulanate +	24
clofencet(1-) +	0
clonixin(1-) +	0
clorazepic acid anion +	0
cochalate	0
coenzyme B(3-)	0
creatinate	0
cremeomycin(1-)	0
cuevaene A(1-)	0
cyclic 2,3-bisphospho-D-glycerate(3-)	0
cyclitol carboxylic acid anion +	0
cyclohex-1,4-dienecarboxylate +	0
cyclohex-2,5-dienecarboxylate +	0
cyclohexadienecarboxylate +	0
cyclohexanecarboxylate +	0
cyclohexenecarboxylate +	0
cyclopropanecarboxylate +	0
dTDP-D-galacturonate(3-)	0
dehydroabietate	0
delphinidin-5-olate 3-O-(6''-O-carboxylatoacetyl)-beta-D-glucoside(1-)	0
delphinidin-5-olate 3-O-(6''-O-carboxylatoacetyl)-beta-D-glucoside-3'-O-beta-D-glucoside(1-)	0
deoxycholic acid 24-O-(beta-D-glucuronide)(1-)	0
deoxylimonoate	0
deoxyviolaceinate	0
dermatan sulfate polyanion +	0
desmethylnaproxen(1-)	0
dethiobiotin(1-)	0
dicarboxylic acid monoamide(1-) +	0
dichloroacetate	0
diclofenac(1-) +	0
difluoroacetate	0
dihydroartemisinate	0
dihydroferulate	0
dihydroorotate +	0
dihydrourocanate	0
ditrans,polycis-dodecaprenyl phosphate-GalA(2-)	0
divinyl chlorophyllide a(2-)	0
ectoinate	0
ent-7alpha-hydroxykaur-16-en-19-oate	0
ent-Photinus luciferin(1-)	0
ent-glycosmisate	0
ent-kaur-16-en-19-oate	0
epoxy monocarboxylic acid anion +	0
etiocholanolone 3-glucuronide(1-)	0
etrasimod(1-) +	0
fatty acid anion +	130
fenoprofen(1-) +	0
ferulate +	0
firefly D-sulfoluciferin(2-)	0
firefly L-sulfoluciferin(2-)	0
flavokermesate 7-C-beta-D-glucoside(2-)	0
flufenamate	0
flunixin(1-) +	0
fondaparinux(10-) +	0
formate +	0
fosinopril(1-) +	0
fumagillin(1-)	0
fumisoquin C(1-)	0
furancarboxylate +	0
germacra-1(10),4,11(13)-trien-12-oate +	0
glutaramate +	0
glycosmisate	0
glycyrrhetinate	77
guanidinoacetate	0
gypsogenate 28-beta-D-glucoside(1-)	0
gypsogenin(1-)	0
haloacetate(1-) +	0
haloxyfop-P(1-) +	0
hederagenin(1-)	0
heparin disaccharide I-S(4-)	0
hydantoin-5-propionate +	0
hydrogen phosphonatoacetate(2-)	0
hydroxy fatty acid ascaroside anion +	0
hydroxy monocarboxylic acid anion +	76
hyocholic acid 24-O-(beta-D-glucuronide)(1-)	0
hyodeoxycholic acid 24-O-(beta-D-glucuronide)(1-)	0
ibuprofen(1-)	0
icas#1(1-)	0
icas#10(1-)	0
icas#12(1-)	0
icas#9(1-)	0
imidazol-4-ylacetate	0
imidazolyl carboxylic acid anion +	0
indol-3-yl carboxylic acid anion +	0
indole-3-carboxylate	0
indolecarboxylate +	0
isopimarate	0
karetazan(1-) +	0
kermesate	0
ketorolac(1-) +	12
laccaic acid D(1-)	0
leukotriene A4(1-)	0
lithocholic acid 24-O-(beta-D-glucuronide)(1-)	0
loganate	0
lonazolac(1-) +	0
luteolin 7-O-beta-D-glucosiduronate	0
m-hydroxyhippurate	0
magnesium 13(1)-hydroxyprotoporphyrin 13-monomethyl ester(1-)	0
magnesium 13(1)-oxoprotoporphyrin 13-monomethyl ester(1-)	0
magnesium protoporphyrin 13-monomethyl ester(1-)	0
maleamate +	0
marilonates +	0
marinolate C	0
meclofenamic acid(1-) +	0
meglumine amidotrizoate	16
methacrylate	0
methoxyacetate +	0
methyl 8-\{[N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl]oxy\}nonanoate(1-)	0
methyl 8-\{[N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl]oxy\}nonanoate(1-)	0
montelukast(1-) +	0
mupirocin(1-) +	0
mycophenolate +	0
nalidixic acid anion	0
naphthoate +	0
naproxen(1-) +	0
naptalamate	0
neopentalenolactone D(1-)	0
neurosporaxanthin(1-)	0
nocardicin E(1-)	0
nocardicin E(2-)	0
ochratoxin A(1-)	0
ochratoxin B(1-)	0
oleanolate	0
oleanolate 3-O-beta-D-glucoside	0
olivetolate +	0
oroxylin A 7-O-beta-D-glucuronate	0
oxamate	0
oxo monocarboxylic acid anion +	0
p-hydroxyhippurate	0
p-tolyl beta-D-glucuronide(1-)	0
pantothenate +	0
penamcarboxylate +	0
penicillinate anion +	0
penilactone B(1-)	0
penilactone D(2-)	0
penta-2,4-dienoate +	0
pentalenolactone D(1-)	0
pentalenolactone E(1-)	0
pentalenolactone F(1-)	0
pentalenolactone(1-)	0
pepstatin A(1-)	0
perillate	0
perindopril(1-) +	0
phaseic acid anion	0
phenazine-1-carboxylate	0
phenguignardate	0
phenoxyacetate +	0
phenylacetate +	0
phenylacetylglycine(1-)	0
phenylpyruvate +	0
phomoidride A(1-)	0
phosphoenolpyruvate	2
phosphonatoenolpyruvate	0
phosphonoformate(2-)	0
piperidinecarboxylate +	0
piperonylate	0
pivalate +	0
platencin(1-)	0
platensimycin(1-)	0
pravastatin(1-) +	0
primary fluorescent chlorophyll catabolite(1-)	0
primary fluorescent dioxobilin-type chlorophyll catabolite(1-) +	0
propionylglycinate	0
propynoate	0
protochlorophyllide b(1-)	0
protochlorophyllide(1-)	0
protochlorophyllide(2-)	0
protodeoxyviolaceinate	0
protoviolaceinate	0
pseudaminate +	0
pseudomonates +	0
pteroates +	0
purinecarboxylate +	0
pyrazine-2-carboxylate	0
pyridinemonocarboxylate +	39
pyridinium-3-carboxylate-5-thiocarboxylate mononucleotide(3-)	0
pyrimidinecarboxylate anion +	0
pyrrolecarboxylate +	0
pyruvate oxime	0
quiannulatate	0
quillate	0
quinclorac(1-) +	0
quinoline-4-carboxylate	0
quinolinemonocarboxylate +	0
rebaudioside B(1-)	0
retinoate +	0
ribavirin carboxylate	0
rigosertib(1-) +	0
rose bengal(2-) +	8
rosmarinate +	0
salicylurate	0
scutellarin(1-)	0
sesterfisherate	0
soyasapogenol A 3-O-beta-glucuronate	0
soyasapogenol B 3-O-beta-glucuronate	0
soyasapogenol E 3-O-beta-glucuronate	0
soyasaponin I(1-)	0
soyasaponin III(1-)	0
stellatate	0
steviol(1-)	0
steviolbioside(1-)	0
steviolmonoside(1-)	0
streptothricin D acid (pH 7.3)	0
streptothricin F acid (pH 7.3)	0
succinamate	0
sulbactam(1-) +	0
sulfonatoacetate	0
tafamidis(1-) +	0
tartrazine(3-) +	94
ternatin C5(2-)	0
thiazolidinemonocarboxylate +	0
thioglycolate(1-) +	0
thioglycolate(2-)	0
thiomorpholine-3-carboxylate	0
thiophene-2-carboxylate	0
thromboxane A2(1-) +	0
tolmetin(1-) +	0
trans-2-chloro-4-carboxylatomethylenebut-2-en-1,4-olide(1-)	0
trans-heme d hydroxychlorin gamma-spirolactone(1-)	0
trichloroacetate	0
trifluoroacetate +	5
trihazone A(2-)	0
ureidoacrylate	0
urocanate +	0
uronate +	0
valerenate	0
violaceinate	0
wogonin 7-O-beta-D-glucuronate	0
yersiniabactin(1-) +	0
zealexin A1(1-)	0
zofenopril(1-) +	0
zofenoprilat(1-) +	0
zolasartan(2-)	0
Path 2
Term	Annotations
CHEBI ontology	19841
subatomic particle	19839
composite particle	19839
hadron	19839
baryon	19839
nucleon	19839
atomic nucleus	19839
atom	19839
main group element atom	19789
p-block element atom	19789
carbon group element atom	19737
carbon atom	19733
organic molecular entity	19733
organic ion	9866
organic anion	3616
carboxylic acid anion	2480
monocarboxylic acid anion	1591
(+)-DCA-CL(1-)	0
(+)-artemisinate	0
(+)-pisiferate	0
(-)-DCA-CL(1-)	0
(-)-phomoidride B(1-)	0
(10aS)-10,10a-dihydrophenazine-1-carboxylate	0
(11R)-carlactonoate +	0
(1R)-1,4,5,10-tetrahydrophenazine-1-carboxylate	0
(1R,10aS)-1,4,10,10a-tetrahydrophenazine-1-carboxylate	0
(1S,3R)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate	0
(2-chloro-5-oxo-2,5-dihydro-2-furyl)acetate +	0
(2-hydroxyphenyl)acetate	0
(2E,6E,10R,11S)-10,11-epoxy-3,7,11-trimethyltrideca-2,6-dienoate	0
(2R,3R,5S)-2-(S-pantetheinyl)-carbapenam-3-carboxylate	0
(2R,3R,5S,6R)-6-(ethyl)-2-(S-pantetheinyl)-carbapenam-3-carboxylate	0
(2R,3R,5S,6R)-6-(methyl)-2-(S-pantetheinyl)-carbapenam-3-carboxylate	0
(2S)-3-(4-hydroxyphenyl)-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]propanoate	0
(2S)-3-methyl-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]butanoate	0
(2S)-3-phenyl-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]propanoate	0
(2S)-4-methyl-2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]pentanoate	0
(2Z,4Z)-2-hydroxyhexa-2,4-dienoate	0
(2xi)-3-deoxy-7-O-phosphonato-beta-D-threo-hept-6-ulopyranosonate +	0
(2xi)-D-gluco-heptonate +	0
(3,5-dichlorophenyl)ureidoformate	0
(3-nitro-4-oxidophenyl)acetate	0
(3R)-7,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate	0
(3R,5S)-fluvastatin(1-) +	0
(3S)-1,2-diazinane-3-carboxylate	0
(3S)-3-(\{(2S)-2-[5-tert-butyl-3-\{[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]amino\}-2-oxopyrazin-1(2H)-yl]butanoyl\}amino)-5-[hexyl(methyl)amino]-4-oxopentanoate	0
(3S)-7,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate	0
(3S,5R)-fluvastatin(1-) +	0
(3S,5S)-carbapenam-3-carboxylate	0
(4-hydroxy-3-nitrophenyl)acetate	0
(4-hydroxy-5-iodo-3-nitrophenyl)acetate	0
(4-nitrophenyl)acetate	0
(4-octa-1-enyl-2,5-dioxo-2,5-dihydro-3-furanyl)acetate	0
(4R,5S)-dethiobiotin(1-)	0
(4S)-4,16-dihydroxyretinoate	0
(5R)-carbapenem-3-carboxylate	0
(7R)-6-deoxy-D-manno-oct-7-ulosuronate	0
(8E,10S,12Z,15Z)-10-hydroperoxyoctadec-8,12,15-trienoate	0
(9E)-12-(phosphonooxy)octadecenoate(3-)	0
(9Z)-18-hydroxyoctadec-9-enoate 18-O-beta-D-glucoside	0
(9Z,11E,13S,14Z)-13-hydroperoxyoctadeca-9,11,14-trienoate	0
(E)-3-(indol-3-yl)acrylate(1-)	0
(R)-2-(4-chloro-2-methylphenoxy)propanoate	0
(R)-2-O-sulfonatolactate(2-)	0
(R)-3,5-bisphosphonatomevalonate(5-)	0
(R)-3-sulfolactate	0
(R)-5-diphosphonatomevalonate(4-)	0
(R)-dichlorprop(1-)	0
(R)-dihydrocamalexate	0
(R)-imazamox(1-) +	0
(R)-imazapic(1-) +	0
(R)-imazapyr(1-) +	0
(R)-imazaquin(1-) +	0
(R)-lorglumide(1-) +	0
(R,R)-chrysanthemate	0
(S)-2-(4-chloro-2-methylphenoxy)propanoate	0
(S)-2-O-sulfonatolactate(2-)	0
(S)-2-chloropropanoate	0
(S)-4-amino-5-oxopentanoate	0
(S)-5-carboxymethyl-tetronate(1-)	0
(S)-alpha-hydroxyglutarate-gamma-lactone	0
(S)-dichlorprop(1-)	0
(S)-dihydrocamalexate	0
(S)-haloxyfop(1-)	0
(S)-imazamox(1-) +	0
(S)-imazapic(1-) +	0
(S)-imazapyr(1-) +	0
(S)-imazaquin(1-) +	0
(S)-lorglumide(1-) +	0
(Z)-2-methylureidoacrylate	0
(Z)-3-amino-2-methylacrylate	0
(Z)-3-aminoacrylate	0
(aminooxy)acetate +	0
(methylthio)acetate	0
1,2-diacyl-3-[3-(alpha-D-N-acetylneuraminyl)-beta-D-galactosyl]-sn-glycerol(1-)	0
1,4-dihydroxy-6-naphthoate	0
1,6-anhydro-N-acetyl-beta-muramate	0
1,6-dihydroxy-2-methylcyclohexa-2,4-diene-1-carboxylate	0
1-(2-carboxylatophenylamino)-1-deoxy-D-ribulose 5-phosphate(3-)	0
1-O-hexadecyl-2-(8-carboxyoctanoyl)-sn-glycero-3-phosphocholine(1-)	0
1-deoxypentalenate	0
1-hexadecyl-2-glutaryl-sn-glycero-3-phosphocholine(1-)	0
1-hexadecyl-2-succinyl-sn-glycero-3-phosphocholine(1-)	0
1-methyl-4-imidazoleacetate	0
1-naphthaleneacetate	0
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine(1-)	0
1-phosphonato-alpha-D-galacturonate(3-)	0
1-phosphonato-alpha-D-glucuronate(3-)	0
1-piperideine-6-carboxylate +	0
1-pyrrolinecarboxylate +	0
12-(octadecanoyloxy)octadecanoate	0
12-(phosphonooxy)octadecanoate(3-)	0
12-[(9Z)-hexadecenoyloxy]octadecanoate	0
12-[(9Z)-octadecenoyloxy]octadecanoate	0
12-ethyl-8-isobutyl-3-vinylbacteriochlorophyllide d(1-)	0
12-ethyl-8-propyl-3-vinylbacteriochlorophyllide d(1-)	0
13-(beta-D-glucosyloxy)docosanoate	0
13-(octadecanoyloxy)octadecanoate	0
13-[(9Z)-hexadecenoyloxy]octadecanoate	0
13-[(9Z)-octadecenoyloxy]octadecanoate	0
16-epiestriol 16-O-(beta-D-glucuronide)(1-)	0
16-epiestriol 3-O-(beta-D-glucuronide)(1-)	0
16-feruloyloxypalmitate	0
16-sinapoyloxypalmitate	0
17-(4-hydroxyphenyl)heptadecanoate	0
17-epiestriol 16-O-(beta-D-glucuronide)(1-)	0
17-epiestriol 17-O-(beta-D-glucuronide)(1-)	0
17-epiestriol 3-O-(beta-D-glucuronide)(1-)	0
17alpha-(N-acetyl-D-glucosaminyl)estradiol 3-glucosiduronate	0
17alpha-estradiol 3-glucosiduronate	0
17beta-estradiol 17-glucosiduronate +	0
19-(4-hydroxyphenyl)nonadecanoate	0
2,3,6,8,9-pentahydroxy-1-oxo-3-(2-oxopropyl)-1,2,3,4-tetrahydroanthracene-2-carboxylate	0
2,3-bisphosphonato-D-glycerate(5-)	0
2,4,5-trihydroxyphenylacetate	0
2,4-dichloro-5-oxo-2,5-dihydro-2-furylacetate	0
2,4-divinyl protochlorophyllide a(1-)	0
2,6-dihydroxynicotinate	0
2-O-(4-deoxy-beta-L-threo-hex-4-enopyranuronosyl)-alpha-L-rhamnopyranose(1-)	0
2-O-(6-phospho-alpha-D-mannosyl)-D-glycerate	0
2-O-(alpha-D-glucopyranosyl)-3-O-phosphonato-D-glycerate(3-)	0
2-O-[alpha-D-mannopyranosyl-(1->2)-alpha-D-glucopyranosyl]-3-O-phosphonato-D-glycerate(3-)	0
2-O-[alpha-D-mannosyl-(1->2)-alpha-D-glucosyl]-D-glycerate	0
2-O-alpha-L-rhamnosyl-alpha-L-rhamnosyl-3-hydroxydecanoyl-3-hydroxydecanoate	0
2-[(1R,8S,14R,15R)-11-hydroxy-14,15-bis[(6E)-oct-6-en-1-yl]-3,5,9-trioxo-4,10-dioxatetracyclo[9.4.0.0(2,6).0(8,12)]pentadeca-2(6),12-dien-8-yl]acetate	0
2-[(E)-\{[(2R,3S,4R,5R)-2,3,4,5-tetrahydroxyoxan-2-yl]methylidene\}amino]acetate	0
2-[1-(\{5-hydroxy-4-oxo-3-[2-(sulfonatooxy)phenyl]-4H-chromen-6-yl\}oxy)-2-oxoethoxy]-3-oxopropanoate	0
2-acetamido-2-deoxy-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronate)-4-O-sulfonato-D-galactopyranose(2-) +	0
2-acetamido-2-deoxy-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronate)-6-O-sulfonato-D-galactopyranose(2-) +	0
2-amino-2-deoxy-D-gluconate	0
2-amino-3-oxo-4-(phosphonatooxy)butanoate	0
2-carboxylato-D-arabinitol 1-phosphate(3-)	0
2-carboxylato-D-arabinitol(1-)	0
2-chloroacrylate	0
2-cis-abscisate +	0
2-dehydro-3,6-dideoxy-6-sulfo-D-gluconate(2-)	0
2-dehydro-3-deoxy-6-phosphonato-D-gluconate(3-)	0
2-ethylacrylate	0
2-hydroxy-17beta-estradiol 2-O-(beta-D-glucuronide)(1-)	0
2-hydroxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
2-hydroxyestrone 2-O-(beta-D-glucuronide)(1-)	0
2-hydroxyestrone 3-O-(beta-D-glucuronide)(1-)	0
2-imino-3-(7-chloroindol-3-yl)propionate(1-)	0
2-imino-3-(indol-3-yl)propanoate	0
2-iminopropanoate	0
2-methoxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
2-methoxyestrone 3-O-(beta-D-glucuronide)(1-)	0
2-methylvalerate	0
2-oxindole-3-acetate	0
2-oxo-1,2-dihydroquinoline-4-carboxylate	0
2-oxo-4-phosphonobutanoate(2-)	0
2-phosphonatoglycolate(3-)	0
3'-dehydrocarminate(2-)	0
3,3',5-triiodo-L-thyroninate +	0
3,4,5-trimethoxybenzoate	0
3,4,5-trimethoxydihydrocinnamate	0
3,4-dehydrothiomorpholine-3-carboxylate	0
3,4-dimethylindole-2-carboxylate	0
3,5-dibromo-4-oxidobenzoate(2-)	0
3-(1-hydroxyethyl)bacteriochlorophyllide a(2-)	0
3-(1-hydroxyethyl)chlorophyllide a(2-)	0
3-(1H-indol-3-yl)propanoate	0
3-(2,3-dihydroxyphenyl)propanoate	0
3-(2-hydroxyphenyl)propanoate	0
3-(3,4-dihydroxyphenyl)propanoate	0
3-(3-hydroxyphenyl)propanoate	0
3-(3-sulfooxyphenyl)propanoate(2-)	0
3-(4-oxo-4,5-dihydro-1H-imidazol-5-yl)propanoate(1-)	0
3-(cis-5,6-dihydroxycyclohexa-1,3-dienyl)propanoate +	0
3-(dioxido-lambda(5)-azanylidene)propanoate(2-)	0
3-(trimethylsilyl)propionate +	0
3-ADP-2-phosphoglycerate(5-)	0
3-D-glucuronosyl-N(2),6-disulfonato-beta-D-glucosamine(3-)	0
3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronate)-D-galactosamine(1-)	0
3-acetylchlorophyllide a(2-)	0
3-aci-nitropropanoate	0
3-butynoate	0
3-carboxy-3-hydroxypropanoyl-CoA(5-) +	0
3-chloroacrylate	0
3-dehydro-L-gulonate 6-phosphate	0
3-dehydroshikimate	0
3-deoxy-D-glycero-beta-D-galacto-nonulosonate	0
3-deoxy-alpha-D-manno-2-octulosonate-8-phosphate(3-)	0
3-deoxy-alpha-D-manno-oct-2-ulosonate	0
3-hydroxy-2-isopropyl-4-methoxy-4-oxobutanoate	0
3-hydroxy-3-(4-O-beta-D-glucosyl-3-methoxyphenyl)propanoate	0
3-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propanoate	0
3-hydroxy-3-(4-hydroxyphenyl)propanoate	0
3-hydroxy-3-phenylpropionate	0
3-mercapto-2-mercaptomethylpropanoate(1-)	0
3-methylvalerate	0
3-nitroacrylate	0
3-nitropropanoate	0
3-phenylpropionate +	0
3-phosphonatopyruvate(2-)	0
3-phosphonatopyruvate(3-)	0
3-sulfinatopropionate	0
3-ureidoisobutyrate(1-)	0
3-vinyl-bacteriochlorophyllide d(1-)	0
3-vinylbacteriochlorophyllide a(1-)	0
3-vinylbacteriochlorophyllide a(2-)	0
3-vinylbacteriochlorophyllide d(1-)	0
3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oate(1-)	0
4'''-demalonylsalvianin(1-)	0
4,4'-diapolycopen-4-oate	0
4,4'-diaponeurosporenoate	0
4-(2,4-dichlorophenoxy)butanoate	0
4-O-beta-D-glucosyl-4-coumarate +	0
4-O-beta-D-glucosyl-trans-ferulate	0
4-O-beta-D-glucosyl-trans-sinapate	0
4-acetamidobutanoate	0
4-carboxylato-4'-sulfonatoazobenzene	0
4-carboxylatomethyl-3-methylbut-2-en-1,4-olide(1-)	0
4-carboxylatomethyl-4-methylbut-2-en-1,4-olide(1-)	0
4-carboxylatomethylenebut-2-en-4-olide	0
4-chlorophenylacetate	0
4-deoxy-Delta(4)-beta-D-GlcpA2S-(1->3)-beta-D-GalpNAc(2-)	0
4-deoxy-L-threo-hex-4-enopyranuronate +	0
4-deoxy-beta-L-threo-hex-4-enopyranuronate	0
4-guanidinobutanoate	0
4-hydroxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
4-hydroxy-17beta-estradiol 4-O-(beta-D-glucuronide)(1-)	0
4-hydroxyestrone 3-O-(beta-D-glucuronide)(1-)	0
4-hydroxyestrone 4-O-(beta-D-glucuronide)(1-)	0
4-hydroxyphenylacetate	0
4-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate	0
4-methoxy-17beta-estradiol 3-O-(beta-D-glucuronide)(1-)	0
4-methoxy-4-oxo-3-phenylbutanoate	0
4-methoxyestrone 3-O-(beta-D-glucuronide)(1-)	0
4-methyl-3-oxopentanoate	0
4-methylumbelliferone beta-D-glucuronide(1-)	0
4-sulfanylbutanoate	0
5(S),8(R)-DiHODE(1-)	0
5,10-dihydro-9-dimethylallylphenazine 1-carboxylate	0
5,10-dihydrophenazine-1-carboxylate	0
5,6,7,8-tetrahydropterin-6-carboxylate	0
5,6-epoxyretinoate	0
5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)-1,3-benzothiazol-6-yl beta-D-glucuronide(1-)	0
5-(2,3-dimethoxy-4-methylphenyl)pentanoate	0
5-(2-carboxylatoethyl)-4-oxo-4,5-dihydro-1H-imidazol-5-ide	0
5-[(9Z)-hexadecenoyloxy]octadecanoate	0
5-[(9Z)-octadecenoyloxy]octadecanoate	0
5-amino-4-chloro-2-(2-oxidomuconoyl)pyridazin-3(2H)-one(2-)	0
5-aminolevulinate	0
5-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium-3-carbonyl adenylate(3-)	0
5-chloromuconolactone(1-)	0
5-dehydro-4-deoxy-2-O-sulfo-D-glucuronic acid(2-)	0
5-dehydro-D-gluconate	0
5-dehydro-L-gluconate	0
5-deoxy-D-glucuronate	0
5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate	0
5-hydroxy-6-methylpyridine-3-carboxylate	0
5-hydroxyectoinate	0
5-hydroxyferulate +	0
5-hydroxyimidazole-4-acetate	0
5-oxo-2,5-dihydro-2-furylacetate	0
5-oxo-4,5-dihydro-2-furylacetate	0
5alpha-androstane-3alpha,17beta-diol 17-glucosiduronate	0
5alpha-androstane-3alpha,17beta-diol 3-glucosiduronate(1-)	0
5alpha-androstane-3beta,17beta-diol 17-O-(beta-D-glucuronide)(1-)	0
5alpha-dihydrotestosterone 17-O-(beta-D-glucuronide)(1-)	0
6-[(4-hydroxy-3-nitrophenyl)acetamido]caproate	0
6-deoxy-6-sulfo-D-gluconate(2-)	0
6-formamidopenicillanate	0
6-hydroxynicotinate(1-)	0
6-ketopiperidine-2-carboxylate	0
6-phospho-D-gluconate	0
6-phosphonato-2-dehydro-3-deoxy-D-galactate(3-)	0
6-phosphonatooxy-D-gluconate	0
6alpha-hydroxygermacra-1(10),4,11(13)-trien-12-oate	0
7(1),7(1)-dihydroxybacteriochlorophyllide d(1-)	0
7(1)-hydroxybacteriochlorophyllide d(1-)	0
7(1)-hydroxychlorophyllide a(2-)	0
7,7-dihydroxybacteriochlorophyllide c(1-)	0
7-carboxylato-7-deazaguanine	0
7-deoxyloganate	0
7-deoxyloganetate	0
7-hydroxybacteriochlorophyllide c(1-)	0
7-phospho-2-dehydro-3-deoxy-D-arabino-heptonate	0
8(R)-HPODE(1-)	0
8,12-diethyl-3-vinylbacteriochlorophyllide d(1-)	0
8-phosphonato-3-deoxy-D-manno-oct-2-ulosonate(3-)	0
9(R)-HPODE(1-)	0
9(S)-HPODE(1-)	0
9-(octadecanoyloxy)octadecanoate	0
9-[(10Z)-heptadecenoyloxy]-octadecanoate	0
9-[(9Z),(12Z)-octadecadienoyloxy]-octadecanoate	0
9-[(9Z)-hexadecenoyloxy]octadecanoate	0
9-[(9Z)-octadecenoyloxy]octadecanoate	0
9beta-pimara-7,15-dien-19-oate	0
ADP-5-ethyl-4-methylthiazole-2-carboxylate(3-)	0
CMP-5'-phosphonoformate(3-)	0
D-galactopyranuronate +	0
D-glucopyranuronate +	0
D-glucuronate 1-phosphate	0
F420-0(2-)	0
L-5-carboxylatomethylhydantoin(1-)	0
L-rhamnonate	0
L-rhamnosyl-3-hydroxydecanoyl-3-hydroxydecanoate	0
L-thyroxine(1-) +	0
N,N-dihydroxy-L-isoleucinate	0
N,N-dihydroxy-L-valinate	0
N-(1H-1,3-benzodiazol-2-yl)carbamate	0
N-(2-furoyl)glycinate	0
N-(2-hydroxy,5-methoxyphenyl)malonamate	0
N-(2-hydroxyphenyl)malonamate	0
N-(3,4-dichlorophenyl)malonamate	0
N-(3-carboxypropanoyl)-N-hydroxycadaverine zwitterion	0
N-(3-carboxypropanoyl)-N-hydroxyputrescine zwitterion	0
N-(indol-3-ylacetyl)glutaminate	0
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-gamma-aminobutanoate	0
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-gamma-aminobutyrate	0
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]glycinate	0
N-[(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]glycinate	0
N-[(R)-pantothenoyl]-L-cysteinate	0
N-acetyl-1-methyl-L-histidinate	0
N-acetyl-3-methyl-L-histidinate	0
N-acetyl-D-6-sulfogalactosamine(4-)	0
N-acetyl-D-glucosaminate	0
N-acetyl-D-muramoyl-L-alanyl-D-isoglutamine(1-)	0
N-acetyl-L-alaninate	0
N-acetyl-L-alpha-phenylglycinate	0
N-acetyl-L-cysteinate +	0
N-acetyl-L-isoleucinate	0
N-acetyl-L-threoninate	0
N-acetyl-L-tryptophanate	0
N-acetyl-L-tyrosinate	0
N-acetyl-L-valinate	0
N-acetyl-alpha-D-muramate 1-phosphate(3-)	0
N-acetyl-alpha-neuraminate +	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-6-sulfooxy-glucosaminide(2-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-Fuc-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-Fuc-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-6-sulfooxy-glucosaminide(2-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosamine(1-)	0
N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-N-acetyl-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminide(1-)	0
N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminide(1-)	0
N-acetyl-beta-D-6-sulfogalactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-D-6-sulfogalactosamine(3-)	0
N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-beta-D-4-sulfogalactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-D-4-sulfogalactosamine(4-)	0
N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide anion	0
N-acetyl-beta-D-muramoyl-L-alanyl-D-isoglutamine(1-)	0
N-acetyl-beta-neuraminate	0
N-acetylmethioninate +	0
N-acetylmuramate 6-phosphate +	0
N-acetylphosphinothricin(2-) +	0
N-acetyltryptophanate	0
N-acyl-gamma-aminobutyrate +	0
N-arachidonoyl-gamma-aminobutyrate	0
N-carbamoyl-D-phenylglycine(1-)	0
N-carbamoyl-beta-alaninate	0
N-carbamoylsarcosinate	0
N-cinnamoylglycinate	0
N-formylmaleamate	0
N-hexadecanoyl-O-(1-octadecanoyl-2-oleoyl-sn-glycero-3-phospho)-L-serine(2-)	0
N-hexanoylglycinate	0
N-hydroxy-L-isoleucinate	0
N-hydroxy-L-valinate	0
N-isobutyrylglycinate	0
N-isovalerylglycinate	0
O-formylcefamandole(1-) +	0
Photinus luciferin(1-)	0
[1-(5-phosphonatoribosyl)imidazol-4-yl]acetate(3-)	0
[2-methoxy-5-(\{[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl\}methyl)anilino]acetate	0
a carboxymycobactin(1-)	0
abietate	0
abscisates +	0
acetate +	41
acrylate +	2
adenin-9-yl riburonosate(1-)	0
aldehydic acid anion +	0
aldonate +	21
all-trans-13,14-dihydroretinoate +	0
all-trans-3,4-didehydroretinoate(1-)	0
allantoate	0
alpha-D-FucNAc4-(1->4)-beta-D-ManNAcA-(1->4)-D-GlcNAc-undecaprenyl diphosphate(3-)	0
alpha-D-mannopyranuronate	0
alpha-D-talopyranuronate	0
alpha-L-iduronyl-(1->3)-N-acetyl-D-6-sulfogalactosamine(3-)	0
alpha-L-iduronyl-(1->3)-N-acetyl-beta-D-4-sulfogalactosaminyl-(1->4)-alpha-L-iduronyl-(1->3)-N-acetyl-D-4-sulfogalactosamine(4-)	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminide(1-) +	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide(1-) +	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminide(1-) +	0
alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine(1-) +	0
alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine(1-)	0
alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide(1-)	0
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc(1-)	0
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc(1-) +	0
alpha-sulfophenylacetate	0
amidotrizoic acid anion +	16
aminocyclopyrachlor(1-) +	0
arsonoacetic acid anion	0
ascr#1(1-) +	0
ascr#10(1-) +	0
ascr#12(1-) +	0
ascr#14(1-)	0
ascr#16(1-)	0
ascr#9(1-) +	0
asnovolin I(1-)	0
asparagusate	0
asperaculane D(1-)	0
asperaculane E(1-)	0
asperaculane G(1-)	0
bacteriochlorophyllide a(2-) +	0
bacteriochlorophyllide c(1-)	0
bacteriochlorophyllide d(1-)	0
bacteriochlorophyllide e(1-)	0
bacteriochlorophyllide f(1-) +	0
bacteriochlorophyllide g(2-)	0
baicalin(1-)	0
benazolin(1-) +	0
benzoates +	1275
beraprost(1-) +	0
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-D-GlcpNAc(1-) +	0
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc(1-)	0
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc(1-)	0
beta-D-ManNAcA-(1->4)-alpha-D-GlcNAc-1-diphospho-ditrans,polycis-undecaprenol(3-)	0
beta-D-galactosyl-(1->3)-[N-acetyl-alpha-neuraminyl-(2->6)]-N-acetyl-alpha-D-galactosaminide(1-)	0
bile acid anion +	54
biotinate +	0
biotinate sulfoxide(1-)	0
bisorcic(1-)	0
bispyribac(1-) +	0
bromfenac(1-) +	0
bumadizone(1-) +	0
butyrylglycinate	0
calcitroate	0
candesartan(2-)	0
carbocyclic thromboxane A2(1-) +	0
carboprost(1-) +	0
carminate(2-)	0
carnosate	0
carumonam(1-) +	0
catechol beta-D-glucuronide(1-)	0
cefmenoxime(1-)	0
ceftizoxime(1-) +	0
cefuzonam(1-) +	0
chenodeoxycholic acid 24-O-(beta-D-glucuronide)(1-)	0
chlorfenac(1-) +	0
chlorogenate	0
chlorophenoxyacetate anion +	0
chlorophyllide a(2-)	0
chlorophyllide b(1-)	0
chlorophyllide b(2-)	0
chlorophyllide(2-) +	0
cholic acid 24-O-(beta-D-glucuronide)(1-)	0
chromenemonocarboxylate +	0
cinnamates +	0
cis-2-chloro-4-carboxylatomethylenebut-2-en-1,4-olide	0
cis-heme d hydroxychlorin gamma-spirolactone(1-)	0
clavaldehyde(1-)	0
clavulanate +	24
clofencet(1-) +	0
clonixin(1-) +	0
clorazepic acid anion +	0
cochalate	0
coenzyme B(3-)	0
creatinate	0
cremeomycin(1-)	0
cuevaene A(1-)	0
cyclic 2,3-bisphospho-D-glycerate(3-)	0
cyclitol carboxylic acid anion +	0
cyclohex-1,4-dienecarboxylate +	0
cyclohex-2,5-dienecarboxylate +	0
cyclohexadienecarboxylate +	0
cyclohexanecarboxylate +	0
cyclohexenecarboxylate +	0
cyclopropanecarboxylate +	0
dTDP-D-galacturonate(3-)	0
dehydroabietate	0
delphinidin-5-olate 3-O-(6''-O-carboxylatoacetyl)-beta-D-glucoside(1-)	0
delphinidin-5-olate 3-O-(6''-O-carboxylatoacetyl)-beta-D-glucoside-3'-O-beta-D-glucoside(1-)	0
deoxycholic acid 24-O-(beta-D-glucuronide)(1-)	0
deoxylimonoate	0
deoxyviolaceinate	0
dermatan sulfate polyanion +	0
desmethylnaproxen(1-)	0
dethiobiotin(1-)	0
dicarboxylic acid monoamide(1-) +	0
dichloroacetate	0
diclofenac(1-) +	0
difluoroacetate	0
dihydroartemisinate	0
dihydroferulate	0
dihydroorotate +	0
dihydrourocanate	0
ditrans,polycis-dodecaprenyl phosphate-GalA(2-)	0
divinyl chlorophyllide a(2-)	0
ectoinate	0
ent-7alpha-hydroxykaur-16-en-19-oate	0
ent-Photinus luciferin(1-)	0
ent-glycosmisate	0
ent-kaur-16-en-19-oate	0
epoxy monocarboxylic acid anion +	0
etiocholanolone 3-glucuronide(1-)	0
etrasimod(1-) +	0
fatty acid anion +	130
fenoprofen(1-) +	0
ferulate +	0
firefly D-sulfoluciferin(2-)	0
firefly L-sulfoluciferin(2-)	0
flavokermesate 7-C-beta-D-glucoside(2-)	0
flufenamate	0
flunixin(1-) +	0
fondaparinux(10-) +	0
formate +	0
fosinopril(1-) +	0
fumagillin(1-)	0
fumisoquin C(1-)	0
furancarboxylate +	0
germacra-1(10),4,11(13)-trien-12-oate +	0
glutaramate +	0
glycosmisate	0
glycyrrhetinate	77
guanidinoacetate	0
gypsogenate 28-beta-D-glucoside(1-)	0
gypsogenin(1-)	0
haloacetate(1-) +	0
haloxyfop-P(1-) +	0
hederagenin(1-)	0
heparin disaccharide I-S(4-)	0
hydantoin-5-propionate +	0
hydrogen phosphonatoacetate(2-)	0
hydroxy fatty acid ascaroside anion +	0
hydroxy monocarboxylic acid anion +	76
hyocholic acid 24-O-(beta-D-glucuronide)(1-)	0
hyodeoxycholic acid 24-O-(beta-D-glucuronide)(1-)	0
ibuprofen(1-)	0
icas#1(1-)	0
icas#10(1-)	0
icas#12(1-)	0
icas#9(1-)	0
imidazol-4-ylacetate	0
imidazolyl carboxylic acid anion +	0
indol-3-yl carboxylic acid anion +	0
indole-3-carboxylate	0
indolecarboxylate +	0
isopimarate	0
karetazan(1-) +	0
kermesate	0
ketorolac(1-) +	12
laccaic acid D(1-)	0
leukotriene A4(1-)	0
lithocholic acid 24-O-(beta-D-glucuronide)(1-)	0
loganate	0
lonazolac(1-) +	0
luteolin 7-O-beta-D-glucosiduronate	0
m-hydroxyhippurate	0
magnesium 13(1)-hydroxyprotoporphyrin 13-monomethyl ester(1-)	0
magnesium 13(1)-oxoprotoporphyrin 13-monomethyl ester(1-)	0
magnesium protoporphyrin 13-monomethyl ester(1-)	0
maleamate +	0
marilonates +	0
marinolate C	0
meclofenamic acid(1-) +	0
meglumine amidotrizoate	16
methacrylate	0
methoxyacetate +	0
methyl 8-\{[N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl]oxy\}nonanoate(1-)	0
methyl 8-\{[N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl]oxy\}nonanoate(1-)	0
montelukast(1-) +	0
mupirocin(1-) +	0
mycophenolate +	0
nalidixic acid anion	0
naphthoate +	0
naproxen(1-) +	0
naptalamate	0
neopentalenolactone D(1-)	0
neurosporaxanthin(1-)	0
nocardicin E(1-)	0
nocardicin E(2-)	0
ochratoxin A(1-)	0
ochratoxin B(1-)	0
oleanolate	0
oleanolate 3-O-beta-D-glucoside	0
olivetolate +	0
oroxylin A 7-O-beta-D-glucuronate	0
oxamate	0
oxo monocarboxylic acid anion +	0
p-hydroxyhippurate	0
p-tolyl beta-D-glucuronide(1-)	0
pantothenate +	0
penamcarboxylate +	0
penicillinate anion +	0
penilactone B(1-)	0
penilactone D(2-)	0
penta-2,4-dienoate +	0
pentalenolactone D(1-)	0
pentalenolactone E(1-)	0
pentalenolactone F(1-)	0
pentalenolactone(1-)	0
pepstatin A(1-)	0
perillate	0
perindopril(1-) +	0
phaseic acid anion	0
phenazine-1-carboxylate	0
phenguignardate	0
phenoxyacetate +	0
phenylacetate +	0
phenylacetylglycine(1-)	0
phenylpyruvate +	0
phomoidride A(1-)	0
phosphoenolpyruvate	2
phosphonatoenolpyruvate	0
phosphonoformate(2-)	0
piperidinecarboxylate +	0
piperonylate	0
pivalate +	0
platencin(1-)	0
platensimycin(1-)	0
pravastatin(1-) +	0
primary fluorescent chlorophyll catabolite(1-)	0
primary fluorescent dioxobilin-type chlorophyll catabolite(1-) +	0
propionylglycinate	0
propynoate	0
protochlorophyllide b(1-)	0
protochlorophyllide(1-)	0
protochlorophyllide(2-)	0
protodeoxyviolaceinate	0
protoviolaceinate	0
pseudaminate +	0
pseudomonates +	0
pteroates +	0
purinecarboxylate +	0
pyrazine-2-carboxylate	0
pyridinemonocarboxylate +	39
pyridinium-3-carboxylate-5-thiocarboxylate mononucleotide(3-)	0
pyrimidinecarboxylate anion +	0
pyrrolecarboxylate +	0
pyruvate oxime	0
quiannulatate	0
quillate	0
quinclorac(1-) +	0
quinoline-4-carboxylate	0
quinolinemonocarboxylate +	0
rebaudioside B(1-)	0
retinoate +	0
ribavirin carboxylate	0
rigosertib(1-) +	0
rose bengal(2-) +	8
rosmarinate +	0
salicylurate	0
scutellarin(1-)	0
sesterfisherate	0
soyasapogenol A 3-O-beta-glucuronate	0
soyasapogenol B 3-O-beta-glucuronate	0
soyasapogenol E 3-O-beta-glucuronate	0
soyasaponin I(1-)	0
soyasaponin III(1-)	0
stellatate	0
steviol(1-)	0
steviolbioside(1-)	0
steviolmonoside(1-)	0
streptothricin D acid (pH 7.3)	0
streptothricin F acid (pH 7.3)	0
succinamate	0
sulbactam(1-) +	0
sulfonatoacetate	0
tafamidis(1-) +	0
tartrazine(3-) +	94
ternatin C5(2-)	0
thiazolidinemonocarboxylate +	0
thioglycolate(1-) +	0
thioglycolate(2-)	0
thiomorpholine-3-carboxylate	0
thiophene-2-carboxylate	0
thromboxane A2(1-) +	0
tolmetin(1-) +	0
trans-2-chloro-4-carboxylatomethylenebut-2-en-1,4-olide(1-)	0
trans-heme d hydroxychlorin gamma-spirolactone(1-)	0
trichloroacetate	0
trifluoroacetate +	5
trihazone A(2-)	0
ureidoacrylate	0
urocanate +	0
uronate +	0
valerenate	0
violaceinate	0
wogonin 7-O-beta-D-glucuronate	0
yersiniabactin(1-) +	0
zealexin A1(1-)	0
zofenopril(1-) +	0
zofenoprilat(1-) +	0
zolasartan(2-)	0

paths to the root